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ABSTRACT 
Von Willebrand factor (VWF), a multimeric protein that has a central role in 
hemostasis, has been shown to interact with complement components. However results 
are contrasting and inconclusive. 
By studying 20 patients with congenital thrombotic thrombocytopenic purpura (cTTP) 
who can not cleave VWF multimers due to genetic ADAMTS13 deficiency, we 
investigated the mechanism through which VWF modulates complement, and its 
pathophysiological implications for human diseases. 
Using assays of ex-vivo serum-induced C3 and C5b-9 deposits on endothelial cells we 
documented that in cTTP complement is activated via the alternative pathway on the 
cell surface. This abnormality was corrected by restoring ADAMTS13 activity in cTTP 
serum, which prevented VWF multimer accumulation on endothelial cells, or by an 
anti-VWF antibody. This study documented: 1) ADAMTS13 is able to interact with FB, 
but how this interaction could modulate complement activation remains still unknown; 
2) VWF does not affect regulatory complement activity of FH for inactivation of C3b or 
dissociation of C3 convertase, in contrast to what reported in literature; 3) VWF 
interacts with C3b through its A2 domain and initiates a previously unrecognized 
Calcium-dependent mechanism of alternative pathway activation, with assembly of 
active C3 and C5 convertases and formation of the terminal complement products, C5a 
and C5b-9. Finally, this work documented that in condition of ADAMTS13 deficiency, 
VWF-mediated formation of terminal complement products, particularly C5a, alters the 
endothelial anti-thrombogenic properties and induces microvascular thrombosis in a 
perfusion system.  
Altogether, the results demonstrated that VWF provides a platform for the activation of 
the alternative pathway of complement, which profoundly alters the phenotype of 
microvascular endothelial cells. These findings link hemostasis-thrombosis with the 
alternative pathway of complement and open new therapeutic perspectives in cTTP and 
in general in thrombotic and inflammatory disorders associated with endothelium 
perturbation, VWF release and complement activation.   
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Von Willebrand factor (VWF), a multimeric protein that has a central role in 
hemostasis, has been shown to interact with complement components. However results 
are contrasting and inconclusive. 
By studying 20 patients with congenital thrombotic thrombocytopenic purpura (cTTP) 
who can not cleave VWF multimers due to genetic ADAMTS13 deficiency, we 
investigated the mechanism through which VWF modulates complement, and its 
pathophysiological implications for human diseases. 
Using assays of ex-vivo serum-induced C3 and C5b-9 deposits on endothelial cells we 
documented that in cTTP complement is activated via the alternative pathway on the 
cell surface. This abnormality was corrected by restoring ADAMTS13 activity in cTTP 
serum, which prevented VWF multimer accumulation on endothelial cells, or by an 
anti-VWF antibody. This study documented: 1) ADAMTS13 is able to interact with FB, 
but how this interaction could modulate complement activation remains still unknown; 
2) VWF does not affect regulatory complement activity of FH for inactivation of C3b or 
dissociation of C3 convertase, in contrast to what reported in literature; 3) VWF 
interacts with C3b through its A2 domain and initiates a previously unrecognized 
Calcium-dependent mechanism of alternative pathway activation, with assembly of 
active C3 and C5 convertases and formation of the terminal complement products, C5a 
and C5b-9. Finally, this work documented that in condition of ADAMTS13 deficiency, 
VWF-mediated formation of terminal complement products, particularly C5a, alters the 
endothelial anti-thrombogenic properties and induces microvascular thrombosis in a 
perfusion system.  
Altogether, the results demonstrated that VWF provides a platform for the activation of 
the alternative pathway of complement, which profoundly alters the phenotype of 
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microvascular endothelial cells. These findings link hemostasis-thrombosis with the 
alternative pathway of complement and open new therapeutic perspectives in cTTP and 
in general in thrombotic and inflammatory disorders associated with endothelium 
perturbation, VWF release and complement activation.   
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Thrombotic microangiopathies 
The term “thrombotic microangiopathy” defines a lesion of the microvasculature 
characterized by detachment and swelling of the endothelial cells from the basement 
membrane, deposition of amorphous material in the subendothelial space, and 
intraluminal platelet aggregation leading to microthrombosis with partial or complete 
obstruction of the vessel lumina (Ruggenenti et al. 2001). 
Microvascular thrombosis is the mechanical obstruction of the vessels of microscopic 
bore (as arterioles and capillaries), caused by the accumulation of platelets, tissue factor 
and fibrin on the disrupted endothelium, happening when regulatory mechanisms are 
overwhelmed (Furie and Furie 2008). This process hampers blood perfusion, producing 
fragmented erythrocytes, called “schistocytes” or “helmet cells” and generating 
microangiopathic haemolytic anemia (MAHA) related to the destruction of the red 
blood cells (Tsai 2013).  
Thrombotic microangiopathies (TMA) manifest clinically with a spectrum of 
multisystemic rare diseases characterized pathologically by occlusive microvascular 
thrombosis and clinically by profound thrombocytopenia, MAHA, and variable signs 
and symptoms of organ ischemia (Moake 2002; Zheng and Sadler 2008). TMA is 
diagnosed in patients experiencing one or more episodes of MAHA and 
thrombocytopenia (platelet count less than 150000/mm3, hematocrit < 30%, 
haemoglobin < 10 g/dl, Lactate Dehydrogenase - LDH > 460 IU/l, undetectable serum 
Haptoglobin, red cell fragmentation in the peripheral blood smear) with fever. These 
symptoms reflect consumption and disruption of platelets and erythrocytes in the 
microvasculature of kidney, brain, and other organs that leads to their consequent tissue 
dysfunctions (Ruggenenti et al. 2001; Zheng and Sadler 2008; Zipfel et al. 2011). 
1. INTRODUCTION 
 
8 
 
TMA are considered a group of diseases with overlapping clinical characteristics and 
heterogeneous etiology, highlighting the multicausal nature of microvascular thrombotic 
disease. The two most important forms of TMA are thrombotic thrombocytopenic 
purpura (TTP) and haemolytic uremic syndrome (HUS) (Moake 2002; Tsai 2013).  
 
1.1 Thrombotic thrombocytopenic purpura 
The term TTP was first introduced in 1924 by Eli Moschcowitz who described a 16 
year-old female patient with abrupt onset of petechiae, acute febrile attack, haemolytic 
anemia, bleeding, renal failure, neurologic involvement and death within two weeks. 
Autopsy revealed widespread hyaline thrombi in terminal arterioles and capillaries of 
heart and kidney (Moschcowitz 2003). Other similar identified TTP cases were reported 
in a paper that was published in Blood in 1947 (Singer et al. 1947). The disease was 
clinically established in 1966 as a pentad of symptoms: thrombocytopenia, haemolytic 
anemia, renal dysfunction, neurological involvement and fever (Moschcowitz 2003). In 
the subsequent decades, thanks to the successful treatment of different TTP-like 
episodes, the disease was named the Upshaw-Schulman syndrome (Schulman et al. 
1960; Upshaw 1978), and up to 1980 almost 500 cases have been reported and deeply 
described in the literature (Cuttner 1980; Kennedy et al. 1980). Nowadays the term 
“thrombotic thrombocytropenic purpura” is used to describe microangiopathic 
haemolytic anemia and thrombocytopenia occurring in adults without an apparent 
alternative cause, with or without neurologic or renal abnormalities (George 2006; 
Scully et al. 2012). Neurological symptoms can be seen in more than 90% of patients 
during the entire course of the disease, while renal impairment has been reported in 
around 25% of patients, although severe renal insufficiency is rare (Ruggenenti et al. 
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2001). In the majority of the cases TTP manifests as a single, sporadic acute episode, 
which can cause death if it is not treated. The 20 - 50 % of patients that survive from the 
acute bout develop the chronic form of the disease with a relapse within 6 months 
(George 2000; Sadler 2008).  
 
1.1.1 Classification 
TTP has been considered one of the most intriguing and mysterious disorders for years, 
and its pathogenesis remained disregarded until the end of 19th century. In 1982, Moake 
described patients with chronic relapsing TTP with circulating “unusually large” (UL) 
multimers of von Willebrand Factor (VWF), a multimeric glycoprotein that plays an 
essential role in platelet-mediated primary hemostasis (Moake et al. 1982). Moake 
proposed that his patients lacked a VWF depolymerase, which later was named VWF-
cleaving protease (VWF-CP) (Furlan et al. 1996; Tsai 1996) and identified as a new 
member of the super family ADAMTS (A Disintegrin-like And Metalloprotease with a 
ThromboSpondin type1) designated as ADAMTS13 (Gerritsen et al. 2001; Soejima et 
al. 2001). Since then, TTP diagnosis remained clinical but the measurement of 
ADAMTS13 activity within patient plasma could help to confirm the diagnosis and 
monitor the course of the disease. 
Today, two forms of acute TTP with severe ADAMTS13 deficiency (<5% of that in 
normal human plasma) are distinguished: 
- Congenital severe ADAMTS13 deficiency is found in hereditary TTP, also called 
Upshaw–Schulman syndrome, and it is the result of compound heterozygous or 
homozygous mutations in the ADAMTS13 gene (Levy et al. 2001; Kokame et al. 2002; 
Matsumoto et al. 2004; Veyradier et al. 2004; Donadelli et al. 2006; Schneppenheim et 
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al. 2006; Kokame et al. 2008). Severe ADAMTS13 deficiency is present both during 
acute and remission phases of the disease, in the absence of anti-ADAMTS13 
autoantibodies. Congenital TTP (cTTP) cases are extremely rare (1 case per million 
person years) and represent approximately 10% of all TTP cases (Galbusera et al. 
2009). Based on reported congenital TTP case reports, 48% of patients develop TTP in 
the neonatal period, 31% during childhood (2 months to 18 years) and 21% during 
adulthood (Lotta et al. 2010). The clinical severity of disease episodes varies between 
patients. Some have asymptomatic episodes of thrombocytopenia and anaemia, whereas 
others have multi-organ failure (Schneppenheim et al. 2003). 
- Acquired idiopathic TTP is an immune-mediated, non-familial form of TTP that most 
likely accounts for the majority of cases (from 60% to 90%) reported to date as acute 
idiopathic or sporadic TTP. In acquired TTP, severe ADAMTS13 deficiency is the 
result of circulating anti-ADAMTS13 autoantibodies either inhibiting ADAMTS13 
activity (Furlan et al. 1998; Tsai and Lian 1998; Shelat et al. 2006) or enhancing 
ADAMTS13 clearance (Scheiflinger et al. 2003; Rieger et al. 2005). Of note, only about 
two thirds of patients clinically diagnosed with acute idiopathic TTP have been found to 
be severely deficient in ADAMTS13 activity (Lammle et al. 2008; Sadler 2008), with 
some patients having normal or moderately reduced ADAMTS13 activity (Zheng et al. 
2004; Bettoni et al. 2012). The ADAMTS13 cysteine-rich and spacer domains have 
been shown to be the primary autoimmune target in patients with TTP (Klaus et al. 
2004; Luken et al. 2005), but the propeptide and thrombospondin domains could also be 
targeted by anti-ADAMTS13 autoantibodies (Luken et al. 2006). It has been reported 
that the characterization of anti-ADAMTS13 antibodies (IG isotype, titre and inhibitory 
effect) could have a prognostic value for the prediction of relapse and the progression of 
the disease (Ferrari et al. 2007). Evidence of the pathogenetic role of TTP-associated 
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anti-ADAMTS13 autoantibodies is derived by finding that they usually disappear from 
the circulation when remission is achieved by effective treatment and this occurs in 
parallel with the normalization of ADAMTS13 activity. The transient nature of the 
acute idiopathic TTP raises the possibility that the antibodies to the protease represent a 
deranged response to certain triggering events (Tsai and Lian 1998). 
A particular diagnosis of acquired TTP is defined as secondary TTP, and it comprises 
about 40% of all cases of TTP. The term secondary TTP has been proposed for cases 
with an associated clinical condition, to distinguish them from the classical idiopathic 
form of TTP. Oxidative injury, free radical formation, a reduced production of 
prostacyclin, impaired fibrinolysis, the presence in the plasma of platelet-aggregating 
agents and an abnormal processing of VWF multimers have been proposed to be 
pathogenically relevant for the development of secondary TTP (Furlan and Lammle 
2001). Secondary TTP is generally associated with cancer, hematopoietic stem cell or 
solid organ transplantation, preeclampsia, systemic infections, drug toxicity, or other 
predisposing conditions. Typically, secondary TTP is not associated with severe 
ADAMTS13 deficiency and rarely responds to the standard therapy of  plasma infusion 
(Sadler 2006). The mechanism of secondary TTP is poorly understood, and a probable 
etiology may involve endothelial damage. 
 
1.1.2 Incidence and risk factors 
TTP is a rare disease with an incidence of approximately 2-10 cases per million person 
years, with a female predominance (female:male ratio, 3:2 to 5:2), it most frequently 
occurs in the fourth decade of the life. Recently, greater awareness and perhaps 
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improved diagnostic facilities have given the impression that the incidence is increasing 
(Terrell et al. 2005; Galbusera et al. 2009; Kappler et al. 2014). 
TTP sometimes occurs in association with pregnancy, autoimmune disease, allogeneic 
bone marrow transplantation, infection, and drugs including quinine, cyclosporin, 
calcineurin inhibitor, mitomycin, ticlopidine and clopidogrel (Elliott et al. 2003). Above 
all, pregnancy is a prominent risk factor for the development of TTP. Pregnancy 
associated TTP is reported to represent 5-10% of all adult TTP cases and is estimated to 
occur in 1 out of 198,000 pregnancies (Moatti-Cohen et al. 2012). However, pregnancy 
can trigger TTP in women who have congenital or acquired ADAMTS13 deficiency 
(George 2003). Autoimmune diseases of various kinds have been described in 
association with severe ADAMTS13 deficiency and thrombotic microangiopathy. 
Patients with idiopathic and severe ADAMTS13 deficiency (<5%) often have 
manifestations of systemic lupus erythematosus, polyarthritis, extramembranous 
glomerulonephritis, or autoimmune thyroiditis (Coppo et al. 2004). The incidence of 
TTP following hematopoietic progenitor cell transplantation varies considerably, 
ranging from 0% to 74% probably due to confounding complications associated with 
the transplant (George et al. 2004). Infection is recognized to be a triggering causal 
factor for acute TTP as it can precipitate an episode in patients with other predisposing 
causal factors such as low ADAMTS13 activity level (Morgand et al. 2014). Of the 
wide variety of drugs observed to cause immune TTP, quinine antibiotics are the first 
described and best-studied probably due to their broad spectrum of action in patients 
following chemotherapy (Cheah et al. 2009). Ticlopidine, a potent antiplatelet agent, 
causes thrombotic microangiopathy with a frequency of a 1 case per 1600 to 5000 
patients treated, often after 2 to 12 weeks of drug use, usually by inducing the formation 
of autoantibodies to ADAMTS13 (Tsai et al. 2000). Clopidogrel, another related 
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antiplatelet drug, has replaced ticlopidine in combination with aspirin, and has been 
associated with TTP with an incidence of 1.2 to 27.8 per million (Pisoni et al. 2001). 
Lastly, different studies reported episodes of human immunodeficiency virus (HIV)-
associated TTP, defined as a subgroup of secondary TTP and considering the virus as an 
identified precipitant of the disease (Hart et al. 2011).  
 
1.1.3 Therapy 
In 1960 Schulman et al demonstrated for the first time the potential value of plasma 
therapy in TTP, reporting a case of an 8-year old girl with repeated episodes of 
thrombocytopenia and haemolytic anaemia who was treated with plasma infusions 
(Schulman et al. 1960). During the next 11 years, Upshaw successfully treated 32 TTP-
like episodes of thrombocytopenia and microangiopathic haemolysis with plasma 
infusions. Upshaw suggested that the efficacy of plasma therapy for TTP could be 
explained as it replaces a single plasma factor that was deficient in the blood of TTP 
patients (Upshaw 1978).  
Up to now, plasma therapy is still conventionally considered the gold standard for the 
treatment of all forms of TTP (Shepard and Bukowski 1987; George 2000; Kremer 
Hovinga and Meyer 2008). Therapeutic plasma administration transformed the 
historically fatal prognosis of TTP (10% survival), leading to the current overall 
survival rates of 90%. Patients with congenital ADAMTS13 deficiency are treated 
during acute episodes by infusion of fresh frozen plasma containing donor ADAMTS13 
to compensate for their deficiency. Prophylactic treatment with plasma infusion every 
2-3 weeks is used to prevent relapses (Barbot et al. 2001; Kentouche et al. 2002). In 
patients with acquired TTP, plasma exchange (PEX) has been the standard of care since 
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the early 1990s, when a randomized clinical trial established that PEX is more effective 
than plasma infusion in the treatment of the disease (Rock et al. 1991). PEX is effective 
because it has the additional benefit of removing the anti-ADAMTS13 inhibitory 
antibodies and inflammatory cytokines from the patient’s blood. Moreover, high-dose 
corticosteroids are frequently used as an adjunct therapy not only to reduce major 
complications risks of PEX, such as infection, thrombosis or haemorrhages, but also to 
provide a more durable response (Kremer Hovinga and Meyer 2008; Som et al. 2012). 
However, there is no indication for administrating steroids to patients with congenital 
TTP. In recurrent or refractory TTP, which occurs in 20-30% of cases, treatment 
options include PEX with splenectomy or others immunosuppressive therapies, but the 
results are variable and often inconclusive (Yomtovian et al. 2004). The anti-CD20 
chimeric monoclonal antibody rituximab (Smith 2003) has been used successfully as an 
additional treatment or pre-emptive therapy in patients with chronic TTP, obtaining a 
progressive disappearance of inhibitors with a subsequent increase of ADAMTS13 
protease activity and maintenance of a remission disease-free state (Chemnitz et al. 
2002; Tsai and Shulman 2003; Bresin et al. 2009). 
Novel successful approaches to treatment of hereditary TTP include infusions of 
recombinant ADAMTS13 (Plaimauer et al. 2011), and plasma cryosupernatant (Moake 
et al. 1985) or solvent-detergent treated plasma (Kentouche et al. 2002) as a source of 
the exogenous protease in single patients. The intermediate-purity plasma-derived 
Factor VIII concentrate (FVIII) Koate (Kedrion Biopharma) contains the highest 
amount of ADAMTS13 activity yet reported and has been used effectively in 
treating congenital TTP (Naik and Mahoney 2013) as well as refractory TTP in 
combination with rituximab, corticosteroids and plasma therapy (Pandey et al. 2015). 
The anti-thrombotic efficacy of anti-VWF agents, such as ARC1779 (Diener et al. 
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2009; Spiel et al. 2009) or the nanobody ALX-0681 (Callewaert et al. 2012) and 
Caplacizumab (Peyvandi et al. 2016), has been proved in several preclinical and clinical 
studies, although with some limitations (Cataland et al. 2012). Other promising agents 
including N-acetylcysteine, bortezomib, and inhibitors of the glycoprotein-Ib/IX-VWF 
axis are under evaluation (Coppo and Froissart 2015). N-acetylcysteine, commonly used 
to reduce the viscosity of mucous secretion in respiratory disorders, has been shown to 
reduce VWF multimers in mouse and baboon models (Tersteeg et al. 2017) and was 
successfully used in conjunction with plasma exchange, corticosteroids and rituximab in 
a patient with refractory acquired TTP (Li et al. 2014). 
 
1.1.4 Pathogenetic mechanisms 
VWF is a multimeric plasma glycoprotein synthesized in endothelial cells and 
megakaryocytes. It mediates the initial platelet adhesion to the subendothelium of the 
damaged vessel wall at high shear rates. From the storage organelles (Weibel-Palade 
bodies) of the activated endothelial cells, VWF is secreted in the form of unusually 
large VWF multimers (ULVWF), which are haemostatically active. In conditions of 
endothelial damage and shear stress, VWF undergoes a conformational transition from a 
globular state to an extended chain conformation, with the exposure of intra-molecular 
globular domains (Siedlecki et al. 1996). At these sites, encountered in arterioles and 
capillaries, the large VWF filaments apparently unfold (Zhang et al. 2009) and establish 
multiple interactions with receptors such as glycoprotein Ib/V/IX and IIb/IIIa on the 
platelet surface (Federici et al. 1989). The numerous interactions of repeating binding 
sites on extended filaments of VWF may dramatically increase the stability of the bonds 
between platelet and VWF, and thus lead to platelet agglutination and vessel repair 
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(Moake et al. 1986). In normal conditions, ADAMTS13 regulates VWF-platelet 
aggregation by cleavage extended filaments of VWF into small multimers (Furlan et al. 
1998; Tsai and Lian 1998; Soejima et al. 2001). Only the highly polymeric forms of 
VWF are haemostatically active whereas the circulating VWF in normal plasma shows 
only weak binding affinity for platelets (Moake et al. 1986). (Fig. 1-1) 
Patients with TTP generally have a congenital or acquired severe deficiency in the 
enzyme ADAMTS13. This deficiency leads to the accumulation of ULVWF multimers 
within the circulation and on endothelial cell surface (Moake et al. 1982), which in turn 
develops into an uncontrolled formation of systemic platelet-rich thrombi into the 
microvasculature of TTP patients, without endothelial injury. The pathophysiological 
hallmarks of acute TTP bouts are VWF-platelet-rich thrombi occluding the 
microvasculature (Asada et al. 1985). In consequence, the cause of the haemolytic 
anaemia is the mechanical fragmentation of erythrocytes during flow through partially 
occluded microvessels, while thrombocytopenia is the likely result of platelet 
consumption in the microcirculation (Tsai 2013). This pathogenetic mechanism results 
in a progressive obstruction in microcirculation of some organs like brain, kidney, 
pancreas, heart and spleen with defects caused in organ functionality (Ruggenenti et al. 
2001). (Fig. 1-1) 
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1.1.5 VON WILLEBRAND FACTOR 
In 1926 Dr. Erik Adolff von Willebrand suggested for the first time the existence of 
VWF from his description of the inherited bleeding disorder “pseudo haemophilia”. 
This condition was later renamed von Willebrand disease (VWD), which, in 1957, was 
confirmed to be determined by the lack of a plasma factor (Nilsson et al. 1957). The 
first immunological detection of what is presently known as VWF was done in 1971 
and initially named FVIII-related antigen (Zimmerman et al. 1971). In the 1980s the 
protein was clearly characterized by various cloning experiments (Sadler et al. 1985). 
A
B
Injury to arterioles or capillaries:
Unfolded VWF
Shear flow
Injured vessel
platelets
VWF-platelet aggregate
Normal circulation:
ULVWF
shear
ADAMTS13
VWF 
small
multimers
C TTP with ADAMTS13 deficiency:
Unfolded
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VWF-platelet aggregation
ULVWF
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Partially
unfolded
VWF
Figure 1-1. Pathogenesis of TTP caused by ADAMTS13 deficiency.  
A. Multimeric VWF adheres to damaged endothelial cells or to connective tissue exposed in the inquired 
vessel wall. Platelets adhere to VWF through their membrane receptors. B. In normal flowing conditions 
ULVWF multimers are stretched and cleaved by ADAMTS13, limiting platelet adhesion. C. In TTP, 
where ADAMTS13 is deficient, VWF-dependent platelet accumulation continues, eventually causing 
microvascular thrombosis, hemolytic anemia and thrombocytopenia. 
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1.1.5.1 Molecular structure 
The VWF gene (VWF) is located on chromosome 12 and contains 52 exons with 178 kb 
of DNA encoding an 8.9 kb mRNA (Ginsburg et al. 1985). The translated product 
precursor protein is initially synthesized as a monomer, which is also referred to as pre-
pro-VWF, consisting of 2813 amino acids with a molecular weight of 380 kDa 
(Goodeve 2010). Pre-pro-VWF contains five distinct types of repeated domains as 
depicted in Fig. 1-2, which mediates interactions with other molecules: 
- Signal (SS) and Pro- peptide, important for the intracellular trafficking and 
maturation of the protein (Titani et al. 1986; Haberichter et al. 2000). 
- D domains, contain binding sites for factor VIII and heparin (Foster et al. 1987; 
Fujimura et al. 1987) and are important for self-multimerization process (Haberichter et 
al. 2000). 
- A domains. The A1 domain contains a binding site for platelet GPIbα in the 
GPIb-IX-V complex and for collagen VI (Mohri et al. 1988). It can also bind to heparin-
like molecules (Fujimura et al. 1987) and to sulfatides (Christophe et al. 1991), playing 
a potentially important role in the immobilisation of soluble VWF onto complex 
extracellular matrices (Ruggeri 1997). Of note, it has been reported that A1 domain 
negatively regulates ADAMTS13 activity on VWF (Nishio et al. 2004). The binding 
and the cleavage sites for ADAMTS13 are located in the A2 domain (Furlan et al. 1996; 
Tsai 1996). The A3 domain includes the binding sites for collagen I and III (Pareti et al. 
1987) and it is proposed to serve as a docking site for ADAMTS13 (Dong et al. 2003). 
- C domains, which include the binding site for the platelet integrin receptor αIIbβ3 
(GPIIb/IIa) (Ruggeri et al. 1982) and, with C-terminal CK domain, are essential for the 
self-dimerization process of the protein (Katsumi et al. 2000). 
1. INTRODUCTION 
 
19 
 
 
During its translation, a series of events occur. First, in the endoplasmatic reticulum, 
pre-pro-VWF subunits engage into a homodimeric structure via disulfide bridge 
formation in the C-terminal domains (Katsumi et al. 2000). Subsequently, the VWF 
dimers are transported to the Golgi complex, where self-multimerization of pro-peptides 
leads to the production of differentially sized VWF multimers, that contain as many as 
60 subunits (Haberichter et al. 2000). After that, the pro-peptide is separated from the 
mature subunit via proteolytic processing by Furin, which then assists in the trafficking 
of mature multimeric VWF (van de Ven et al. 1990). A second important event in the 
maturing of the VWF protein is its extensive glycosylation with both O- and N-linked 
glycans (Titani et al. 1986). 
The production of VWF is restricted to megakaryocytes (Sporn et al. 1985) and 
endothelial cells (Wagner et al. 1982). In both cell types, mature VWF is targeted to 
storage organelles: α-granules in platelets and Weibel-Palade bodies (WPBs) in 
endothelial cells. Release of VWF multimers into the bloodstream from α-granules 
requires activation of platelets by a variety of agents including histamine (Hamilton and 
Sims 1987), thrombin (Levine et al. 1982), fibrin (Ribes et al. 1987), calcium ionophore 
A23187 (Loesberg et al. 1983), the vasopressin analogue 1-desamino-8-D-arginine 
vasopressin (DDAVP) (Mannucci et al. 1975) and phorbol myristate acetate (Loesberg 
et al. 1983). In contrast, VWF multimers are released from endothelial cells in both a 
constitutive and regulated fashion in response to a variety of physiological stimuli such 
Figure 1-2. VWF domain structure. 
Cartoon representing domain organization of VWF SP, signal peptide; D1-4, D domains; A1-3, A 
domains; C1-6, C domains; CK, C-terminal Cysteine knot domain. 
propeptide
D1 CKA1 A2 A3 D4 C1 C2 C3 C4 C6D2 D3SP C5D’
1. INTRODUCTION 
 
20 
 
as thrombin, histamine, fibrin, and the terminal complement complex C5b-9 (Wagner 
1990; Nightingale and Cutler 2013). The half-life of endogenous VWF released into 
circulation is highly individual-dependent and may vary between 6 and 26 h, with 
particular reference to blood group ABO(H) structures (Borchiellini et al. 1996; 
Gallinaro et al. 2008). Circulating VWF multimers have a plasma concentration of 
approximately 10 µg/ml and range in size from 500 KDa to 20,000 KDa (Mayadas and 
Wagner 1991). 
 
1.1.5.2 VWF functions and interactions 
VWF is a glycoprotein secreted into bloodstream as a large polymeric form but exists in 
normal plasma as a series of multimers with progressively smaller sizes. In normal 
physiological conditions, the predominant source of circulating VWF comes from 
endothelial cells (Wagner 1990). There are three types of VWF in the human body: 
soluble plasma VWF, basement membrane VWF (extracellular matrix VWF) and 
cellular VWF. Only the larger extracellular multimers of VWF are effective in the 
control of haemostasis and their biological effectiveness depends directly on the size of 
the concatamers. The primary function of VWF is to support platelet adhesion at sites of 
microvascular injury, where it binds to type I, III and VI collagen and other components 
of the exposed vessel wall, becoming rapidly unfolded and activated by high levels of 
shear stress at blood-vessel wall boundary (Ruggeri 1999). Another important role for 
VWF is to mediate platelet-platelet interactions through two membrane receptors: GPIb 
and GPIIb-GPIIIa complexes (Federici et al. 1989). Notably, unusually large VWF 
multimers derived from endothelial cells are more efficient in platelet interactions than 
the largest VWF forms present in normal plasma (Moake et al. 1986). Shear-induced 
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interactions of platelets in the presence of VWF are essential to prevent excessive 
bleeding, as demonstrated by platelet agglutination abnormalities in VWD patients, who 
have a quantitative deficiency of VWF (Nilsson et al. 1957; Trossaert et al. 2011).  
Apart from platelet plug formation, VWF also acts as a “molecular bus” since it 
circulates in the bloodstream in association with other proteins (Lenting et al. 2012). 
The first and best characterized example of the activity as a circulating carrier is VWF’s 
ability to associate with FVIII (Weiss et al. 1977). Factor VIII (FVIII) is a cofactor of 
the intrinsic clotting cascade, and its deficiency manifests as haemophilia A. VWF is 
considered as the consort of FVIII, since in its absence, FVIII is rapidly removed from 
the circulation, resulting in the pathological progression (Tuddenham et al. 1982). Other 
proteins that are associated with VWF in the circulation include ADAMTS13, factor H, 
osteoprotegerin (Shahbazi et al. 2007), and galectin-1 and 2 (Saint-Lu et al. 2012). With 
regard to ADAMTS13, it has been speculated that binding to VWF would facilitate 
immediate action of the protease to cleave the active platelet-binding VWF 
conformation at the site of injury (Feys et al. 2009; Crawley et al. 2011). Recent reports 
have also identified VWF as an additional protein partner for FH, the major negative 
regulator of the alternative pathway of the complement cascade. Nevertheless, the 
physiological meaning of this interaction has not yet been clearly clarified (Feng et al. 
2013)c;(Rayes et al. 2014). Concerning the other proteins associated with VWF, their 
mutual effects on each other’s functions has been only sparsely investigated here. 
Aside from its well known haemostatic potential, VWF has been becoming involved in 
several pathologic processes beyond coagulation: there is evidence of VWF activity in 
inflammation processes since its deficit provokes impaired P-selectin surface expression 
and subsequent defects in leukocytes recruitment in the early stage of inflammation 
(Denis et al. 2001); recent researches have reported that endothelial VWF deficiency 
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can promote angiogenesis (Starke et al. 2011); in vitro studies have revealed that VWF 
directly stimulates smooth muscle cell proliferation (Qin et al. 2003) and preliminary 
studies have suggested that VWF reduced metastasis by inducing cell death of tumour 
cells (Terraube et al. 2007). 
 
1.1.6 ADAMTS13 
In 1982 Moake and co-workers provided the first description of a “VWF-depolymerase” 
that normally cleaves ULVWF to prevent intravascular platelets aggregation and 
thrombosis that characterize TTP (Moake et al. 1982). In 1996, a candidate VWF-
cleavage protease (VWF-CP) was identified in human plasma by Tsai (Tsai 1996) and 
independently by Furlan (Furlan et al. 1996), and defined as a metal-dependent protease 
that requires divalent cations for its activity. In 2001 the VWF-CP was finally purified, 
cloned and characterized, and identified as the 13rd member of the super family 
ADAMTS (Fujikawa et al. 2001; Levy et al. 2001; Zheng et al. 2001). 
 
1.1.6.1 Molecular structure 
The ADAMTS13 gene (ADAMTS13) contains 29 exons spanning approximately 37 Kb 
on chromosome 9q34 (Levy et al. 2001; Soejima et al. 2001; Zheng et al. 2001), and 
encodes a 4.7 Kb transcript. ADAMTS13 is primarily expressed in the hepatic stellate 
cells (Zhou et al. 2005), but it is produced also in placenta, skeletal muscle, certain 
tumor cell lines, platelets (Suzuki et al. 2004), podocytes (Manea et al. 2007) and 
endothelial cells (Turner et al. 2006; Wang et al. 2016). The concentration of 
ADAMTS13 in plasma of healthy volunteers is approximately 1 µg/ml (Gerritsen et al. 
2001) and its half-life is 2-3 days (Furlan et al. 1999). Up to now, there is no clear 
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evidence for alteration in transcriptional activity of ADAMTS13 that accounts for 
diminished function of the protease in plasma (Claus et al. 2005). 
The full length ADAMTS13 transcript encodes a precursor protein of 1427 aminoacid 
residues. The protein undergoes extensive glycosylation and other post-translation 
modifications that greatly influence its secretion (Ricketts et al. 2007; Zhou and Tsai 
2009). Consistently with the ADAMTS superfamily, ADAMTS13 exhibits a multi-
domain structure (Zheng et al. 2001) (Fig. 1-3): 
- Signal and propeptide domains, which are only responsible for secretion and 
preservation of the integrity of the newly synthesized protease (Majerus et al. 2003). 
- Metalloprotease domain, which contains zinc-coordinating and calcium-binding 
residues that control the cleavage activity of the protein (Di Stasio et al. 2008). Of note, 
this domain alone does not have the ability to specifically bind and cleave VWF. The 
other non-catalytic domains are necessary for substrate recognition (Gao et al. 2012). 
- Disintegrin-like domain, functionally coupled with the metalloprotease domain 
(Ai et al. 2005). It is named for the primary sequence similarity to the snake venom 
disintegrins and it contains important exosites for VWF binding (Akiyama et al. 2009). 
- Thrombospondin (TSP) repeat modules, which are very well conserved among 
ADAMTS family proteases. TSP repeats contain the glycosylation sites and cooperate 
in substrate recognition (Gao et al. 2012) also with disulfide bonds of VWF (Yeh et al. 
2010). Although the TSP-1 repeat between the Dis- and Cys rich- domains is well 
conserved within the ADAMTS proteases, the arrangement and number of TSP-1 
modules following the spacer domain varies. 
- Cysteine-rich domain, structurally similar to the Disintegrin-domain. It appears 
to be important for VWF binding and cleavage (Soejima et al. 2003; Klaus et al. 2004). 
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- Spacer domain, which has the highest binding affinity for the A2 site of VWF 
(Jin et al. 2010; Pos et al. 2010). The spacer and the Cys-Rich domains function closely 
with and similarly to one and other (Soejima et al. 2003; Luken et al. 2005). 
- CUB domain, characteristic for ADAMTS13. The two CUB domains in the C-
terminus of the protein have been shown to mediate binding with VWF for the initial 
docking to the substrate (Zhang et al. 2007; Zanardelli et al. 2009). However, in the 
presence of shear stress, the CUB1 peptide seems to inhibit proteolysis of VWF (Tao et 
al. 2005). 
After cleavage of the signal peptide and propeptide, mature ADAMTS13 is formed 
consisting of 1353 amino acids with a calculated molecular weight of 145 KDa, and an 
observed mass from 150 to 190KDa due to its extensive glycosylation (Zheng et al. 
2001).  
 
The entire crystal structure of ADAMTS13 has not been obtained yet. The crystal 
structure of the region encompassing the disintegrin-like, TSP-1, cysteine-rich and 
spacer domain (DTCS) of ADAMTS13 has been solved (Akiyama et al. 2009), and the 
metalloprotease domain modeled based upon the crystal structure of ADAMTS1, 4 and 
5 (Gerhardt et al. 2007; Mosyak et al. 2008), since it is well conserved within the 
ADAMTS family. Thus, the ADAMTS13-MDTCS (metalloprotease>spacer domain) 
model is currently available. 
 
Figure 1-3. ADAMTS13 domain structure. 
Cartoon representing domain organization of ADAMTS13. S, signal peptide; P, propeptide; M, 
metalloprotease domain; D, Disintegrin-like domain; T1-8, Thrombospondin  repeat modules; C, Cysteine-
rich domain; S, Spacer domain; CUB1-2, CUB domains. 
M D T1 C S T2 T3 T4 T5 T6 T7 T8 CUB1 CUB2PS
1. INTRODUCTION 
 
25 
 
1.1.6.2 ADAMTS13-VWF interaction 
VWF is the only known ADAMTS13 substrate to date. The proteolytic cleavage of 
unusually large multimers of VWF by ADAMTS13 is essential for maintaining the 
delicate balance between haemostasis and coagulation. The remarkable substrate 
specificity is largely achieved by the extensive interactions between VWF and non-
catalytic domains of ADAMTS13 (Majerus et al. 2005; Gao et al. 2008; Akiyama et al. 
2009). Structures remote from the cleavage site (Y1605-M1606) into VWF are also 
known to influence proteolysis (Nishio et al. 2004; Zanardelli et al. 2006). The multiple 
interactions that exist between VWF and ADAMTS13 are illustrated in Fig. 1-4 
(Zanardelli et al. 2009; Crawley et al. 2011). Under normal physiological conditions, 
VWF circulates in plasma in a “ball-of-yarn” conformation where the A2 domain is 
hidden within a hydrophobic core comprised of vicinal Cys residues located at the C 
terminus of the domain (Luken et al. 2010). According to multi-domain binding model, 
firstly ADAMTS13 and VWF make contact with a modest affinity through their C-
terminal domains, which are constitutively exposed. As a consequence of changes in 
local shear stress conditions and the growing of a haemostatic plug, VWF unravels. 
Conformational changes in VWF lead to the exposure and higher affinity binding of 
exosites present in N-terminal region of VWF and ADAMTS13: the spacer domain of 
the protease recognizes VWF residues Glu1660-Arg1668 (Gao et al. 2008); the 
ADAMTS13 Disintegrin-like domain interacts with a complementary exosite on VWF 
involving Asp1614 in a critical binding that helps orientating the scissile bond in the 
active center of ADAMTS13 (de Groot et al. 2009); VWF1596-1604 N-terminal 
sequence contains a structural important determinant that makes VWF Leu1603 and 
Val1604 residues as docking sites for a complementary subsite in ADAMTS13 
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involving Leu198, Leu232, and Leu274 (Xiang et al. 2011). Together, these interactions 
position the scissile bond in the catalytic cleft of ADAMTS13. At this stage, additional 
binding interactions occurring between adjacent domains finally lead to VWF cleavage. 
Once cleavage has taken place, there is a consequent reduction in affinity of protease 
and substrate, enabling ADAMTS13 to recycle (Crawley et al. 2011). Of note, 
ADAMTS13 does not require a fixed spatial relationship between the scissile bond and 
auxiliary binding sites on the substrate. The mobility of protease domains suggests that 
a spectrum of ADAMTS13 conformations exist, with different possibilities of 
interaction modes with VWF molecules, which also present a wide range of 
conformations under shear-stress conditions in circulation (Gao et al. 2008; Akiyama et 
al. 2009). 
1. INTRODUCTION 
 
27 
 
 
Figure 1-4. ADAMTS13 cleavage of VWF. 
Crawley and co-workers in 2011 proposed that the cleavage of ADAMTS13 occurs in 7 distinct steps, 
as follows: ADAMTS13 can reversibly bind to globular VWF (step 1). When shear stress induces the 
unfolding of VWF, additional exosite binding sites on VWF are revealed (step 2). The ADAMTS13 
spacer domain recognises residues Glu1660-Arg1668 (step 3) revealed when the vicinal Cys 
disulphide bind plug is extracted from the hydrophobic core of the A2 domain. This increases the 
affinity of ADAMTS13 for VWF. An ADAMTS13 disintegrin-like exosite involving Arg349 
recognises a complementary site of VWF compromising VWF1614 in a critical but low affinity 
interaction (step 4). Thereafter an essential contact is made between VWF Leu1603 and a 
complementary S3 subsite in ADAMTS13 involving Leu198, Leu232 and Leu274 (step 5). Together 
these interactions bring the Tyr1605-Met1606 scissile bond over the ADAMTS13 active site. This 
allows the P1 (1605) and P1’ (1606) residues to engage their respective S1 and S1’ subsite pockets 
involving Leu151/Val195 (S1) and Asp252-Pro256 (S1’) respectively (step 6). Once cleavage has 
taken place (step 7) there is a reduction in the affinity between ADAMTS13 and VWF, enabling 
ADAMTS13 to recycle. Image modified from (Crawley et al. 2011). 
ADAMTS13
VWF monomer
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1.1.6.3 ADAMTS13 functions 
The primary and unique activity of ADAMTS13 consists of regulating the size of 
circulating VWF multimers by cleavage of the unusually large concatamers into smaller 
ones, thereby determining their haemostatic (and proinflammatory) potential (Tsai 
2006). ADAMTS13 cleaves VWF as soon as it is released from endothelial cells, 
resulting in the shedding of ULVWF from the endothelial cell surface and in 
fragmentation of VWF strings, preventing platelet adhesion (Dong et al. 2003). 
Although ADAMTS13 is constitutively active, VWF is not cleaved without substantial 
changes in its secondary structure to expose the cryptic cleavage site to the surface. 
Indeed, ADAMTS13-VWF complexes can be detected in normal human plasma 
suggesting that ADAMTS13 can bind native VWF without cleaving it (Feys et al. 
2009). Structural studies have provided evidence that ADAMTS13 contains several 
VWF-binding exosites that might function independently to interact with the substrate 
(Gao et al. 2008; Feys et al. 2009). According to the proposed multi-domain binding 
model, substrate recognition takes place in 7 distinct steps, as described in details in the 
section above and in Fig. 1-4. Substrate cleavage only occurs when VWF is in a sheared 
elongated conformation that provides high affinity binding between N-terminal domains 
of VWF and the complementary sites on ADAMTS13 (Crawley et al. 2011).  
ADAMTS13 cleaves VWF precisely at the scissile bond Tyr1605 - Met 1606 on its 
central A2 domain (Furlan et al. 1996; Tsai 1996). VWF Tyr1605 has an aromatic side 
chain, which is a determinant of its adjustment in the S1 pocket that accommodates 
ADAMTS13 Leu151 and Val195 amino acids (Xiang et al. 2011). VWF Met1606 
interacts with ADAMTS13 residues Asp252 - Pro256 that forms a specific compartment 
called S1’ pocket (de Groot et al. 2010). It is proposed that VWF Leu1603, Tyr1605, 
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and Asp1614 contact ADAMTS13 Leu198, Val195, and Arg349, respectively, ensuring 
that the scissile bond is brought into position over the active centre of the protease for 
cleavage to occur (Xiang et al. 2011). In common with the other proteases of ADAMs 
family, the metalloproteinase domain of ADAMTS13 has a putative zinc ion catalytic 
site, one predicted calcium ion-binding site and conserved Asp284 and Met249 that 
support the active site of the protein (Zheng et al. 2001). The role of divalent metal ions 
in ADAMTS13 activity is not fully understood. However, some studies reported that 
cations other than zinc can support enzyme activity, and might mediate protein structure 
(Anderson et al. 2006). Of note, VWF does not have metal ion-dependent adhesion sites 
(MIDAS); so that it is unable to bind divalent ions contained in ADAMTS13.  
VWF proteolytic activity of ADAMTS13 ranges from 40% to 170% in normal plasma 
in children and adults, including the neonatal period, but it may be lower in newborn 
and premature infants up to 6 months of age (Schmugge et al. 2004). Decreased 
ADAMTS13 activity levels have also been reported in healthy individuals older than 65 
years and pregnant woman during the last two trimesters of pregnancy (Mannucci et al. 
2001). In addition, ethnic differences have been reported; for example, Chinese 
individuals seem to possess lower ADAMTS13 antigen levels than Caucasians, 
although this result remains to be corroborated with ADAMTS13 activity levels (Feys 
et al. 2006). 
Cysteine residues in the VWF C-domains are in thiol forms exposed on the surface of 
the quaternary structure of VWF multimers, and capable of forming disulfide bonds 
upon exposure to high shear stress (Choi et al. 2007). Yeh and co-workers demonstrated 
that some of these thiols are targeted and reduced by ADAMTS13, providing evidence 
that ADAMTS13 possess an additional reducing activity on its substrate VWF. Of note, 
the disulfide bond reducing activity does not disrupt both VWF multimer structures and 
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proteolytic cleavage by ADAMTS13 (Yeh et al. 2010). However, the physiological 
significance of this ADAMTS13 activity remains to be further investigated, but it may 
be speculated that it could prevent elongation of VWF multimers via shear-induced 
VWF thiol-disulfide exchange. 
 
1.1.6.4 Regulation of ADAMTS13 activity on VWF 
There have been no physiological inhibitors of ADAMTS13 identified to date. 
ADAMTS13 is secreted as an active protease (Majerus et al. 2003), and it is slowly and 
continuously released into the circulation, providing constant cleavage of long anchored 
VWF strings secreted from the neighboring endothelial cells (Dong et al. 2003; Turner 
et al. 2009) and of circulating sheared ULVWF (Tsai et al. 1994; Tsai 2006). Upon 
secretion, ADAMTS13 is essentially regulated at substrate level (Mannucci et al. 2004; 
Feys et al. 2009), and it could be “consumed” as a consequence of a compensating 
phenomenon of accumulating agglutinating forms of VWF (Mannucci et al. 2001). 
However, several endogenous factors have been shown to affect the interaction between 
ADAMTS13 and VWF and modulate the cleavage activity of the protease, both 
positively and negatively, by various mechanisms.  
Inflammatory cytokines such as interleukin-6, released during the early stage of 
systemic inflammation, may stimulate the ULVWF release and inhibit its cleavage, 
resulting in the accumulation of hyper-reactive multimers in plasma and on the surface 
of endothelial cells, which in turn induce platelet aggregation and adhesion on the 
vascular endothelium (Bernardo et al. 2004). Similarly to anti-ADAMTS13 
autoantibodies, antimicrobial human neutrophil peptides 1-3, released from neutrophils 
following infection or inflammation, may inhibit residual plasma ADAMTS13 activity 
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by interfering with its interaction with VWF. Moreover, it has been reported that high 
concentrations of serum haemoglobin, probably resulting from in vitro haemolysis, 
inhibit ADAMTS13 activity, without a clear clinical association with TTP (Studt et al. 
2005). Of note, in all these conditions, ADAMTS13 inhibition results as a consequence 
of an inflammatory activation and culminates in the amplification of a haemostatic and 
prothrombotic state of endothelium, promoting intravascular coagulation.  
Proteases of the coagulation cascade provide a useful feedback mechanism that turns off 
the intravascular haemostatic process. Following the initiation of coagulation cascade, 
the active form of thrombin and plasmin inhibit ADAMTS13 activity by directly 
cleaving the protease at the site of vascular injury, promoting thrombus growth. In the 
late phase of coagulation, on the surface of the adjacent uninjured endothelium, 
thrombin is recruited by thrombomodulin, and consequently thrombin-dependent 
ADAMTS13 proteolysis would be inhibited, restoring homeostasis (Crawley et al. 
2005).  
Other potential plasma inhibitors including FH (Feng et al. 2013)c;(Rayes et al. 2014) 
and heparin (Nishio et al. 2004) may modulate ADAMTS13 activity through direct 
binding to VWF. 
Inorganic divalent cations, which exert a functional and structural effect on both 
ADAMTS13 and VWF, have been shown to affect the activity of the protease. At 
concentrations exceeding physiological levels, Zn2+ and Ca2+ stabilize the folded 
conformation of VWF impeding its unfolding, consequently protecting it from cleavage 
(Anderson et al. 2006; Lynch et al. 2014). High concentrations of Mg2+, instead, can 
enhance VWF cleavage under flow (Dong et al. 2008). 
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1.2 Haemolytic uraemic syndrome 
Clinically defined by thrombocytopenia, nonimmune microangiopathic haemolytic 
anaemia, and acute kidney impairment, haemolytic uraemic syndrome (HUS) is a 
microvascular occlusive disorder that belongs to the category of diseases known as 
TMA (Ruggenenti et al. 2001). Nowadays, HUS represents the most common 
preventable cause of acute renal failure in children. 
The term “haemolytic uraemic syndrome” was initially described by von Gasser and 
colleagues in 1955 in a clinical report of five children with haemolysis, 
thrombocytopenia and acute renal failure who died with renal cortical necrosis (Gasser 
et al. 1955). Following this, it was recognized that for a small number of patients the 
disease was familial or recurrent (Kaplan et al. 1975), and the clinical course of HUS 
children with a prodrome of diarrhoea, was different from those without diarrhoea 
(Dolislager and Tune 1978). However, it was not until 1983 that the link was made 
between Shiga toxin-producing organisms, diarrhoea and HUS (Karmali et al. 1983; 
Riley et al. 1983). This finding also confirmed the differentiation between diarrhoea-
associated and non-diarrhoeal forms of HUS. The thought of diarrhoea-negative HUS as 
a genetic disease started with the identification of mutations in the CFH gene (Richards 
et al. 2001; Caprioli et al. 2003), which codes for the central inhibitor of the 
complement alternative pathway, factor H. Later on, mutations in additional 
complement genes were identified in HUS patients (Bu et al. 2012). 
The bloody diarrhoea, which occurs in about 90% of cases of HUS, is generally the sign 
indicating that enteric E. coli infection is occurring. Post-diarrhoeal HUS patients have 
a low haemoglobin level and thrombocytopenia (low platelet count), may manifest 
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pallor and fatigue, and may present in different stages of acute renal impairment (Elliott 
and Robins-Browne 2005; Garg et al. 2009). 
The initial presentation of diarrhoea-negative HUS, typically as a severe onset, includes 
haemolytic anaemia (low haemoglobin, decreased haptoglobin, increased lactate 
dehydrogenase, and positive schistocytes) and thrombocytopenia without preceding 
diarrhoea. Some patients show complement activation in the form of low C3 plasma 
levels and a decreased plasma C3/C3d ratio. Disease manifestation is often preceded by 
an infection, reported as a triggering event. Some patients experience one episode of 
kidney failure only, recover, and experience no disease recurrence, while others have 
multiple relapses or the progression to end-stage renal disease (ESRD) (Noris et al. 
2010). 
 
1.2.1 Classification 
Twenty-two years ago today, Karmali and colleagues found a toxin, named verotoxin, 
lethal to cultured African green monkey (Vero) kidney cells in stools of children with 
post-diarrhoeal HUS. This toxic property was attributed to E. coli of various serotypes 
and the toxin was later on called Shiga-like toxin (Stx). Since that, following the 
recognition of clinical patterns of HUS, cases should be assigned to one of the 
subclasses of the disease based on the presence or the absence of diarrhoea and/or 
detection of Stx-producing bacteria and their products in stool cultures (Ariceta et al. 
2009). These two major subtypes of HUS are the following.  
- Typical HUS, also defined as post-diarrhoea or diarrhoea-positive HUS (D+HUS) is 
the most frequent form of HUS (90 %), and it is associated with infections by Shiga like 
toxin (Stx) producing bacteria (STEC), such as enterohaemorrhagic Escherichia Coli 
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(EHEC) or Shigella dysenteriae and it is more appropriately referred as STEC HUS. 
The most frequently isolated E.coli serotype in cases of D+HUS is E.coli 0157:H7 (Tarr 
1995). Stx is divided into two major subtypes, Stx1 and Stx2, which have 
approximately 50% homology each other. STEC HUS is acquired as a food-borne 
illness or from contaminated water. It affects predominantly children, except in 
epidemics when it may occur in individual with a wider range of ages (Tarr et al. 2005). 
Rare cases of typical HUS are triggered by neuraminidase producing Streptococcus 
pneumoniae. These forms are classified as pneumococcal-HUS or neuraminidase-
associated HUS (Copelovitch and Kaplan 2010).  
Patients with the typical STEC HUS present haemolytic anaemia, thrombocytopenia 
and acute kidney injury with almost 40-50 % of cases requiring dialysis (Garg et al. 
2009). Usually they recover, and renal function returns to normal. 
- The atypical HUS (aHUS) has been historically used to describe rare cases of the 
disease (less than 10%) in which infections by Stx producing bacteria or S. Pneumoniae 
or other secondary causes can be excluded. aHUS is also improperly defined as 
diarrhoea negative HUS (D-HUS) (indeed about 30% of patients present with 
diarrhoea), and can be hereditary, affecting members of the same family several years 
apart (Kaplan et al. 1975), or sporadic (Noris et al. 2010). In 1998, Warwicker et al. 
(Warwicker et al. 1998) studied three families with HUS and he firstly established 
linkage in the affected individuals to the complement cluster gene on human 
chromosome 1q32, which encodes for several regulatory proteins of the complement 
system, the major non-specific defense mechanism of the innate immune system. 
During the last two decades, genetic or acquired defects leading to the dysregulation of 
complement cascade have been discovered in about 60% of patients with aHUS (Noris 
and Remuzzi 2009; Noris et al. 2010). Up to now, different HUS-associated mutations 
1. INTRODUCTION 
 
35 
 
or polymorphisms were identified in complement genes encoding for: Factor H (FH) 
(Caprioli et al. 2003), Factor I (FI) (Fremeaux-Bacchi et al. 2004), Membrane Cofactor 
Protein (MCP) (Noris et al. 2003; Fremeaux-Bacchi et al. 2006), Component 3 (C3) 
(Fremeaux-Bacchi et al. 2008), Factor B (FB) (Goicoechea de Jorge et al. 2007), 
complement Factor H Related 5 (FHR5) (Monteferrante et al. 2007), complement Factor 
H Related 1 and 3 (FHR1, FHR3) (Zipfel et al. 2007), Thrmobomodulin (THBD) 
(Delvaeye et al. 2009), and diacylglycerol kinase epsilon (DGKE) (Lemaire et al. 2013). 
In about 10% of juvenile patients with aHUS, the disease correlates with the deficiency 
for complement Factor H Related proteins (CFHRs) in combination with the presence 
of anti-FH autoantibodies. This form represents a unique subtype of aHUS called 
DEAP-HUS [Deficiency of CFHR plasma proteins and Autoantibody Positive form of 
Haemolytic Uremic Syndrome] (Skerka et al. 2009; Zipfel et al. 2010). Also 
autoantibodies to FI have been recently reported in patients carrying FH mutations, but 
their role remains still unclear (Kavanagh et al. 2012). Acknowledged theories assume 
the need of multiple hits by gain-of-function mutations in complement activators, loss-
of-function mutations in complement inhibitors, and/or presence of autoantibodies for 
complete penetrance of HUS (Esparza-Gordillo et al. 2006; Kavanagh and Goodship 
2011). Similarly, it has been proposed that the “complotype”, defined as the repertoire 
of inherited abnormalities in complement genes, likely confers a predisposition to 
developing aHUS, rather than directly causing the disease (de Cordoba et al. 2012). 
Conditions that trigger complement activation may precipitate an acute event in those 
patients with the predisposing genetic background (Caprioli et al. 2006; Noris et al. 
2010). aHUS can be recurrent and patients can develop ESRD. 
- There are many other forms of HUS, due to a variety of causes, which are called 
secondary aHUS. These forms are associated with different conditions, including viral 
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(human immunodeficiency virus and H1N1 influenza A) and other bacterial infections, 
parasites such as Plasmodium falciparum (Kute et al. 2013) or S. pneumonia (Brandt et 
al. 2002), cancer chemotherapy (Lesesne et al. 1989) and several categories of drugs 
(Dlott et al. 2004), bone marrow or solid organ transplantation (Bonser et al. 1984; 
Ostronoff et al. 2007), malignant hypertension (Shibagaki and Fujita 2005), 
autoimmune disorders such as systemic lupus erythematosus (Zhao et al. 2011), HELLP 
(Haemolytic anemia, Elevated Liver enzymes, Low Platelet) syndrome (Fang et al. 
2008), glomerulopathies (Manenti et al. 2013), or, in children, methyl malonic aciduria 
with homocystinuria, cblC type, a rare hereditary defect of cobalamine metabolism 
(Sharma et al. 2007). As TTP, also HUS is pregnancy-associated (George 2003; Noris 
and Remuzzi 2005; Fakhouri et al. 2010), since during pregnancy increased pro-
coagulants factors concentrations may act as predisposing agents. However, many of the 
above conditions often act as a trigger of the disease in individuals with a genetic 
background leading to complement dysregulation. Triggering and underlying clinical 
condition have been reported in up to 70% of patients with complement gene mutations, 
showing that both genetic predisposition and a precipitating event are required for the 
development of the disease (Caprioli et al. 2006; Noris et al. 2010). 
 
1.2.2 Incidence 
The annual incidence of STEC HUS is overall about 0.2-1/100,000 persons/year, with a 
peak of 5 to 6 per 100,000/year in children under the age of 5 years (Noris and Remuzzi 
2009). Interestingly, there is some geographic variation in incidence both internationally 
(Elliott et al. 2001; Lynn et al. 2005) and within countries (Tozzi et al. 2003). In 2011, 
several European countries, particularly Northern Germany, experienced one of the 
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largest STEC HUS outbreaks ever reported (Frank et al. 2011). The annual incidence of 
aHUS is thought to be about 2 per million for adults (Constantinescu et al. 2004) and 
3.3 per million in children younger than 18 years (Ohanian et al. 2011). Onset during 
childhood (<18 years) appears slightly more frequent than during adulthood 
(approximately 60 and 40% of cases, respectively) (Noris et al. 2010). Both sexes are 
equally affected in childhood, while in adults the incidence and prevalence is greater in 
females (Sullivan et al. 2010). A familial occurrence is observed in approximately 20% 
of aHUS patients and genetic predisposition can be inherited in an autosomal 
dominant or autosomal recessive manner by a pathogenic variant(s) in a single gene, or, 
rarely, in a multi-gene panel (Noris and Remuzzi 2009).  
 
1.2.3 Diagnostic measures for aHUS 
Patients suspected of having aHUS should be initially screened by measuring 
complement C3, C4, FB, FH, MCP, FI, FHRs and autoantibodies against FH. 
Classically, serum C3, C4 and FB levels are determined by nephelometry, using a 
standard procedure and commercially available diagnostic kits (Siemens Healthcare 
Diagnostics or Beckman Coulter). For the assessment of plasma levels of complement 
components FB, FH, FI and MCP a variety of different complement assays are being 
undertaken but they remain within the specialized diagnostic laboratories. FH, FI and 
FB levels are measured by immunochemical methods (Oppermann et al. 1990; Dragon-
Durey et al. 2004) or by functional analysis (Lesavre et al. 1979; Goicoechea de Jorge et 
al. 2007; Martinez-Barricarte et al. 2010; Marinozzi et al. 2014). Anti-FH or anti-FI 
autoantibody screening is currently performed by home-made ELISA assays (Dragon-
Durey et al. 2005; Kavanagh et al. 2012). Membrane expression of MCP is usually 
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analyzed using granulocytes or peripheral blood mononuclear cells (PBMC) in a flow 
cytometry analysis (FACS) (Kolev and Kemper 2014). Functional FH complement 
regulatory defects can be detected in the patients’ sera with a FH-dependent haemolytic 
assay (Sanchez-Corral et al. 2004). Assays like the CH50, AP50 and the Wieslab 
complement system are used to assess the functional capacity of the different 
complement pathways. C5a and SC5b-9 have been used as surrogate biomarkers of 
complement activation with some limitations since their circulating levels remain 
normal in almost 40-60% of patients during the acute phase. A useful alternative assay 
was recently proposed for the assessment of complement activation and the monitoring 
of the therapy in aHUS patients. In this test, sera from aHUS patients compared to 
healthy subjects caused more C3 and C5b-9 deposition on ADP-activated endothelial 
cells (Noris et al. 2014).  
All these studies highlight the lack of the “perfect assay” to test and monitor 
complement activation in aHUS. In the absence of international standards, the normal 
ranges and units vary from laboratory to laboratory. In addition, functional assays of 
specific AP proteins from patient plasma are generally not very sensitive and may not 
provide accurate information. Therefore the assessment of complement protein levels or 
functions in plasma is insufficient and genetic analyses are necessary (Noris and 
Remuzzi 2009). However, the underlying genetic and functional alterations remain 
unknown in approximately half of aHUS patients. Based on the current understanding 
of the pathophysiology of aHUS, several candidate genes can be defined based on the 
role of their encoded proteins as regulators of the complement activation. These 
candidate proteins include properdin, which promotes complement activation, CR1, 
which has overlapping functions of FH and MCP, and heparin, which modulates FH 
localization on endothelial cells (Jokiranta et al. 2007). 
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1.2.4 Therapy 
Clinically, HUS can consist of variable combinations of microangiopathic haemolytic 
anaemia, thrombocytopenia, renal failure, pulmonary oedema, systemic arterial 
hypertension, and neurologic abnormalities (Ruggenenti et al. 2001).  
Patients in all phases of HUS should be monitored carefully and continuously for signs 
and fluid overload, because their renal and vascular statuses are in flux, and volume 
overload or depletion could exacerbate injury. Diuretics, sometimes given during early 
HUS, rarely avert anuria, and thrombus development may be facilitated (Tarr et al. 
2005). Vasodilators are the preferred agents for the treatment of hypertension (Corrigan 
and Boineau 2001). 
HUS patient can become profoundly and rapidly anaemic. Administration of 
erythrocyte and platelets usually produces a transient reversal of the anaemia and 
thrombocytopenia. However blood product transfusions often will cause an 
exacerbation of HUS as a result of rapid worsening of haemolysis and thrombosis; 
consequently blood product transfusions are reserved for patients with life-threatening 
bleeding or markedly symptomatic anemia (Camp-Sorrell 2008). 
Since in most cases, STEC HUS is associated with enterohaemorrhagic colitis, bowel 
rest is important in the management of this disease. Anti-motility agents should be 
avoided since they may prolong the persistency of Stx-producing bacteria in the 
intestinal lumen and therefore increase patient exposure to its toxin. The use of 
antibiotics should be restricted to the very limited number of patients presenting with 
bacteremia since in children with gastroenteritis they may increase the risk of HUS by 
17 folds (Chiurchiu et al. 2003). Moreover, several antimicrobial drugs are potent 
inducers of the expression of Stxs, therefore they should be avoided. 
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The failure of Synsorb-Pk, an oral agent that binds Shiga toxins, to ameliorate the 
course of typical HUS, unresolved the debate in consideration of antitoxin treatment for 
STEC HUS, primarily caused by enteric bacterial infections. Anyway, among newer 
treatments with development of Stx-neutralizing monoclonal antibodies (SHIGATEC, 
NCT0152199) is now the most advanced (Bitzan 2009). Many other approaches, such 
as corticosteroids (Perez et al. 1998), aspirin (O'Regan et al. 1980), heparin and 
urokinase/streptokinase (Diekmann 1980), have been unsuccessful in HUS, and are not 
commonly used today. 
As in the management of other TMAs, plasma exchange and plasma infusion were 
considered first-line therapies in aHUS, but the reported clinical response varies from 
complete remission to no response and immediate end-stage renal failure (ESRF), 
depending on the underlying genetic or acquired defect (Caprioli et al. 2006; Ariceta et 
al. 2009). There is no theoretical justification for plasma therapies in STEC HUS, since 
there is no evidence that TMA originates from some circulating factors that can be 
removed or replaced by plasma exchange. Because elevated levels of circulating 
immune complexes may play a role in aHUS, plasma treatment could theoretically be 
beneficial to remove these complexes (Pisoni et al. 2001). Controversial results are 
reported in response to plasma infusion, since mutant circulating molecules or 
autoantibodies are not removed from blood circulation (Ariceta et al. 2009; Davin et al. 
2009; Noris et al. 2010). Patients with autoantibodies, such as DEAP-HUS patients, 
receive plasma therapy in combination with immunosuppressive agents (steroids, 
azathioprine or even anti-CD20 rituximab, such as in the case of acquired TTP) in order 
to reduce the titer of antibodies (Dragon-Durey et al. 2009); disease recurrence 
following discontinuation of plasma treatment has been reported (Lee et al. 2009).  
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Patients with aHUS tend to require more aggressive and prolonged treatment and have a 
worse renal outcome and higher mortality than patients with STEC HUS. They may 
also have a prolonged disease course and/or recurrent episodes of HUS. The clinical 
outcome of aHUS is unfavorable: up to 50% of cases progress to ESRF and 10-15% 
may die during the acute phase of the disease (Ruggenenti et al. 2001). The majority of 
patients with FH, FI, C3 and THBD mutations or anti-FH antibodies lost renal function 
or died during the presenting episode or progressed to ESRD as a consequence of 
relapses (Noris et al. 2010). Indications for dialysis in HUS are similar to those in other 
forms of acute renal failure: hyperkalaemia (high potassium concentration), high serum 
urea concentrations; persistent acidosis; hypertension; anuria; and volume overload. The 
choice between haemodialysis and peritoneal dialysis varies among specialists and 
centers (Corrigan and Boineau 2001).  
Kidney transplant should be considered as an effective and safe treatment for those 
patients, who progress to ESRD, even if organ graft generally fails to control the 
syndrome. Kidney transplantation in HUS patients is severely compromised by the risk 
of recurrence (Loirat and Niaudet 2003), especially in patients with gene mutations 
encoding for complement plasma proteins synthesized predominantly by the liver, such 
as FH and FI rather than C3 and FB (Bresin et al. 2006). Liver transplantation corrects 
these complement abnormalities preventing disease recurrences but had a high mortality 
rate (Saland et al. 2009; Saland et al. 2009). Plasma prophylaxis has also been proposed 
as a strategy to prevent relapses after single kidney transplantation in aHUS associated 
with FH mutations (Hirt-Minkowski et al. 2009). Combined liver-kidney transplantation 
should be recommended for selected patients with ESRF and FH or FI abnormalities, as 
a way both to restore renal function and to prevent disease reappearance (Saland et al. 
2009). In contrast, outcome of kidney graft alone is favorable in patients with mutations 
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in gene encoding for MCP, a transmembrane protein highly expressed in the kidney 
(Noris et al. 2010).  
Since complement abnormalities are underlying causes of pathophysiology of aHUS 
(Noris and Remuzzi 2009), and that uncontrolled complement activation may contribute 
to microangiopathic lesions of STEC HUS (Morigi et al. 2011; Noris et al. 2012), in the 
last decade complement inhibitors have been proposed as new therapeutic treatments for 
the cure of the disease. The first successful example of complement inhibitor is 
eculizumab (Soliris), a humanized monoclonal antibody that blocks complement 
activity by inhibiting the cleavage of complement C5, thereby preventing the generation 
of the inflammatory peptide C5a and the cytotoxic membrane-attack complex C5b-9 
(Thomas et al. 1996). Eculizumab has been approved for the treatment of paroxysmal 
nocturnal haemoglobinuria, a disease characterized by complement mediated 
haemolysis due to deficiency in glycosylphosphatidylinositol-anchored complement 
regulatory proteins CD55 and CD59 (Hillmen et al. 2004). Its cost is extremely high 
and is associated with a risk of meningococcal sepsis/meningitis (Struijk et al. 2013). 
Different case reports and clinical trials reported that eculizumab induces remission of 
aHUS (Gruppo and Rother 2009; Nurnberger et al. 2009; Legendre et al. 2013; Cofiell 
et al. 2015) and represents a valid first-line alternative treatment of acute episodes 
(Zuber et al. 2012) and also in prevention of recurrences after kidney graft (Chatelet et 
al. 2009). These encouraging results prompted nephrologists to use eculizumab therapy 
in HUS in the STEC O104:H4 outbreak in Germany, but whether eculizumab is a useful 
adjunct to treating the most severe forms of STEC HUS need to be clarified by 
prospective randomized, controlled trials (Kielstein et al. 2012).  
Many other complement inhibitors are currently in development (Ricklin and Lambris 
2013). Monoclonal antibodies that target FD, FB, C3b, properdin and mannose 
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associated serine proteases (MASPs) have been tested with potential application in 
aHUS. Small molecules have been also developed to block C3, FB and FD activities or 
C3a and C5a signaling at their receptors, with the advantage to be administered 
subcutaneously or orally. However, because the complement system is an important part 
of the immune response, the major risk of all therapeutic complement inhibitors remains 
infections. 
 
1.2.5 Pathogenetic mechanisms 
1.2.5.1 In typical HUS 
Stx-producing bacteria, ingested in contaminated food, colonize the mucosa of the 
intestine causing the destruction of brush border villi. Stx, produced by the adherent 
microorganism and elaborated in the gut lumen, is responsible for the early stage watery 
diarrhoea of the disease. Stx is also adsorbed into the circulation and carried throughout 
the body. Internalized in a wide range of endothelial cells by its globotriasoyl ceramide 
(Gb3) receptors, and activated through the Golgi apparatus, Stx exerts its virulent 
intracellular activity. For many years, it has been assumed that the only relevant 
biologic activity of Stxs was to induce cell death by modifying the ribosome and 
blocking protein synthesis (Melton-Celsa 2014), especially in human proximal and 
distal tubular epithelial cells. However, it has been shown that Stxs upregulate mRNA 
expression and protein levels of inflammatory cytokines including TNFα, interleukins, 
and other chemokines, which promote transmigration of leukocytes (Morigi et al. 1995), 
and  initiate intravascular coagulation (Grabowski 2002; Lee et al. 2013). The formation 
of microthrombi causes in turn impaired oxygenation and end-organ damage. Systemic 
effects of Stxs include platelets consumption, haemolysed red blood cells, and damage 
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to the kidney, brain, pancreas, and heart, and other organs in which Gb3 is expressed 
(Elliott and Robins-Browne 2005). Altered complement activation products levels have 
been found in patients with STEC HUS (Stahl et al. 2011; Arvidsson et al. 2015), but 
whether those changes are part of the etiology of the disease or occur as a consequence 
is not clear. In a recent study Stx-induced complement activation, via P-selectin and the 
alternative pathway of complement system, was identified as a key mechanism of 
microvascular thrombosis in STEC HUS (Morigi et al. 2011). Moreover, in a mouse 
model of HUS, obtained by co-injection of Stx2 and lipopolysaccharides, upregulation 
of P-selectin is associated with C3 deposits and platelets clumps (Morigi et al. 2011). 
Altogether those findings suggest a role of complement in the pathogenesis of the STEC 
HUS. 
 
1.2.5.2 In atypical HUS 
The endothelium protects itself from complement attack by interacting with soluble 
complement regulators, such as FH and FI, that inhibit the fluid phase complement 
activation, and by expressing surface molecules with complement inhibitor activity. The 
expression of the membrane-bound complement regulators DAF (decay accelerating 
factor), MCP and CD59 protect the surface of endothelial cells. Reduced control of 
complement activation (due to loss-of-function mutations in complement regulators or 
gain-of-function mutations in complement activating proteins) is thought to be 
responsible for the loss of endothelial cell integrity, the activation of pro-coagulation 
pathways and development of the TMA (Noris and Remuzzi 2009). The kidney is the 
organ that is especially vulnerable to complement-mediated damage, as on the one hand 
it filters substantial amount of blood under high pressure and on the other hand only a 
1. INTRODUCTION 
 
45 
 
single layer, flat endothelium separates the glomerular structures from the bloodstream 
(Tryggvason and Wartiovaara 2005). In aHUS, endothelial cell damage and platelet 
dysfunction represent primary events that lead to microvascular lesions particularly in 
the kidney: endothelial swelling with retraction of the cells and exposure of the basal 
lamina, microthrombi formation that occlude arterioles and capillaries in the kidney 
(Stuhlinger et al. 1974; Warwicker et al. 1998). 
Persistent and remarkably reduced serum levels and glomerular deposition of the 
component 3 (C3) of complement system have been reported since 1974 in both familial 
and sporadic forms of aHUS (Stuhlinger et al. 1974; Noris et al. 1999), confirming an 
inherited defect causing dysregulation of the complement cascade. Moreover, low 
serum C3 level in a aHUS patient who has a normal complement component 4 (C4) 
level indicates selective activation of the alternative pathway of complement system 
(Noris et al. 1999).  
After viral or bacterial infection or endothelial insult, complement is normally activated 
and C3b is formed. In the presence of normal FH, C3b is rapidly inactivated to inactive 
C3b (iC3b) by FI (co-factor activity). In addition, FH binds to polyanionic 
proteoglycans that are present on endothelial cell surface and in the subendothelial 
matrix, where, because of its high affinity for C3b, it entraps fluid-phase C3b, thus, 
preventing its deposition on host surfaces and its binding with FB to form the 
alternative pathway C3 convertase complex (C3bBb), which amplifies the complement 
cascade. In addition FH dissociates the C3convertase (Rodriguez de Cordoba et al. 
2004). The subendothelial matrix lacks endogenous complement regulators, thus, it is 
completely dependent on FH to control complement activation (Zipfel et al. 2006). In 
the same way as FH, MCP inactivates C3b deposited on endothelial cells by favoring its 
cleavage to iC3b by FI, but it only protects those cells on which it is expressed 
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(Goodship et al. 2004). THBD, exposed on endothelial surface, enhances FI-mediated 
inactivation of C3b in the presence of FH and promotes activation of the thrombin-
activatable fibrinolysis inhibitor (TAFI into TAFIa), which degrades anaphylatoxins 
C3a and C5a (Conway 2012). (Fig. 1-5A)  
In the presence of events that enhance alternative pathway activation, carriers of 
complement mutations undergo excess C3b formation and deposition on vascular 
endothelium. An uncontrolled level of C3 convertase leads to more C3b molecules and 
to more C5 convertase, initiating the formation of the membrane-attack complex (C5b-
9), a multimeric structure that forms pores in the membranes of target cells, causing cell 
activation and lysis. The proteolysis of C3 and C5 by convertases causes the release of 
the chemotactic anaphylatoxins C3a and C5a that bind to receptors on inflammatory 
cells and attract them toward the endothelial layer. Complement-mediated endothelial 
injury creates a prothrombotic state through exposure of adhesion molecules such as 
subendothelial collagen, VWF, P-selectin and fibrinogen (Tedesco et al. 1997; Morigi et 
al. 2011) (Fig. 1-5B). Moreover, it has been shown that mutant FH has defective 
binding to platelets, allowing C3 and C9 deposition and platelet activation (Stahl et al. 
2008). In addition, cell injury may reduce the surface expression of regulatory proteins, 
and stimulate local production of complement proteins by renal cells (Farrar et al. 
2006). After endothelial damage, cell detachment ensues and exposes basement 
membranes. In these conditions, platelets from the microcirculation adhere and 
aggregate to the exposed matrix leading to thrombus formation. Mutations in CFH, CFI, 
CFHRs, MCP and THBD genes or FH autoantibodies found in aHUS patients lead to 
systemic FH, FI or MCP deficiency, resulting in the loss of regulation of complement 
activation.  
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Functional analysis of the C3 or FB mutants identified in the cohorts of aHUS has 
demonstrated either increased generation or enhanced stability of the alternative 
pathway C3 convertase. While mutations in DGKE gene, encoding for a protein 
involved in phosphoinositol metabolism, have been detected in patients presenting with 
aHUS under the age of 1 year, the link with complement remains poorly defined 
(Lemaire et al. 2013); DGKE appears to be critical to the normal function of podocytes 
(Ozaltin et al. 2013), and for endothelial cell function and survival (Bruneau et al. 
2015). 
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Figure 1-5. Model for the mechanisms leading from impaired regulation of the alternative pathway 
to thrombotic microangiopathy. 
A. In a normal endothelial cell, complement factor H (FH) binds to the endothelial surface and to C3b 
and together with membrane cofactor protein (MCP) acts as a cofactor for cleavage of C3b, which is 
mediated by complement factor I (FI), a process that prevents its interaction with factor B (FB). FH also 
dissociates the C3 convertase of the alternative pathway (C3b). Thrombomodulin (THBD) enhances FI-
mediated inactivation of C3b in the presence of FH and promotes activation of the thrombin-activatable 
fibrinolysis inhibitor (TAFI into TAFIa), which degrades C3a and C5a. B. In patients with loss-of-
function mutations in complement regulatory genes (FH, FI, MCP, and THBD [the gene encoding 
thrombomodulin]) C3b is not degraded efficiently and forms the C3 and C5 convertases of the alternative 
pathway. Mutated THBD cannot inactivate C5a and C3a because of reduced formation of TAFIa. C5b 
initiates the assembly of the membrane-attack complex (MAC), leading to cell injury and activation, with 
expression of adhesion molecules, such as P-selectin, which together with C3a and C5a recruit and 
activate leukocytes. Subsequent cell detachment results in a prothrombotic state. Aggregated platelets 
release procoagulant platelet-derived microparticles (PMP), which facilitate the assembly of clotting 
enzymes. A similar situation applies to patients with gain-of-function mutations in CFB and C3. Mutant 
FB forms a “superconvertase” that is resistant to dissociation by FH. Mutant C3b does not bind FH and 
MCP and is resistant to degradation by FI. GAG denotes glycosaminoglycans. 
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1.2.6 The Complement System 
The complement system is an important component of the adaptive and innate immune 
system and consists of more than 40 plasma and membrane-associated proteins. 
Nowadays it is more and more evident that the complement system acts both as a first 
line of defense against pathogens and as a guardian of the host homeostasis (Ricklin et 
al. 2010). When complement is activated, a cascade reaction is initiated, leading to the 
cleavage of inert plasmatic complement components that generate bioactive fragments 
with pro-inflammatory, chemoattractant and cell damaging functions. 
The most important roles of complement system are the recognition of pathogens, the 
activation and chemotaxis of leucocytes, and the induction of the non-self cell lysis by 
incorporation of the terminal membrane attack complex (C5b-9, MAC). The 
complement cascade can be activated by three different pathways, classical, lectin and 
alternative (Fig. 1-6). The classical pathway (CP) is activated by immune complexes or 
apoptotic cells after specific recognition of a target structure by C1q. The alternative 
pathway (AP) is permanently active and may attack any surface that is not specifically 
protected. In the lectin pathway (LP), mannose-binding lectin (MBL) or ficolins 
recognize patterns of carbohydrates such as N-acetylglucosamine or mannose, but not 
sialic acid or galactose, which provides selectivity for bacterial, viral, fungal, and 
parasitic cell surfaces. Each pathway leads to the formation of unstable protease 
complexes, named C3 convertases that cleave and activate the central component C3 
protein into C3a and C3b fragments. Notably, activation of both CP and LP results in 
formation of the C3 convertase C4bC2a, while AP activation generates the central AP 
C3 convertase C3bBb, in which converge all three pathways. C3b molecules deposited 
on pathogens or damaged self cells provide a molecular platform for the formation of 
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the surface AP C3 convertase, C3bBb, which enzymatically generates many more C3b 
molecules, resulting in a positive amplification feedback loop of complement activation. 
The binding of C3b to the C3 convertases forms the C5 convertases that cleave the 
complement component C5 producing C5a and C5b. C5b initiates the “late” events of 
complement activation, in which the terminal complement components C6 to C9 
interact to each other to form the membrane-attack complex C5b-9, also called MAC 
(Membrane Attack Complex), which creates a pore in the membranes of unprotected 
cells leading to their lysis. The soluble cytolytically inactive form of this complex, 
called SC5b-9 and stabilized by S-protein and clusterin, has been shown to bind to 
endothelial cells and to induce expression of adhesion molecules and cytokines 
(Tedesco et al. 1997). C3a and C5a, released from the cleavage of C3 and C5 
respectively, are important anaphylatoxins and act as chemoattractants to recruit 
phagocytes to the site of complement activation, generate inflammatory environment 
and modulate adaptive immunity (Morigi et al. 2011). Different cell types carry specific 
complement receptors, which play major role in the phagocytosis of pathogens and 
apoptotic/necrotic cells, in the processing and clearance of immune complexes and in 
mounting immune responses.  
To regulate activation, several inhibitors of complement pathways, are expressed on the 
surface of host cells and also circulate in plasma, with sometime overlapping 
functionality (Zipfel and Skerka 2009). FH, C1 inhibitor (C1INH), C4b-binding protein 
(C4BP), clusterin and vitronectin work as soluble inhibitors of the complement cascade, 
while complement receptors 1 and 2 (CR1 and CR2), MCP (also known CD46), DAF 
(also known CD55), and protectin (also known CD59) act as membrane-bound 
inhibitors protecting self surfaces (Hourcade et al. 1999). In addition, some plasmatic 
regulators, which control complement in the fluid phase, also attach to lipid bilayers or 
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to biomembranes and maintain complement-regulatory activities. FH, MCP, CR1, and 
THBD also act as cofactors for the irreversible proteolytic inactivation of C3b by 
plasma protease FI (Delvaeye et al. 2009). Of note, despite their common activity, these 
complement regulators have different structural requirements for their FI-mediated 
activity (Martinez-Barricarte et al. 2010). Properdin is the only known complement 
regulator that enhances the stability of the C3bBb convertase and the activity of the AP 
(Lesher et al. 2013). Interestingly, FH-related proteins were recently described to 
modulate both C3 and C5 convertases (Hebecker and Jozsi 2012; Jozsi et al. 2015; 
Valoti et al. 2015; Chen et al. 2016), but their physiological relevance is not yet defined. 
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Figure 1-6. Schematic representation of the three pathways of the complement activation: the 
classical (CP), the lectin (LP) and the alternative (AP) pathways. 
The complement cascade can be activated through the classic pathway, the alternative pathway, and the 
mannose binding lectin pathway. The CP is activated by the binding of Fc region of IgG or IgM 
antibodies to the complement component C1. The LP is triggered by mannose binding lectin (MBL), 
Collectin11, Ficolins1-3. The CP and LP converge into the cleavage of complement components C2 and
C4 leading to the formation of the CP/LP C3 convertase (C4bC2a). The AP is continuously activated in 
plasma by low-grade hydrolysis of C3 forming C3(H2O). The latter binds to factor B (FB), which in turn 
is cleaved by factor D (FD) to form the AP fluid-phase C3 convertase.  Activation through each of these 
pathways generates C3-convertases, enzyme complexes that cleave C3 and generate anaphylotoxin C3a 
and C3b. Further amplification of complement activation through the alternative pathway generates 
additional C3b. C3b combines with the C3-convertases to create C5-convertases, enzyme complexes that 
cleave C5, producing the anaphylatoxin C5a and C5b. C5b initiates the late events of complement 
activation leading to the formation of the membrane-attack complex (MAC or C5b-9 complex) by 
interacting with C6-C9 proteins. 
Self surfaces are protected from complement damage by protein regulators (squared in green): C1INH,
C1 inhibitor; FI, complement factor I; C4BP, C4 binding protein; DAF, decay accelerating factor; MCP,
membrane cofactor protein; CR1, complement receptor 1; FH, complement factor H; THBD,
thrombomodulin. 
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1.2.6.1 The Alternative Pathway C3 convertase 
The alternative pathway is the phylogenetically oldest and most important activation 
pathway of the complement system since it is always activated at a low rate level for 
instantaneous complement activation, and since it autoamplifies the entire complement 
cascade. It assists in the maintenance of the integrity of an organism with spontaneous 
and continuous slow-rate activation through the “tick-over” hydrolysis of C3 into C3b-
like molecule C3(H2O) (rate 1% of total C3 per h). The plasma glycoprotein C3 is the 
pivotal complement component and the central element of the activation cascade, which 
leads to the formation of the AP C3 convertase, the key enzyme of the complement 
system responsible for the autoamplification of the entire cascade. The generation of the 
AP C3 convertase begins in vivo with the interaction between C3b-like molecule 
C3(H2O) and FB, in a Mg2+-dependent manner, to form the C3 proconvertase or 
C3(H2O)B. In the presence of FD, FB is cleaved and the N-terminal Ba fragment is 
released from the C3bB complex, resulting in the active AP initiation C3 convertase, 
C3(H2O)Bb. This initial spontaneously formed C3(H2O)Bb complex is the first fluid-
phase convertase which cleaves circulating C3 into C3a and C3b. C3a is an 
anaphylatoxin while C3b binds covalently to any positively charged surfaces including 
pathogens and endogenous molecules, interacts with FB and forms firstly the 
amplification C3bB proconvertase and then C3bBb convertase (Fig. 1-7). These steps in 
turn provide the amplification of AP complement cascade leading to formation of 
further convertases and deposition of C3b molecules on the surfaces of particles. 
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The convertase has a very short half-life (about 90 sec) (Pangburn and Muller-Eberhard 
1986) and released Bb cannot rebind to C3b, due to the loss of the anchoring Ba part. 
The convertase can be stabilized 5 to 10 fold by the binding of the only positive 
complement regulator, properdin. Properdin can also bind directly to microbial targets 
and altered self structures, providing a platform for the formation of C3 convertases 
(Hourcade 2006). 
In order to avoid complement hyperactivation, the AP C3bBb convertase is tightly 
controlled by either soluble or membrane-bound complement regulators (Zipfel and 
Skerka 2009). The role of these complement regulators is both to prevent C3 convertase 
formation, to dissociate already formed convertase and/or degrade and eliminate C3b 
from the cell surface. FH is the main fluid-phase complement regulator (Makou et al. 
2013). FH decays the C3 convertase, inhibits the conversion from the C3 proconvertase 
to the active form C3 convertase, and acts efficiently as a cofactor for FI in the 
inactivation of C3b. However, whilst FH binds and inactivates C3b promptly in the 
fluid phase, its affinity for surface-bound C3b increases in the presence of polyanions, 
such as sialic acids, glycosaminoglycans or sulphated polysaccarides (heparins) 
(Loeven et al. 2015). 
Figure 1-7.  Cartoon representation of C3bB C3 proconvertase assembly and C3bBb C3
convertase formation.  
FB
C3b
FB
C3b
FD
C3bB 
C3 proconvertase
C3bBb
C3 convertase
C3b
Bb
Ba
1. INTRODUCTION 
 
55 
 
Mutations in C3 have been described in ~10% of aHUS (Fremeaux-Bacchi et al. 2008; 
Noris et al. 2010). Functional analysis of 5 of the 9 mutations revealed increased 
resistance to complement regulation and in another two, the mutations resulted in a 
decreased secretion of C3 (Fremeaux-Bacchi et al. 2008). The mechanism by which 
impaired C3 secretion results in aHUS is as yet unclear. The frequency of CFB 
mutations in the cohorts of aHUS patients examined to date is low at less than 3% 
(Goicoechea de Jorge et al. 2007). Functional analysis of the mutants has demonstrated 
that some FB genetic changes resulted in increased generation or enhanced stability of 
the alternative pathway convertase, while 9 out of 15 mutations, identified in aHUS 
patients, are unrelated to disease pathogenesis (Marinozzi et al. 2014). 
 
1.2.6.1.1 C3 
The gene encoding C3 is located on chromosome 19 and comprises 41 exons, 16 of 
which encode the β-chain and 25 the α-chain. With a concentration of 1.0-1.5 mg/ml, 
C3 is one of the most abundant human plasma proteins, and the hepatocytes are by far 
the major source of circulating C3. It is now clear that almost all cells, including the 
renal cells, in the human body can produce complement proteins, and bone marrow-
derived cells contribute 40% of total C3 in the serum (Morgan and Gasque 1997). 
Besides, the local production of complement C3 can be induced and/or increased by 
pro-inflammatory cytokines, which suggests that extrahepatic production, in particular 
in the renal tissue, evolved to respond to immune requirement (Shavva et al. 2013). 
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 Locally occurring complement activation is triggered when a cell-activating signal, 
such as T cell, initiates the generation and secretion of C3, FB and FD, leading to C3 
and in turn C5 convertases formation in the extracellular space and/or on cell surface 
(Kolev et al. 2014). 
 
C3 is synthesized as single-chain precursor (190 kDa) and the native protein (187 kDa) 
is composed of the two disulfide-bounded polypeptide chains: the 115 kDa α-chain and 
the 75 kDa β-chain (Fig. 1-8). Central to the function of C3 is the internal thioester bond 
formed between Cys988 and Gln991. The crystal structure of native C3 has been 
resolved at atomic resolution using X-ray crystallography, and reveals an intricate 
arrangement of 13 domains, including an anaphylatoxin domain (ANA; C3a), a small 
link (LNK) domain, a core of eight homologous macroglobulin domains (MG1-8) 
forming a ring (MG ring), a CUB domain connecting this ring with ThioEster Domain 
(TED) that contains the reactive thioester moiety, and the C345C domain (Fig. 1-8) 
Figure 1-8. C3 domain structure. 
Cartoon representing domain organization of human complement component C3, C3a and C3b. MG1-8, 
eight homologous macroglobulin domains; LNK, link domain; ANA, anaphylatoxin domain; α’NT, 
α’NT domain; CUB, CUB domain; TED, TED domain that contains the reactive thioester, shown as a 
red triangle; anchor, linker domain; C345C, C-terminal domain. In the bottom, activation of C3 into C3b 
and C3a obtained by C3 convertase or auto-hydrolysis, and C3b degradation in C3c, C3dg and C3f by 
FI-mediated cleavage. 
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(Janssen et al. 2005). As indicated previously, the reactive thioester is shielded in native 
C3 so that it is not accessible.  
Activation of C3 into C3b (or C3(H2O)) induces a huge conformational displacement of 
the TED domain exposing the reactive group to nucleophylic reagents such as hydroxyl 
or amine groups (Janssen et al. 2006). However, this thioester is exposed for a brief 
period of time (60 µs) before the molecule is inactivated. This short half-life restricts 
AP activation locally and, in time, ensures that activation proceeds within the 
immediate vicinity. The newly formed C3b expresses multiple binding sites for 
complement components which are not accessible in the C3 molecule. Release of C3a 
(ANA domain) from the α-chain of C3 generates a novel C3 domain termed α’NT. The 
α’NT and C345C domains in C3b include binding sites for FB required for the AP C3 
convertase formation. These domains are located in a part of the C3 molecule which 
undergoes large rearrangement upon activation of C3 into C3b, which explains why C3 
does not interact with FB. Similarly, structural analyses have suggested that formation 
of the AP C3 convertase probably depends on the structure and orientation of the CUB 
domain of C3b and that the interaction between C3b and FB is independent of the TED 
domain (Gros et al. 2008). So far four separate sites on C3b have been determined that 
may either represent a binding site or residues that are indirectly involved in the binding 
of FB (Janssen and Gros 2007). These putative binding sites are: residues 727-745 of 
α’NT, residues 933-942 in the CUB domain, residues 200-220 in MG2-MG3 loop and 
C345C domain. Various studies have shown that residues 727-767, located in α’NT and 
MG6 domains of C3b, form an important interaction site for both FH and CR1. Notably, 
the fore-mentioned residues are the same or are close to residues important for FB 
interaction, which implies that convertase dissociation may be based in part on steric 
hindrance between FH and FB. In addition, FH has other binding sites on C3b, situated 
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Figure 1-9. FB domain structure. 
Cartoon representing domain organization of human complement component Factor B (FB). CCP1-3, 
three complement control protein domains; VWA, von Willebrand type A domain; SP, serine protease 
domain. The Arg234-Lys235 scissile bond is indicated. 
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on TED domain (Perkins et al. 2012). FI irreversible cleavage takes place in three sites 
inside the CUB domain of C3b (Arg932-Ser933, Arg1281-Ser1282 and Arg1298-
Ser1299), resulting in the formation of C3c, C3dg and C3f fragments (Fig. 1-8, bottom) 
(Gros et al. 2008). 
 
1.2.6.1.2 Factor B 
The gene encoding factor B (CFB) is located on chromosome 6p21.3 and consists of 18 
exons coding for a five domain glycoprotein. FB is a single-chain 93 kDa polypeptide 
and circulates in plasma as an inactive pro-enzyme at a concentration ranging between 
93 and 380 mg/l (Waters and Licht 2011). As for C3, the expression of FB is not 
restricted to the liver, but involved also: monocytes, macrophages, fibroblasts, 
endothelial cells, muscle and epithelial cells, adipocytes and astrocytes. Besides, local 
expression of FB can be either constitutively or under cytokine drive (Morgan and 
Gasque 1997). 
  
The structural analyses of FB crystal reveal that it is composed of five structural 
domains (Fig. 1-9) (Milder et al. 2007). The Ba fragment (33 kDa) at the N-terminus 
comprised three short complement control protein domains (CCPs), whereas the larger 
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Bb fragment (60 kDa) at the C-terminal comprised a von Willebrand type A (VWA) 
domain followed by a serine protease (SP) domain (Fig. 1-9). The SP domain is 
responsible for the cleavage of new C3 molecules by C3 convertase complex, so that it 
is necessary for amplification of the alternative pathway cascade. FB also possesses the 
Mg2+-dependent metal ion-dependent adhesion site (MIDAS) in the α1 helix in the 
VWA domain of the Bb fragment, which mediates the initial recognition of C3b by FB. 
This initial interaction also involves contacts between C3b and the SCR1-3 domain of 
Ba fragment (Milder et al. 2007). 
Recently, it has been described that properdin contacts both the C345C domain in C3b 
and the VWA in Bb, indicating that properdin stabilizes the C3bBb convertase by 
holding together the two components of this enzymatic complex. 
 
 
1. INTRODUCTION 
 
60 
 
1.3 Differential diagnosis of microangiopathic haemolysis 
The clinical distinction between thrombotic thrombocytopenic purpura and haemolytic 
uraemic syndrome has not been always a clear-cut. 
TTP and HUS conditions were been considered part of a disease spectrum for years, 
since their clinical symptoms are often overlapping. The fundamental lesion which 
consists of vessel wall thickening with swelling and detachment of the endothelial cells 
from the basement membrane and intraluminal thrombosis, is identical in the two 
diseases (Remuzzi 1987; George 2000). However, specific clinical features could be 
distinguished between TTP and HUS patients. Although both conditions are 
characterized by thrombotic occlusion of small arteries and arterioles, the pattern of 
distribution of this abnormality is different, being largely confined to the kidney in HUS 
but widespread (in heart, pancreas, kidney, adrenal, and brain) in TTP (Hosler et al. 
2003). There are also evident clinical differences. HUS is the prevalent clinical form in 
childhood, characterized by renal involvement, often with renal failure; TTP occurs 
mostly in adults and manifests with marked thrombocytopenia but minimally impaired 
renal function, almost invariably involves the central nervous system, and frequently 
recurs. Anyway, several authors reported exceptions to these definitions, including 
cases of adults in HUS (Hosler et al. 2003), children in TTP (Schneppenheim et al. 
2003; Pecoraro et al. 2015), HUS patients with multiorgan disease (Sheth et al. 1986), 
and TTP patients with acute renal failure (Shibagaki et al. 2006; Zafrani et al. 2015). 
Consequently, the pathologic features appear important to make a distinction between 
the two entities: thrombi in TTP are mainly composed of numerous, variably 
degranulated and altered platelets, and a small amount of amorphous materials (Asada 
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et al. 1985); instead, in HUS fibrin/red cell-rich thrombi are present with few platelets 
(Morel-Maroger et al. 1979).  
Altogether these observations suggest that symptoms alone cannot differentiate TTP 
from HUS given the potential for overlapping clinical manifestations. 
 
1.3.1 Is deficiency of ADAMTS13 specific for TTP? 
Approximately 80% of TTP cases is triggered by deficient activity of ADAMTS13, and 
its importance in the pathogenesis of the disease is well established. However, 
ADAMTS13 deficiency alone is not sufficient to cause TTP. Indeed, targeted deletion 
of ADAMTS13 in mice does not result in a spontaneous thrombotic phenotype (Desch 
and Motto 2007). Only with the introduction of a predisposing genetic background that 
induces elevated plasma VWF levels and the treatment with microbe-derived 
Shigatoxins, as a trigger, ADAMTS13-deficient mice exhibit a striking syndrome 
closely resembling human TTP (Motto et al. 2005).  
Compound heterozygous or homozygous mutations in the ADAMTS13 gene result in 
congenital severe ADAMTS13 deficiency, which is considered the underlying cause of 
hereditary TTP. However, mutations or polymorphisms within ADAMTS13 gene have 
been described for some diseases such as HUS (Feng et al. 2013)a, venous thrombosis 
(Lotta et al. 2013), coronary heart disease (Schettert et al. 2010), ischaemic stroke 
(Hanson et al. 2009), response to ACE inhibitors (Rurali et al. 2013) and malaria 
(Kraisin et al. 2014). However many of the studies were performed in a small number of 
patients and the effect of some of these polymorphisms or mutations in vivo still 
remains to be determined. 
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Evaluation of ADAMTS13 activity in patient plasma is performed using tests based on 
the capability of the protease to cleave standard VWF multimers in vitro (Gerritsen et 
al. 1999; Kokame et al. 2005). In patients presenting with TMAs, if ADAMTS13 
activity is <10%, a diagnosis of TTP is established,  if  ADAMTS13 activity is >10% 
and Shiga toxin assay is negative, a diagnosis of aHUS must be considered. 
Unfortunately, there is no definitive test to make a diagnosis of aHUS, and genetic 
screening can predict an underlying complement cause only in 60% cases of aHUS 
(Noris and Remuzzi 2009). Severe deficiency of ADAMTS13 activity is typically not 
found in individuals affecting HUS (Galbusera et al. 2006), and this feature, together 
with platelet count and serum creatinine, is nowadays used to discriminate TTP from 
HUS (Cataland et al. 2012; Cataland and Wu 2013), especially for treatment choice. 
However, there are some exceptions. Severe deficiency of ADAMTS13 activity is also 
found in adult patients with clinical diagnosis of HUS (Remuzzi et al. 2002; Remuzzi 
2003; Veyradier et al. 2003), or in individuals carrying both ADAMTS13 and CFH 
pathogenic variants (Noris et al. 2005). Moreover, VWF-cleaving protease deficiency 
has also been observed in individuals who have recovered from or never had TTP, such 
as disseminating intravascular coagulation (DIC) (Ono et al. 2006), thrombocytopenic 
disorders other than TTP (Moore et al. 2001), various inflammatory conditions and even 
in healthy controls (Mannucci et al. 2001). On the other hand, not all of the patients 
with clinically defined TTP diagnosis present with severely reduced ADAMTS13 
activity (Sadler 2006). Although a severe deficiency of the ADAMTS13 protease is 
more consistent with a diagnosis of TTP over aHUS, all the above observations suggest 
that measurable ADAMT13 activity alone could not exclude the clinical diagnosis of 
TTP.    
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In TTP patients with severe ADAMTS13 deficiency, the pathologic presence in the 
circulation of uncleaved ultralarge VWF multimers is considered as the mechanism 
responsible for VWF-mediated platelet aggregation and thrombosis (Moake et al. 1982). 
Consequently, the clinical severity of TTP is heterogeneous both in terms of short and 
long term prognosis as it directly depends on the ratio between high-molecular-weight 
(HMW) to low-molecular-weight (LMW) multimers (Remuzzi et al. 2002). However, 
this could not be a reliable indicator since VWF multimer size distribution is determined 
by a kinetic balance among secretion, proteolysis, and VWF-platelets binding, and its 
expression is broadly heterogeneous in endothelial cells (Pusztaszeri et al. 2006). 
Interestingly, it has been reported a group of TTP patients in which circulating ULVWF 
multimers were never been found either in the acute phase of the disease or in remission 
(Galbusera et al. 1999). Moreover, the reduced plasma ADAMTS13 activity and 
increased plasma ULVWF are risk factors for the development of other arterial and 
inflammatory diseases, including myocardial infarction (Andersson et al. 2012), 
ischemic stroke (Bongers et al. 2006), preeclampsia (Stepanian et al. 2011), and 
cerebral malaria (Lowenberg et al. 2010). In addition, in some patients with TTP, there 
is enhanced or alternative cleavage of VWF (Mannucci et al. 1989; Galbusera et al. 
1999). Thus, it has been hypothesized that in individuals who have severely deficient 
ADAMTS13 activity without manifestations of TTP, the VWF proteolytic activity of 
activated leukocytes may be sufficient to prevent platelet thrombosis. Conversely, in 
patients with active TTP, there may be deficiencies in both leukocyte protease-mediated 
and ADAMTS13-mediated proteolysis of VWF (Thompson and Howard 1986; Raife et 
al. 2009). As alternative VWF proteolysis, certain tumor cells have armed themselves 
against VWF accumulation via the production of ADAM-28 (Mochizuki et al. 2012). 
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All these observations clearly indicate that ADAMTS13 deficiency does not always 
differentiate TTP from aHUS, speculating that these two acute disorders are based on 
common principles with a similar pathophysiology (Zipfel et al. 2011; Noris et al. 
2012). 
 
1.3.2 Complement activation in TTP 
Activation of the alternative pathway of complement and dysregulation of the 
complement activity are central to the pathophysiology of aHUS, with low levels of C3 
and normal C4 (Noris and Remuzzi 2009). With the understanding of aHUS as a 
disorder of complement activation, it is reasonable to presume that more specific 
biomarkers of complement may be able to help in the differentiation of aHUS from TTP 
and other TMAs. Recently several published data however suggested that complement 
system may also play a role in the pathophysiology of ADAMTS13 deficiency in TTP, 
but its biochemical explanation is not already clear.  
Previous studies have indeed shown that complement is activated during acute episodes 
of TTP, with reduced levels of serum C3 or elevated platelet-associated C3 
(Weisenburger et al. 1977; Garvey and Freedman 1983; Noris et al. 1999; Wright et al. 
1999), with the reservation that older studies did not apply ADAMTS13 evaluation 
when making the diagnosis of TTP. More recently, many authors investigated 
complement activation markers in TTP patients with documented severe ADAMTS13 
deficiency. Ruiz-Torres et al. showed lower serum levels of C3 during the acute phase 
of the disease, and C3 and C5b-9 deposition on microvascular endothelial cells, 
suggesting a selective activation of the alternative pathway of the complement system 
(Ruiz-Torres et al. 2005). Réti et al. studied 23 patients with a diagnosis of TTP and 
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ADAMTS13 activity <5% at presentation and found evidence for activation of 
complement as defined by significantly increased levels of C3a and C5b-9 compared to 
healthy controls, normalizing at remission, although this study did not find a parallel 
decrease in serum C3 (Reti et al. 2012). Wu et al. have also demonstrated complement 
activation, as defined by increased levels of C3a and C5a, in patients with acquired TTP 
at the presentation with an acute episode (Wu et al. 2013). The acute event from which 
the patients did not survive were characterized by significantly increased factor Bb, 
C5a, and C5b-9 compared to those episodes from which the patients survived. 
Moreover, in a recent report of a patient with acute TTP associated with acquired severe 
ADAMTS13 deficiency, a skin biopsy revealed endothelial deposition of C3d, C4d and 
C5b-9 (Chapin et al. 2012). The patient described in the case report was successfully 
treated with the anti-human C5 antibody eculizumab, which is the gold standard therapy 
for aHUS, also suggesting a role for complement activation in TTP in this case (Tsai et 
al. 2013). Anti-C5 treatment success for TTP was confirmed in a 12-year-old boy 
suffering from a congenital form of the disease, which achieved complete remission 
both at the onset and during recurrences, supporting the idea that the complement 
pathway is activated in the presence of ADAMTS13 deficiency (Pecoraro et al. 2015). 
Furthermore, it has been reported that endothelial microparticles and VWF-platelets 
strings isolated from plasma samples of TTP patients are coated with complement C3 
and C9 (Tati et al. 2013); and plasma from 8/49 patients with ADAMTS13 deficiency 
induced haemolysis of sheep erythrocytes (Feng et al. 2013)b. The latter is a common in 
vitro assay to test complement-mediated haemolysis by using serum samples (Sanchez-
Corral et al. 2004), otherwise the authors didn’t reported the reasons why they used 
citrate platelet-poor plasma samples instead of serum, since citrate would block 
complement activation by chelating divalent cations as Ca2+. However, some studies 
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from Japan documented that complement can be activated in citrate plasma collected in 
clinic tubes, since their citrate concentration is not inhibiting (Kobayashi et al. 1999). 
Besides, Mg2+ ions are not chelated by citrate, thus allowing the activation of the 
alternative pathway of the complement system, which can promote the haemolysis of 
sheep erythrocytes.  
An additional link between complement activation and severe ADAMTS13 deficiency 
was reported by Turner et al., who studied the role of ULVWF in complement 
activation (Turner and Moake 2013). C4 released from human umbilical vein 
endothelial cells (HUVEC) did not attach to the ULVWF multimer strings, ruling out 
activation of the classical and lectin complement pathways by ULVWF. In contrast, 
components of the alternative pathway (C3, FB, C5 and properdin) attached to the 
ULVWF multimer strings in quantitative patterns consistent with the assembly of the 
alternative pathway components into active complexes (Turner et al. 2014). This would 
provide a plausible mechanism for the activation of the alternative pathway in condition 
with severe deficiency of the ADAMTS13 protease that induce ULVWF accumulation 
in the bloodstream.  
All these observations raise the possibility of additional factors besides ADAMTS13 
deficiency involved in the pathophysiology of TTP. 
 
1.3.3 Coagulation and complement system interplay 
ADAMTS13 is an important regulatory protease of the coagulation cascade, while the 
alternative pathway is a pivotal activation system of the complement cascade. The 
coagulation and complement systems are linked through both direct and indirect 
interactions and serve as innate defense against foreign invasion (Fig. 1-10). The 
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endothelium itself and the vascular bed on which they reside probably play an important 
role in this interaction.  
It is well documented that, during thrombus formation and progression, both clotting 
cascade and innate immunity are coordinately activated and several complement factors, 
including C3, C4, C3a, C5a and FH are incorporated into the blood clot (Distelmaier et 
al. 2009; Howes et al. 2012). Besides, Polley et al showed that the presence of 
complement proteins C3, C5, C6, C7, C8, and C9 enhanced thrombin-mediated platelet 
aggregation and the release of serotonin (Polley and Nachman 1978).  
 
1.3.3.1 The complement system stimulates coagulation cascade and 
immune response 
The complement system directly modulates thrombus stability and development by 
enhancing thrombogenic properties of endothelium: C3a reduces thrombomodulin 
expression on the endothelial surface, and exocytosis of P-selectin and VWF from 
intracellular Weibel-Palade bodies (Morigi et al. 2011), while C5a amplifies 
endothelium activation through loss of heparan sulfate and other glycosaminoglycan 
from the plasma membranes of endothelial cells, reducing the anticoagulant property of 
the endothelial surface (Platt et al. 1991). Terminal complement pathway complexes 
formed as C5 is activated, have also multiple procoagulant properties: C5b-9 deposition 
on endothelial cells induces exposure of VWF and upregulation of adhesion molecules 
for platelets on endothelial cell surface, which favor platelet adherence to the vessel 
wall (Tedesco et al. 1999); incorporation of the C5b-9 complex into the cell membrane 
activates platelets and results in the exposure of procoagulant lipids (Sims and Wiedmer 
1995) and of the procoagulant extracellular matrix (Saadi and Platt 1995). In addition, 
C5a has also been found to induce the expression of plasminogen activator inhibitor-1 
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in human mast cells and basophyls, indicating that the complement may also contribute 
to the mechanisms of thrombosis by inhibiting fibrinolysis (Wojta et al. 2002). 
Furthermore, FH, the major negative regulator of the complement system, has been 
proposed to control also coagulation cascade through the interaction with VWF. FH, 
bound to VWF, increases ADAMTS13-mediated cleavage of VWF-A2 domain, 
probably due to a conformational change in VWF that potentially makes the latter more 
accessible to the metalloprotease (Feng et al. 2013)c. However another study showed an 
opposite inhibitory effect of FH on VWF cleavage by ADAMTS13 (Rayes et al. 2014). 
Complement also modulates proinflammatory cytokines response and promotes 
infiltration of immune mediators. Release of anaphylatoxins C3a and C5a following 
complement activation is considered a critical determinant of neutrophil recruitment and 
activation in thrombosis (Distelmaier et al. 2009). C5a and the cytolytically inactive 
form of the MAC, SC5b-9, directly induce the expression of tissue factor (TF), one of 
the primary initiators of blood coagulation, by leucocytes and human endothelial cells 
(Ritis et al. 2006). C3a and C5a, through C3aR and C5aR signalling, influence 
production and secretion of tumour necrosis factor-alpha (TNF-α), interleukin-8 (IL-8) 
and interleukin-6 (IL-6) by macrophages (Markiewski et al. 2007) and upregulate 
adhesions (Schraufstatter et al. 2002). In turn, TNF-α is a potent enhancer of TF 
expression on monocytes surface, which facilitates the interaction with activated 
platelets and endothelial cells via binding of P-selectin. IL-6 increases the production 
and thrombogenicity of platelets (Oleksowicz et al. 1994). Microparticles, secreted by 
activated endothelium, express negatively charged phospholipids and TF, and thus 
promote coagulation (Combes et al. 1999). Inflammatory cytokines also decrease the 
level of several anticoagulants (Shebuski and Kilgore 2002). 
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1.3.3.2 The complement system activates platelets 
Complement products are also able to directly influence platelets activation. C3 and 
C5b-9 deposition on the surface of platelets markedly increase the rate of conversion of 
prothrombin and thrombin, cause the secretion of dense α-granules, which are essential 
component of primary hemostasis (Sims and Wiedmer 1991), and stimulate the 
formation of platelets microparticles, that enhance thrombus formation (Tans et al. 
1991). The pathophysiological relevance of complement activation on platelets has also 
been demonstrated by the finding that platelet function is impaired in C3-deficient mice 
(Gushiken et al. 2009).  
 
1.3.3.3 The coagulation pathway influences complement activation 
On the other hand, also coagulation system directly modulates complement activation. 
Both C3 and C5 could be activated in a convertase-independent manner, by several 
specific proteases of the coagulation cascade such as cathepsin L (Liszewski et al. 
2013), cathepsin D (Huber-Lang et al. 2012), thrombin (Huber-Lang et al. 2006), factor 
Xa and XIa (Amara et al. 2008), trypsin (Ekdahl and Nilsson 1999), kallikrein (Wiggins 
et al. 1981) and factor VII-activating protease (Kanse et al. 2012). However, C5 is a 
poor substrate for these proteases, raising questions as to its importance in contributing 
to C5a generation during thrombosis formation in vivo. What is becoming 
physiologically important is that plasmin, the strongest effector enzyme in the 
fibrinolytic cascade, is able to cleave C5 at a similar rate as the canonical C5 convertase 
formed from complement components (Foley et al. 2016). This finding is important 
since fibrinolysis occurs after and regulates coagulation and therefore the C5 cleavage 
products will be present during clot resolution as well as clot formation and regulation. 
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Besides, plasmin generation is increased acutely in blood of patients suffering for 
thrombotic disorders (Wada et al. 1989), suggesting an important regulatory role of 
plasmin in proinflammatory complement-mediated events. However, some recent 
findings described plasmin as a negative regulator of the complement activation, since it 
is able to inactivate C3b into several fragments similarly to FI-mediated cleavage (Foley 
et al. 2015). Anyway, further validation studies are required for both mechanisms. 
Notably, activation of complement by a “single” protease is rapid, requires less energy 
expenditure and may have evolved before convertase enzyme complex-mediated 
“activation”, suggesting that it may have important far-reaching functions that are yet to 
be discovered. However, research into convertase-independent complement activation 
poses an interesting area to explore and may deliver some novel and unexpected 
therapeutic targets to control complement (Kolev et al. 2014).  
 
1.3.3.4 Thrombomodulin: a key protein between the coagulation 
cascade and the complement system 
Another important modulator of the complement system is thrombomodulin (THBD), a 
crucial regulatory protein of the coagulation cascade. THBD is a transmembrane 
glycoprotein, highly expressed in endothelial cells and numerous other cell types. 
THBD has an anticoagulant role by acting as a cofactor for thrombin, which activates 
protein C. Activated protein C in turn inactivates factor Va and factor VIIIa of the 
coagulation cascade and limits clot development (Conway 2012). THBD provides also 
protection against inflammation: THBD sequesters thrombin on the cell membrane 
surface thus limiting its pro-inflammatory activities, mediated by protease activated 
receptors (PARs), in expression and/or release of chemotactic molecules for monocytes 
and neutrophils. Besides, THBD-thrombin complex promotes TAFI activation and 
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hence down-regulates fibrinolysis by reducing plasmin generation and function on 
fibrinogen and complement C3 and C5. Interestingly, the activated form of TAFI 
(TAFIa) also inhibits the potent anaphylatoxins C3a and C5a by their des-argination. 
Thus, well-known activities of THBD in protecting against inflammation and 
thrombosis require mediation of thrombin. However, different studies reported also a 
direct interaction of THBD with the proteins of the complement system. The lectin-like 
domain of THBD interferes with in vitro activation of the classical and the lectin 
pathways (Van de Wouwer et al. 2006). In vitro, THBD binds FH and C3b-FH 
complexes, and negatively regulates complement by accelerating FI-mediated 
inactivation of C3b (Delvaeye et al. 2009) and supporting FH in its regulatory activities 
on the cell surface (Heurich et al. 2016). In contrast to all these results describing 
THBD as a negative regulator of complement system, a recent publication proposed 
THBD as a complement activator by enhancing C3 activation in a similar fashion to 
properdin (Tateishi et al. 2016). Nevertheless, the physiological meaning of the dual 
modulating functions of THBD in the AP complement system remains still unclear.   
Additionally, THBD can be release from endothelial cell surfaces, in a mechanism 
referred as shedding, mediated by neutrophil-derived proteases and accompanied by cell 
damage. THBD shedding is thought to contribute to increase risk of thrombosis 
associated with inflammation, and it is described in TTP/HUS patients (Mori et al. 
2001), in coagulation-related syndromes or in several autoimmune disorders (Boehme et 
al. 2000; Ware et al. 2003). Thus, soluble THBD can be considered a reliable marker for 
endothelial damage in conditions where coagulation and/or complement are 
dysregulated.  
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1.3.3.5 VWF: a new player in complement modulation 
More recent studies offer an innovative link between the coagulation cascade and 
complement activation, provided by VWF. The multimeric VWF, which initiates 
haemostasis by promoting platelet adhesion, also interacts at various levels with 
complement components, including C3 and C5, and acts as a complement amplifier on 
endothelial cell surface (Turner et al. 2009; Turner and Moake 2013). Contrary to these 
findings, there are also some evidence providing a role for VWF as a negative regulator 
of the complement system. VWF has been shown to favor C3b inactivation by 
enhancing FH cofactor activity for FI-mediated cleavage (Rayes et al. 2014). Another 
study proposed that normal plasma VWF multimers alone may exert cofactor activity, 
while ULVWF multimers lacked cofactor activity and did not inhibit the generation of 
C3b from C3 (Feng et al. 2015). Since FH binds to VWF, and VWF-FH complexes 
were detected in normal plasma (Feng et al. 2013)c, the contribution of contaminating 
FH in plasma derived VWF preparation to the observed cofactor activity cannot be 
excluded. Finally, Noone et al recently suggested that VWF has a role in protecting the 
endothelium from complement deposition, based on findings of increased C3c 
deposition on cultured blood outgrowth endothelial cells (circulating endothelial 
progenitor isolated from peripheral blood) from patients with type 3 VWF disease that 
have severe deficiency of VWF (Noone et al. 2016). However, the precise molecular 
mechanism through which VWF modulates complement, and its pathophysiological 
implications for human diseases have not been clarified yet, and further studies are 
needed. 
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1.3.3.6 Intracellular complement system: a new concept 
As mentioned before, the complement system is one of the oldest components of 
immunity and is central to the detection and destruction of invading pathogens. Finding 
that complement activation is not confined to the extracellular space but occurs also 
within cellular compartments (Liszewski et al. 2013), suggest new functions for 
complement cascade in different cell effectors immune-related and non-immune-related 
systems. Recently, it has been demonstrated that peripheral blood cells are able to 
uptake C3(H2O) from the circulation, and this uptake allows for recycling of the 
activated C3 as a source of C3a, which in turn can modulate cell activation phenomena 
and result in enhanced proinflammatory and survival phenotypes. This new concept, 
called Intracellular Complement System (ICS), is proposed to be an original gateway to 
activation of complement system in cells, on membranes and in the interstitium, in order 
to assist in a rapid and local response of the host to danger (Elvington et al. 2017). 
Nevertheless, much still remains to be discovered about this ancient and pivotal system, 
and there are many open questions to be fully addressed about its new functions. 
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Figure 1-10. Coagulation and complement system interplay. 
Cartoon summarizing the effects of complement proteins on the coagulation systems, and viceversa.  
The anaphylatoxins C3a and C5a induce release of TNF-α, IL-6 and IL-8 from macrophages, which 
stimulate tissue factor (TF) expression, activate platelets, recruit neutrophils, and, together with C5b-9, 
activate endothelial cells (EC) through loss of heparin sulphate (HS), glycosamminoglycans (GAG) 
and thrombomodulin (THBD), and secretion of von Willebrand Factor (VWF) and P-selectin from 
Weibel-Palade bodies. C5b-9 induces TF expression, providing clot development. After activation, 
platelets release a-granules and microparticles, which stimulate thrombin generation and promote clot 
formation. Thombin and plasmin promote C3 and C5 cleavage. Thrombin binds THBD on cell surface 
and promotes activation of thrombin-activatable fibrinolysis inhibitor (TAFI in TAFIa), which 
inactivates C3a and C5a, and stimulates fibrinolysis for clot breakdown. THBD inhibits lectin and 
classical pathway activation, and supports factor H (FH) in its regulatory activity on C3b. VWF 
modulates complement activation via C3 and FH binding.   
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A disruption of the endothelial cell lining by mechanical or chemical stimuli may 
activate the complement system and clotting. The focal nature of haemostatic control 
and thus the thrombotic tendency of each organ vary depending on the distribution of 
the anticoagulant and procoagulant factors throughout its vascular tree (Rosenberg and 
Aird 1999). With regard to environmental triggers, otherwise innocuous seasonal 
infections, pregnancy and certain drugs have all been reported to induce endothelial 
perturbation which promotes complement activation and ULVWF multimers release. In 
healthy individuals, these events are self-limiting as a result of multiple, redundant 
regulatory mechanisms which control complement inflammatory response and ULVWF 
thrombogenic potential. Individuals carrying genetic abnormalities affecting 
complement regulation or ADAMTS13 activity on ULVWF cleavage are particularly 
vulnerable to these events and predisposed to microvascular thrombosis. Although 
complement system and ADAMTS13/VWF belong to two distinct pathways, their 
crosstalk is recently proposed and it is gaining importance in the understanding of the 
underlying causes of thrombosis. Besides, hyperactivation of the complement system, 
with its prothrombotic and proinflammatory effects, is emerging as a common 
pathogenetic effector in different TMA manifestations, such as HUS and TTP.  
Several publications have highlighted the fact that complement activation via the 
alternative pathway may occur in TTP patients (Chapin et al. 2012; Reti et al. 2012; 
Feng et al. 2013)b;(Tati et al. 2013; Tsai et al. 2013; Wu et al. 2013; Pecoraro et al. 
2015). The study reported in this thesis is basically focused to elucidate whether 
complement activation in TTP is a pathogenetic factor or rather an epiphenomenon. The 
overall objectives of this thesis were to clarify whether direct interactions could exist 
between ADAMTS13 and/or VWF and complement proteins, and to investigate the 
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contribution of impaired VWF cleavage due to ADAMTS13 deficiency in complement 
activation in TTP. 
 
 
Specific Aims 
 
1. To verify whether complement is activated also in congenital forms of TTP 
(cTTP), since most patients analyzed in published reports are affected by acquired 
deficiency of ADAMTS13 and it could not be excluded that complement activation 
found in them is secondary to the presence of autoantibodies. 
 
2. To evaluate whether, in cTTP, complement is activated on microvascular 
endothelium, considering that this disease, similarly to HUS, is a disorder of endothelial 
injury. 
 
3. To study whether ADAMTS13 directly modulates complement activation 
through the interaction with FB, which together with C3b is responsible for the 
formation of the C3 convertase, the key enzyme of the alternative pathway of 
complement cascade. 
 
4. To study and clarify whether VWF modulates complement activation through its 
interaction with FH, the major regulatory protein of the AP of complement. 
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5. To study and verify whether VWF influences complement activation through its 
interaction with C3b, the key protein of the complement cascade, and whether this 
interaction promotes complement activation. 
 
6. To study whether VWF-mediated complement activation modulates 
thromboresistant endothelial phenotype and promotes thrombus formation. 
 
 
 
 
 
 
AIM OF THE STUDY 
 
82 
 
2. METHODS 
 
83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. METHODS 
 
 
 
 
2. METHODS 
 
84 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. METHODS 
 
85 
 
2.1 Patient recruitment 
All patients with TTP or aHUS referred to the International Registry of HUS/TTP  
(http://www.marionegri.it/it_IT/home/medico/ricerca_clinica/registri_patologia) were 
evaluated for inclusion in this study. The International Registry has been established in 
1996 under the coordination of the Clinical Research Center for Rare Diseases Aldo e 
Cele Daccò and till now has included patients from Italian, European and extra-
European Centers. The patients have been enrolled in the study under an approved 
protocol by the Ethical Committee of the Azienda Sanitaria Locale Bergamo, Italy 
(U0148858/III). All participants (patients and their relatives) or their legal guardians 
have received information on the purpose and design of the study, and have provided 
written informed consent to the study. 
The HUS/TTP Registry has been established in order to study the genetic and 
biochemical abnormalities of HUS/TTP, to collect clinical and genetic data of patients 
and their families, to find the best therapeutic approach for patients and to give up-to-
date information to physicians and families. For this purpose, a Case Report Form, 
which is completed for each patient by the referring physician, is prepared. The Form 
included information on signs, symptoms, associated features, plasma and urine routine 
biochemical analysis, follow-up data and family history. Each patient and their relatives 
are pseudonymized by assignment of a DNA code and a family number. Only this code 
is used to label the biomaterial samples. Only the local physicians in charge of the study 
know the code annotation. 
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2.1.1 TTP or aHUS Diagnosis 
TTP or aHUS, firstly identified as TMA, was diagnosed in all cases reported to have 
one or more episodes of microangiopathic haemolytic anemia and thrombocytopenia 
defined on the basis of hematocrit (Ht)<30%, hemoglobin (Hb)<10 g/dl, platelet count 
<150,000/µl, serum lactate dehydrogenase (LDH)>460 IU/l, undetectable haptoglobin 
and the presence of fragmented erythrocytes in the peripheral blood smear, with or 
without neurological symptoms and with or without acute renal impairment during 
bouts.  
In patients with TMA (low platelet count, increased lactate dehydrogenase and 
haemolytic anemia) it is important to establish the correct diagnosis (TTP or aHUS). As 
first, plasma ADAMTS13 activity was measured by the Collagen Binding Assay 
(CBA); severe deficiency of ADAMTS13 activity (<10% as measured) in remission and 
absence of inhibitory anti-ADAMTS13 auto-antibodies as tested by CBA leads to 
diagnosis of TTP. If ADAMTS13 activity is normal (>50%), tests for Shiga toxin-
producing bacteria in stools and/or serum antibodies against Shiga-toxin (ELISA) 
and/or LPS O157, O26, O111, or O145 (ELISA) are performed. Positive tests are 
consistent with diagnosis of STEC HUS. Diagnosis of aHUS is done by exclusion in 
patients in whom these tests are negative and with no evidence of secondary conditions 
(autoimmune diseases, drugs, malignancies). In aHUS patients genetic screening for 
aHUS-associated genes (Noris and Remuzzi 2009) was performed.  
Congenital TTP (cTTP) was diagnosed in TTP patients with homozygous or compound 
heterozygous ADAMTS13 mutations. Details of the ADAMTS13 mutations (most of 
them have been functionally characterized previously (Donadelli et al. 2006; Lotta et al. 
2012; Rurali et al. 2015) and the clinical parameters of the 20 cTTP patients are 
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reported in Table 4 3-1. For these patients, ADAMTS13 antigen levels were measured 
in plasma using a commercial ELISA (Imubind, American Diagnostica). 
An important inclusion criterion of this study was the availability of plasma and/or 
serum taken either during the acute phase (before plasma treatment) and/or in remission, 
at least 30 days after the last plasma treatment. Complete remission was defined as 
normalization of both hematological parameters (Ht >30%; Hb >10 g/dl; LDH <500 
IU/l; platelets >150,000/µl) and renal function (serum creatinine <1.3 mg/dl for adults, 
<0.5 mg/dl for children below 5 years of age and <0.8 mg/dl for children 5-10 years 
old). TTP patients with renal involvement were screened for common aHUS associated 
genes, which allowed us to exclude the presence of genetic abnormalities predisposing 
to complement dysregulation (Prestidge et al. 2012; Pecoraro et al. 2015; Rurali et al. 
2015). 
 
2.2 Collection of biological samples from patients and 
healthy controls 
For each patient and healthy subject controls, 6 ml of whole blood were collected in a 
BD Vacutainer K2EDTA Blood Collection Tube (Becton, Dickinson & Co., Mountain 
View, CA, USA) and stored at -20°C until DNA extraction. In parallel, 8 ml of whole 
blood were collected also in ice-cold K2EDTA, Sodium Citrate (105M / 3.2%) and 
serum silicone-coated Blood Collection tubes, all from BD (Vacutainer), and 
immediately centrifuged at 4°C to avoid ex vivo complement activation. Plasma and 
serum from K2EDTA,Sodium Citrate and silicone tubes respectively, were quickly 
separated and frozen at -80°C until assay.  
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2.3 Determination of ADAMTS13 activity: Collagen 
Binding Assay (CBA)  
ADAMTS13 activity was measured using the residual Collagen Binding Assay (CBA) 
previously described by Gerritsen et al. (Gerritsen et al. 1999) with some modifications. 
This is an indirect assay based on the decreased collagen binding activity of the small 
VWF multimers compared to that of the fully multimerized VWF (Veyradier and Girma 
2004). Briefly, VWF prepared from normal human plasma was used as substrate for the 
protease and patient’s serum sample was used as source of ADAMTS13 to measure 
patient’s ADAMTS13 cleaving activity of VWF (Gerritsen et al. 1999; Franchini and 
Mannucci 2008). Moreover, a pool of normal human sera (NHS) obtained from about 
30 healthy donors with known ADAMTS13 activity levels selected to obtain a pool 
containing 100% of protease activity was used as reference for the assays. The steps are 
described following. 
 
2.3.1 VWF substrate preparation 
Four fresh-frozen plasma bags from four healthy donors (250 ml/each, Azienda 
Ospedaliera Papa Giovanni XXIII, Bergamo, Italy) were pooled in aliquots of 20 ml and 
stored at -80°C. After thawing, an aliquot of this pool was added with 230 µl of 2 mM 
Pefabloc SC buffer (Sigma Aldrich srl) and 1.6 ml of 0.2 M EDTA pH 7.4. After 
incubation for 3 hours at room temperature, the mixture was exhaustively dialyzed in a 
Visking cellulose tubing (Prodotti Gianni) against dialysis buffer (4.5% polyethylene 
glycol 20,000, 5 mM Trizma base, pH 8.0) to remove EDTA and Pefabloc. The dialysis 
was performed three times: initially for 1 hr, then overnight, and finally for 3 hr, each 
time against a 25-fold volume of dialysis buffer (500 ml). The resulting cloudy plasma 
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was free from ADAMTS13 proteolytic activity and was stored in 4.3 ml aliquots at -
80°C. Before use, the substrate was thawed for 10 min at 37°C and added with 1 ml of 
substrate dilution buffer 1 (8 M urea, 5 mM Trizma base, pH 8.0). The substrate was 
then centrifuged for 10 min at 1100 x g and the supernatant was used in the assay. 
 
2.3.2 VWF substrate digestion by ADAMTS13 
Patients’ serum samples were diluted 1:10, 1:20, and 1:40 with sample dilution buffer 2 
(1.5 M urea, 5 mM Trizma base, pH 8.0). Aliquots of 50 µl were then pre-incubated 
with 5 µl of 93 mM BaCl2 for 30 min at 37° C to achieve partial degradation of patient’s 
endogenous VWF. Subsequently, 100 µl of VWF substrate was added to the sample in 
the presence of 3 mM BaCl2 and incubated for 1 hr 45 min at 37°C. The VWF digestion 
was stopped by adding 10 µl of 0.825 M Na2SO4 and the incubation mixtures were 
centrifuged for 3 min at 4200 x g. The obtained supernatants were used to quantify the 
residual VWF substrate by its collagen binding activity.  
Fifty µl aliquots of 1:5, 1:10, 1:20, 1:40, 1:80, 1:160, and 1:320 NHS dilutions in 
sample dilution buffer 1 characterized by 400%, 200%, 100%, 50%, 25%, 12.5% and 
6.25% ADAMTS13 activity level, respectively, were used for the calibration curve. 
 
2.3.3 Collagen binding activity of the digested VWF substrate  
Nunc CovaLink multiwell plate (Thermo Fisher Scientific) was coated with 100 µl of  
Collagen Solution (0.5 mg/ml Human Placenta Villi Collagen type III, Southern 
Biotechnology) for 2 hr and blocked with 2.5% BSA in PBS. Forty µl aliquots of 
digested samples were diluted with 160 µl of sample dilution buffer 2 using a Nunc-
Immuno Maxisorp microtiter plate (Thermo Fisher Scientific) that had been previously 
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blocked with 0.5% BSA,  0.05% Tween20 in PBS 1X for 30 min. Subsequently, 100 µl 
of each diluted digested sample were transferred into wells of the Nunc CovaLink 
multiwell plate previously coated with Human Collagen type III. After a 1 hr 45 min 
incubation, the bound VWF multimers were incubated with 100 µl of a peroxidase-
conjugated anti-human VWF antibody diluted 1:4000 in sample dilution buffer 2. 
Between each step, the wells of the microtiter plates were washed three times with 
Wash buffer (0.05% Tween20 in PBS 1X). The chromogenic reaction was performed 
by addition of 3 tablets of o-phenylenediamine (OPD, Dako) dissolved in 13.5 ml 
ddH2O containing 7.5 µl of 30% (v/v) H2O2. The reaction was stopped by adding 100 µl 
of 2 M H2SO4 and the absorbance was read at 492 nm with the MDL680 Microplate 
Reader (BioRad). 
The values of ADAMTS13 activity were read from a dose-response curve obtained for 
each assay run by testing serial dilutions from 1:5 to 1:320 of the reference NHS. The 
within-assay (n=18) coefficient of variation was 8%, the between-assay (n=100) 
coefficient of variation was 14%, and the lower limit of sensitivity of the method was 
6% of the normal protease levels (Mannucci et al. 2001). Interference of endogenous 
VWF in test samples has been excluded by finding similar protease levels in normal 
plasma and in plasma after cryoprecipitation to remove a large amount of VWF, 
particularly of the larger multimers more reactive with type III collagen (Mannucci et 
al. 2001). Patient samples with activity levels below the detection limit of the assay 
(6%) were defined as having complete deficiency of ADAMTS13 (Remuzzi et al. 
2002). 
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2.4 Genetic screening 
Genetic screening of all exons and intronic flanking regions of aHUS associated genes 
(CFH, CD46, CFI, CFB, C3 and THBD) and ADAMTS13 were performed through Next 
Generation Sequencing (NGS) by my colleagues of the Laboratory of Rare Diseases, 
coordinated by Dr. Marina Noris. Genomic DNA was extracted from blood leukocytes 
(NucleoSpin Blood L, Macherey-Nagel) and sequenced using the Ion Torrent Personal 
Genome Machine (PGM) platform (Thermo Fisher Scientific) which works with the Ion 
semiconductor sequencing method. Ion Torrent technology is capable of directly 
translating chemical signals into digital information. The Ion semiconductor sequencing 
is a method of DNA sequencing based on the detection of hydrogen ions that are 
released during the polymerization of DNA. Naturally, a proton is released when a 
nucleotide is incorporated by the polymerase in the DNA molecule, resulting in a 
detectable local change of pH. Each micro-well of the Ion Torrent semiconductor 
sequencing chip contains approximately million copies of a DNA molecule. The PGM 
sequencer sequentially floods the chip with one nucleotide after another. If a nucleotide 
complements the sequence of the DNA molecule in a particular micro-well, it will be 
incorporated and hydrogen ions are released. The pH of the solution changes in that 
well and is detected by the ion sensor, essentially going directly from chemical 
information to digital information. If there are two identical bases on the DNA strand, 
the voltage is double, and the chip records two identical bases. If the next nucleotide 
that floods the chip is not a match, no voltage change is recorded and no base is called. 
Since this detection is direct, each nucleotide incorporation is measured in sec enabling 
very short run times.  
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The Ion next generation sequencing requires a very simple work-flow: 
1) DNA preparation. DNA must be pure and not degradated. The purity was evaluated 
as 260/280 and 260/230 absorbance ratios, which must be in the range of 1.8 – 2.2 and 
1.5 – 2.2 respectively, using the NanoDrop ND-1000 spectrophotometer. The 
degradation and RNA contamination were evaluated by agarose gel electrophoresis. 
DNA concentration was then confirmed by Qubit 3.0 Fluorometer. 
2) Genomic DNA Library preparation. Libraries were prepared by ultra-high multiplex 
PCRs using the Ion Ampliseq Library Kit v2 and the Ion Plus Fragment Library Kit 
(both from Thermo Fisher Scientific) containing 311 primer pairs (sub-divided into 7 
pools). Then, PCR products were pooled per individual DNA sample, and subjected to 
end-repair (to create blunt ends), to barcode adapter ligation (important for the 
simultaneous sequencing of several samples) and to nick repair reaction (important to 
complete the linkage between the adapters and the amplicons). 
3) Template preparation (Emulsion PCR). The emulsion PCR was performed using the 
Ion PGM Template OT2 200 Kit (Thermo Fisher Scientific) to amplify a single DNA 
fragment on a single Ion Sphere Particles (ISP) in an aqueous droplet (micelle). As 
result of this step each ISP is coated with millions of copies of a single DNA fragment. 
4) Sequencing on Ion Chip. In this step the templated ISP were loaded into a 318 Ion 
chip (Thermo Fisher Scientific) and sequenced using the Ion Sequencing Kit (Thermo 
Fisher Scientific). In Ion sequencing, all four nucleotides were provided in a stepwise 
fashion, and their incorporation into the nascent strand results in a shift in the pH of the 
surrounding solution, converted to a voltage and digitized by off-chip electronics. 
5) Data analysis. Once data were generated on the Ion PGM sequencer, they were 
automatically transferred to the required Torrent Server, that produce the DNA 
sequences associated with individual reads. Read alignment and variant calling were 
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performed using the Torrent Suite software, mapping reads to the reference human 
genome (UCSC build hg19). Genetic variants were functionally annotated using the 
ANNOVAR software: dbSNPbuild137, 1000 genomes ESP6500 and ExAC databases 
were used to distinguish new variants from those already reported; new coding variants, 
coding variants MAF <1% in cases of autosomal recessive inheritance and coding 
variants with MAF <0.1% in cases of autosomal dominant inheritance were analyzed by 
SIFT and Polyphen-2 softwares to identify potentially damaging variants. Intronic 
variants localized 10bp from junctions were analyzed by the Human Splicing Finder 
and Genscan Softwares. Putative mutations and coding regions not adequately covered 
by NGS were validated and analyzed by Sanger sequencing, respectively. 
 
2.5 Serum and plasma complement profile 
Complement C3 and C4 levels in serum were measured by nephelometry, using a 
standard procedure and commercially available diagnostic kits (Siemens Healthcare 
Diagnostics or Beckman Coulter). SC5b-9 levels were evaluated in EDTA plasma 
samples by MicroVue SC5b-9 Plus EIA (Quidel). Levels below or above the limits of 
normal ranges (defined as mean ± 2 SD of the laboratories of the “Azienda Ospedaliera 
Papa Giovanni XXIII”, Bergamo for C3 and C4: C3, 83-180 mg/dl; C4, 15-40 mg/dl, 
and as mean ± 2 SD of 50 healthy controls tested at least twice for SC5b-9, 127-400 
ng/ml) were considered abnormal.  Healthy subjects, considered as controls, were 
recruited by “Azienda Ospedaliera Papa Giovanni XXIII”, Bergamo, and  by the 
Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Ranica BG. The 
protocol was approved by the Ethical Committee of the Azienda Sanitaria Locale 
2. METHODS 
 
94 
 
Bergamo, Italy (U0148858/III). Participants or their legal guardians provided written 
informed consent.  
 
2.6 Ex vivo studies with HMEC-1 and cTTP serum  
The ex vivo studies used here were set up for aHUS and described in detail previously 
(Noris et al. 2014). The human microvascular endothelial cell line of dermal origin 
(HMEC-1, a kind gift from  Dr. Edwin Ades and Francisco J. Candal of CDC and Dr. 
Thomas Lawley of Emory University, Atlanta, GA) was cultured as described (Ruiz-
Torres et al. 2005; Noris et al. 2014). In a previous work of the same Laboratory where 
this study was performed, it has been demonstrated that in primary human 
microvascular endothelial cells of dermal origin (HDMECs) treated with Verotoxin-1, 
expression of endothelial markers such as vitronectin receptor, P-selectin, and PECAM-
1, and thrombus formation were similar to those observed in the HMEC-1 line (Morigi 
et al. 2001). These results indicated that HMEC-1 line manifests the physiological 
sensitivity of the primary cells and could be considered a reliable and representative ex 
vivo model for microvascular endothelium. The growth medium consisted of MCDB 
131 (Life Technologies) supplemented with 10% fetal bovine serum (Life 
Technologies), 1 mg/ml hydrocortisone, 100 U/ml penicillin (Life Technologies), 100 
mg/ml streptomycin (Life Technologies), 2 mM glutamine (Life Technologies), and 50 
mg/ml endothelial cell growth factor (TEBU-BIO srl) (Maciag et al. 1979). For the test, 
HMEC-1 (about 75,000 cells) were plated on glass coverlips and used when confluent. 
Cells were washed three times with test medium (HBSS: 137 mmol/l NaCl, 5.4 mmol/l 
KCl, 0.7 mmol/l Na2HPO4, 0.73 mmol/l KH2PO4, 1.9 mmol/l CaCl2, 0.8 mmol/l 
MgSO4, 28 mmol/l Trizma base pH 7.3, 0.1% dextrose; with 0.5% BSA) and then 
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activated with 10 µM ADP (Sigma Aldrich srl) in test medium for 10 min (ADP-
activated cells) or incubated with test medium alone (resting cells). Then, cells were 
washed three times with test medium and then incubated for 4hr with serum diluted 1:2 
with test medium (final volume 300 µl). At the end of the incubation, HMEC-1 were 
washed two times with PBS, fixed in 3% paraformaldehyde, washed again twice with 
PBS and then blocked with PBS with 2% BSA for 1 hr. The cells were stained with the 
following specific antibodies: FITC-conjugated rabbit anti-human C3c-complement 
(Dako, which recognizes C3c, part of C3 and C3b), or rabbit anti–human complement 
C5b-9 complex (Calbiochem, which recognizes new epitopes of human C5b-9 
complement complex) followed by FITC-conjugated secondary antibody (Jackson 
ImmunoResearch Laboratories), or goat anti-human C4α (Santa Cruz Biotechnology, 
which recognizes an internal region of C4 of human origin) followed by donkey anti-
goat Cy3-conjugated secondary antibody (Jackson ImmunoResearch Laboratories), or 
rabbit polyclonal anti-human VWF (Dako) followed by Cy3-conjugated secondary 
antibody (Jackson ImmunoResearch Laboratories), or mouse anti-human 
thrombomodulin (R&D System) followed by Cy3-conjugated secondary antibody 
(Jackson ImmunoResearch Laboratories). Isotype-matched irrelevant antibodies were 
used as negative controls. In selected experiments, soluble complement receptor 1 
(sCR1, TP-10, 150 µg/ml, a gift from CellDex), an inhibitor of the classical, alternative, 
and lectin pathways of complement activation, or CR2-CFH (TT30 150 µg/ml; a gift 
from Taligen Therapeutics), or a FH concentrate from human plasma (230 µg/ml; LFB 
Biotechnologies), or rADAMTS13 (4 µg/ml; R&D Systems), or eculizumab (100  
µg/ml, Alexion), or an anti-VWF antibody (100 µg/ml, Dako), or an irrelevant antibody 
(normal rabbit IgG, 100  µg/ml, Santa Cruz Biotechnology), or the serine protease 
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inhibitor  aprotinin (200 KIU, Sigma Aldrich srl) were added to serum (before diluition 
with test medium) that was incubated with HMEC-1 for 4 hr. 
In each experiment, serum from a healthy control was tested in parallel with cTTP 
serum; the background (non-specific staining, usually less than 100 pixel2/field) was 
defined in a sample run in parallel of HMEC-1 cells incubated with test medium alone 
without serum and then processed with the same antibodies. The effect of 10 min 
exposure of HMEC-1 to 10 µM ADP on C3 and VWF deposition / expression, and 
VWF-C3 costaining was evaluated by rabbit polyclonal anti-human VWF antibody 
(Dako) followed by a Cy3-conjugated secondary antibody and by mouse anti-human C3 
monoclonal antibody (Abbiotec) followed by a FITC-conjugated secondary antibody. 
C5aR expression on HMEC-1, either resting or activated with 10 µM ADP for 10 min, 
was analyzed using a mouse anti-human CD88 (anti-C5aR, AbD Serotec) followed by a 
Cy3-conjugated secondary antibody. The effect of C5a on VWF and thrombomodulin 
staining was evaluated by challenging HMEC-1 with 200 ng/ml of C5a (Complement 
Technology Inc.) for 10 min. The cells were then treated with rabbit polyclonal anti-
human VWF antibody (Dako) or mouse anti human thrombomodulin (R&D System) 
followed by the specific Cy3-conjugated secondary antibodies. 
Negative controls run in parallel with isotype-matched antibodies showed no staining. 
A confocal inverted laser microscope (LSM 510 Meta, Zeiss) was used for the 
acquisition of the fluorescent staining on the endothelial cell surface. Fifteen fields, 
systematically digitized along the surface, were acquired using a computer-based image 
analysis system. The area occupied by the fluorescent staining was evaluated by 
automatic edge detection using built-in specific functions of the software Image J (NIH, 
Bethesda, MD), and expressed as pixel2 per field analyzed. For each sample the mean of 
the 15 fields was calculated. In order to obtain unbiased quantification of 
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immunofluorescence stainings, the technician who routinely acquired the images from 
the microscope and quantified the fluorescent signal of each of them, did not know 
details about serum samples used, such as phase of disease, mutations or treatment. 
  
2.7 Computational studies on FB, VWF and ADAMTS13 
structures 
2.7.1 In silico comparison between von Willebrand type A 
domain of Factor B and A2 domain of VWF  
Published 3D crystal structures of VWA domain of FB and A2 domain of VWF were 
collected from the free open-source Protein Data Bank (PDB) website. 1Q0P is the PDB 
reference number for the crystal of A domain of Factor B (VWA, FB), while 3ZQK is 
the PDB reference number for the crystal of Von Willebrand Factor A2 domain (VWF-
A2), the latter obtained in the presence of calcium. Aminoacidic sequence alignment of 
the two domains was performed by UNIPROT (http://www.uniprot.org/align). The 
results of the alignment are expressed as a degree of identity, calculated as the ratio 
between the number of identical aminoacids and the length of the considered sequence x 
100, and display the following symbols denoting the scale of conservation observed in 
each column (refering to Fig. 3-7 in Results): 
• An * (asterisk) indicates positions which have a single, fully conserved residue. 
• A : (colon) indicates conservation between groups of strongly similar properties - 
scoring > 0.5 in the Gonnet PAM 250 matrix. 
• A . (period) indicates conservation between groups of weakly similar properties - 
scoring =< 0.5 in the Gonnet PAM 250 matrix. 
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2.7.2 Three dimensional  structural model of ADAMTS13  
Structural models of ADAMTS13 were designed using I-TASSER software 
(http://zhanglab.ccmb.med.umich.edu/I-TASSER) (Zhang 2008; Roy et al. 2010) (Fig. 
2-1). 
 
Aminoacids 75-1427 (protein sequence without signal peptide and propeptide) of 
human ADAMTS13 were submitted to I-TASSER server and the structural models of 
the sequence were built based on the alignment with the structural coordinates of 
proteins chosen as threading templates, reported in Table 2-1. The best structural 
prediction of ADAMTS13 obtained a C-score of -0.73 and an expected TM-score of 
0.62±0.14, indicating a model of correct topology and folding. C-score is typically in 
Figure 2-1. Screenshot of I-TASSER web interface. 
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the range of [from -5 to 2], where a C-score of higher value signifies a model with a 
high confidence and vice-versa.  In general, models with C-score >-1.5 have a correct 
fold (Roy et al. 2010).  
Table 2-1. Templates used for the reconstruction of the tridimensional model of human 
ADAMTS13. 
Rank1  PDB-ID2  Ident1
3
  Ident24  Cov5  Norm  Z-score6  Protein
7
  
1  3gawA  0.12  0.18  0.86  2.49  Solution structure of Human Complement Factor H in 250 mM NaCl buffer  
2  2eroA  0.16  0.06  0.30  2.13  Crystal structure of vascular apoptosis-inducing protein-1(orthorhombic crystal form)  
3  3ghnA  0.99  0.27  0.27  2.63  Crystal structure of the exosite-containing fragment of human ADAMTS13 (form-2)  
4  3ghmA  1.00  0.27  0.27  3.71  Crystal structure of the exosite-containing fragment of human ADAMTS13 (form-1)  
5  2rjqA  0.30  0.06  0.21  2.34  Crystal structure of ADAMTS5 with inhibitor bound  
6  3gauA  0.10  0.18  0.84  6.14  Solution structure of Human Complement Factor H in 50 mM NaCl buffer  
7  2rjqA  0.30  0.06  0.21  3.53  Crystal structure of ADAMTS5 with inhibitor bound 
8  2v4bA  0.30  0.07  0.21  3.85  Crystal structure of human ADAMTS1 catalytic domain and Cysteine-rich domain (apo-form) 
9  3gavA  0.12  0.18  0.81  2.24  Solution structure of Human Complement Factor H in 137 mM NaCl buffer 
10  3q2gA  0.30  0.07  0.21  1.81  ADAMTS1 in complex with a novel N-hydroxyformamide inhibitors  
1Template ranks represent the top ten threading templates used by I-TASSER; 2PDB-ID is the 
ProteinDataBank (PDB) reference number of the template proteins; 3Ident1 is the percentage sequence 
identity of the templates in the threading-aligned region with the query sequence; 4Ident2 is the 
percentage sequence identity of the whole template chains with the query sequence; 5Cov. represents the 
coverage of the threading alignment and is equal to the number of aligned residues divided by the length 
of query sequence; 6Norm. Zscore is the normalized Z-score of the threading alignments (>1 reflects a 
good alignment and vice versa); 7The name of the crystal structures used as template. 
The model was then manipulated using the program PyMOL (The PyMOL Molecular 
Graphics System, Version 1.2r3pre, Schrodinger, LLC). 
 
2.7.3 In silico prediction of ADAMTS13-FB interaction 
The computational docking of target protein structures was perfomed by the fully 
automated web-based program ClusPro 2.0 (https://cluspro.bu.edu/login.php) (Comeau 
et al. 2004; Comeau et al. 2004) (Fig. 2-2).  
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ClusPro is one of the most efficient software for the automatic prediction of protein-
protein docking. ClusPro is a web server developed by the laboratory of Structural 
Bioinformatics of the Boston University. It provides many different options for 
molecular docking because good results go hand-in-hand with experimental knowledge 
of the complex.  
Models are ranked by cluster size, which is how the models coming out of Cluspro, and 
which is the most efficiently used method in Critical Assessment of Predicted 
Interactions (CAPRI) and on various protein docking benchmarks. The score results as a 
translation of the ligand rotations on a grid relative to the receptor, and refers to binding 
site RMSDs (root-mean-square deviation of atomic positions, the measure of the 
average distance between the atoms of the ligand relative to the receptor). The ligand 
position with the most "neighbors" in 9 angstroms becomes a cluster center (Center in 
Figure 2-2. Screenshot of ClusPro web interface. 
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the Table 2-2). The “stability” of a cluster was then evaluated by testing the lowest local 
energy minimum in Monte Carlo simulation (Lowest Energy in the Table 2-1).  
Coordinate files of ADAMTS13 structural model, obtained with I-TASSER software, 
and PDB code of FB structure (2OK5) were uploaded through ClusPro's web interface 
as Receptor and Ligand, respectively. The docking algorithms evaluated billions of 
putative complexes, retaining a preset number with favourable surface 
complementarities, and good electrostatic and desolvation free energies. Since it is 
unknown of which forces govern ADAMTS13-FB complex, docking results have been 
chosen by balanced coefficients, which took into consideration electrostatic,  
hydrophobic and  van der Waals forces concurrently (Table 2-2). 
 
Table 2-2. List of putative ADAMTS13-FB complexes. 
Cluster Members Representative Weighted Score 
0 36 
Center -1320.3 
Lowest Energy -1320.3 
1 34 
Center -1052.1 
Lowest Energy -1221.1 
2 31 
Center -997.4 
Lowest Energy -1111.4 
3 29 
Center -964.8 
Lowest Energy -1090.5 
4 21 
Center -1041.5 
Lowest Energy -1296.5 
5 19 
Center -1003.2 
Lowest Energy -1114.3 
6 17 
Center -1125.7 
Lowest Energy -1125.7 
7 15 
Center -1054.5 
Lowest Energy -1054.5 
8 15 
Center -1034.8 
Lowest Energy -1034.8 
9 15 Center -979.5 
Lowest Energy -1152.4 
10 14 
Center -1052.0 
Lowest Energy -1178.4 
11 12 
Center -991.6 
Lowest Energy -1065.3 
12 12 
Center -1168.1 
Lowest Energy -1168.1 
13 12 
Center -1088.9 
Lowest Energy -1132.2 
14 11 Center -1026.0 
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Lowest Energy -1052.7 
15 11 Center -1070.6 
Lowest Energy -1070.6 
16 11 
Center -1051.9 
Lowest Energy -1089.3 
17 11 
Center -1040.7 
Lowest Energy -1148.9 
18 11 
Center -1016.1 
Lowest Energy -1180.2 
19 11 
Center -961.1 
Lowest Energy -1107.3 
20 10 
Center -974.6 
Lowest Energy -1054.3 
21 10 
Center -1012.4 
Lowest Energy -1191.1 
22 9 
Center -1005.9 
Lowest Energy -1095.1 
23 8 
Center -964.1 
Lowest Energy -1063.7 
24 7 
Center -971.9 
Lowest Energy -1122.4 
25 5 
Center -1019.4 
Lowest Energy -1086.3 
26 3 
Center -984.2 
Lowest Energy -984.2 
 
The models were manipulated using the Educational-use-only program PyMOL  
(https://www.pymol.org/, The PyMOL Molecular Graphics System, Version 1.2r3pre). 
PyMOL is a molecular visualization system on an open source foundation, maintained 
and distributed by Schrödinger.  
 
2.8 rADAMTS13-FB interaction  
2.8.1 SPR binding assays 
In order to study whether ADAMTS13 interacts with FB, Surface Plasmon Resonance 
(SPR) experiments were performed using a BIAcore 2000 system in collaboration with 
Dr. Marco Gobbi and coworkers of the laboratory of Pharmacodynamics and 
Pharmacokinetics in “Mario Negri” Institute in Milano. Commercial human 
rADAMTS13 (R&D Systems) was diluted in sodium acetate pH 5.0 and immobilized 
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onto a flow channel surface of a Proteon GLC sensor chip (Biorad) by amine coupling 
chemistry. Three different concentrations (1, 2 and 4 µM) of purified human FB 
(Complement Technology Inc.) were flowed over immobilized rADAMTS13 at a flow 
rate of 30 ml/min. To evaluate the binding specificity, a single concentration (1µM) of 
purified human C3b or C3 (Complement Technology Inc.) was injected over 
immobilized rADAMTS13. All the assays were performed at 25°C. The sensorgrams 
were normalized to a base-line value of 0. The signal observed in the surfaces 
immobilizing the protein was corrected by subtracting the nonspecific responce 
observed in the reference surface. 
 
2.8.2 ELISA binding assays 
Different amounts of FB 50-0 nM (diluition 1:2) were incubated over rADAMTS13 
coated wells (2.5 ug/mL), and the ADAMTS13-FB complexes were detected by goat 
anti-human FB antibody (1:10000, Quidel) followed by HRP-conjugated anti-goat 
antibody (1:40000, Sigma Aldrich srl). Colour was developed using TMB substrate 
(3,3′,5,5′-Tetramethylbenzidine, Bethyl) and stopped with H2SO4 2M, and absorbance 
was measured at 450 nm. Each reaction was performed in duplicate and the OD values 
averaged. Bovine and human albumin serum (BSA and HSA, Sigma Aldrich srl) were 
considered as irrelevant negative controls.  
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2.9 rADAMTS13 cleavage assays 
2.9.1 Cleavage of FB, FD and C3b 
A mixture of FB (27 nM or 5.6 nM, Complement Technology Inc.) or C3b (14 nM, 
Complement Technology Inc.) or FD (110 nM, Complement Technology Inc.) was 
incubated in the presence of different concentrations of rADAMTS13 (R&D Systems; 
0.56 nM, 100 ng/ml; 0.168 nM, 30 ng/ml; 1.4 nM, 250 ng/ml; 2.8 nM, 500 ng/ml; 5.6 
nM, 1000 ng/ml), for 2hr at 37°C in 5 mM Tris-HCl buffer containing 1.5 M urea and 3 
mM BaCl2, pH 8. For FB cleavage assay, ADAMTS13 concentrations range from the 
physiological molar ratio 330:1=FB:ADAMTS13 to non-physiological 10:1. For C3b 
and FD cleavage assays, ADAMTS13 amount correspond to the concentration that 
provides the cleavage of 100 ng of rVWF-A1A2A3. The reactions were stopped by 
adding Na2SO4 and the cleavage products were subjected to 10% SDS-PAGE and 
visualized by Silver Staining (Sigma Aldrich srl) or western blot (WB) with rabbit anti-
FB antibody (1:500, ATLAS) followed by HRP conjugated anti-rabbit antibody 
(1:30000; Vector Lab.) and ECL system (Amersham). 
 
2.9.2 Cleavage of rVWF fragment 
Recombinant ADAMTS13 activity was evaluated by cleavage of a rVWF fragment. In 
particular, a mixture of purified recombinant VWF fragment comprising A1-A2-A3 
domains (residues 1271-1874) of VWF (rVWF-A1A2A3) (Donadelli et al. 2006) was 
incubated and processed as previously described (Remuzzi et al. 2002). Briefly, rVWF-
A1A2A3 (10 ng/ml) was mixed with 0.2 nM of rADAMTS13 (R&D system) and 
incubated for 2 hr at 37°C in the presence of 5 mM tris buffer containing 1.5 M urea and 
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3 mM BaCl2, pH 8.0. The cleavage was stopped by adding 5.7 µl of 0.825 M Na2SO4. 
Fifteen µl of the reaction were subjected to 10% SDS-PAGE and transferred to a PVDF 
membrane (Biorad). The membrane was then stained with the primary mouse 
monoclonal antibody directed against the carboxy-terminal of the rVWF-A1A2A3 
(dilution 1:500, kindly provided by Prof. Z. M. Ruggeri, The Scripps Research Institute, 
La Jolla, CA), followed by the secondary HRP-conjugated rabbit anti-mouse IgG 
antibody (1:2000, Zymed). Signals were developed using ECL chemiluminescence 
detection system (Amersham). The amount of proteolytic fragment formed (about 30 
kDa) from the cleavage of the rVWF A1-A2-A3 (80 kDa) by rADAMTS13. The results 
were expressed as the mean of n=3 experiments. 
 
2.10 C3 proconvertase and C3 convertase formation assays 
2.10.1 C3bBb(Mn2+) C3 proconvertase and C3bBb(Mg2+) 
C3 convertase formation  in microplate/WB assays 
Novel user-friendly methods based on combined microplate and WB techniques were 
set up to selectively generate and detect AP C3bB proconvertase and C3bBb convertase 
(Marinozzi et al. 2014). The setup is explained in details as follows. 
For the generation of C3bB and C3bBb complexes in vitro, an ELISA assay was first 
tested as described previously by Hourcade et al. (Hourcade et al. 1995)). ELISA plates 
were coated with 3 µg/ml C3b (Complement Technology Inc.) in PBS by overnight 
incubation at 4°C, blocked with 1% BSA, 0.1% Tween20 in PBS for 1h at 37°C, and 
washed with wash buffer (8.1 mM Na2HPO4, 1.8 mM NaH2PO4, 0.1% Tween20 and 25 
mM NaCl) supplemented with 2 mM NiCl2. C3bB and C3bBb complexes were formed 
by incubating C3b-coated wells at 37° C for 2hr with different concentrations of FB 
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(Complement Technology Inc., 0–500 ng/ml, 1:2) in the absence or in the presence of 
FD (Complement Technology Inc., 25 ng/ml), respectively, both diluted in assay buffer 
(8.1 mM Na2HPO4, 1.8 mM NaH2PO4, 4% BSA, 0.1% Tween20 and 75 mM NaCl) 
containing 2 mM NiCl2. After washes, the C3bB and C3bBb complexes were detected 
by ELISA using polyclonal goat anti-human FB antibody (1:10000, Quidel) followed 
by HRP-conjugated anti-goat antibody (1:40000, Sigma Aldrich srl), both diluted in 
antibody buffer (8.1 mM Na2HPO4, 1.8 mM NaH2PO4, 4% BSA, 0.1% Tween20 and 25 
mM NaCl) supplemented with 2 mM NiCl2. Colour was developed using TMB 
substrate and stopped with H2SO4 2 M, and absorbance was measured at 450 nm. Each 
reaction was performed in duplicate and the OD values averaged. As shown in Fig. 2-
3A, the ELISA curves from the reaction of coated C3b with either FB alone or FB plus 
FD showed dose-dependent superimposable profiles. In parallel experiments, the 
complexes originated on wells were detached from microplate by incubation with 10 
mM EDTA and 1% SDS for 1hr at room temperature, subjected to 10% SDS-PAGE, 
transferred by electroblotting to a PVDF membrane (Biorad), and analyzed on WB with 
polyclonal rabbit anti-human FB antibody (1:500, Atlas) followed by HRP-conjugated 
anti-rabbit antibody (1:30000, Vector Laboratories) and the ECL chemiluminescence 
detection system (Amersham). C3bB and C3bBb formation was evaluated by the 
visualization by WB of the B band (93 kDa) and the Bb band (60 kDa), respectively. 
When the complexes that formed in the presence or in the absence of FD were detached 
from the wells both B and Bb bands were found in both conditions (Fig. 2-3A, right 
side) indicating that this experimental protocol could not selectively discriminate 
between C3bB and C3bBb complexes formation. Indeed, in the presence of FD only a 
portion of C3bB was converted to C3bBb. Conversely, in the absence of FD, some 
C3bBb also formed besides C3bB, possibly due to FD contamination in commercial FB 
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plasma-purified protein (Harris et al. 2005). As a result, this protocol, based on Ni2+ 
ions, was abandoned due to the simultaneous stabilization of both enzymes.  
In an effort to specifically generate either C3bB or C3bBb complexes in an in vitro 
assay, selective stabilization abilities of different divalent cations have been taken into 
account. Hourcade and Mitchell (Hourcade and Mitchell 2011) documented that Mn2+ 
stabilizes C3bB in a form susceptible to FD cleavage, but the C3bBb(Mn2+), once 
formed, is highly unstable and dissociates immediately, so that only the C3bB(Mn2+) 
complex could be detected. At variance, Mg2+ stabilizes C3bBb but not the proenzyme 
C3bB (Fishelson and Muller-Eberhard 1982). On the basis of this evidence, the ELISA 
described above was repeated replacing Ni2+ with Mn2+ or Mg2+ ions to stabilize either 
the C3bB or the C3bBb, respectively. ELISA plates were coated with C3b, blocked, and 
then washed with wash buffer supplemented with 2 mM MnCl2 or 10 mM MgCl2 for 
C3bB or C3bBb, respectively. C3bB(Mn2+) complexes were assembled by incubating 
C3b-coated wells at 37 °C for 2hr with FB (500 ng/ml), diluted in assay buffer 
containing 2 mM MnCl2. C3bBb(Mg2+) complexes were formed by incubating C3b-
coated wells at 25 °C for 30 min with FB (500 ng/ml) and FD (25 ng/ml), in assay 
buffer with 10 mM MgCl2. In parallel with ELISA, the complexes were detached from 
microplate and analyzed on WB as above. As shown in Fig. 2-3, B and C, in either 
condition the amount of the complexes formed was too small to be detected by ELISA 
(left panels), likely due to degradation of the C3bB(Mn2+) and the C3bBb(Mg2+) during 
post-reaction incubation times with primary and secondary antibodies. At variance, 
when we detached the complexes immediately at the end of the reaction, and analyzed 
them on WB, the B and Bb bands of C3bB(Mn2+) and C3bBb(Mg2+), respectively, 
could be visualized well (Fig. 2-3, B and C, right panels). It is relevant that only the B 
band of C3bB was visualized in the product of the reaction with Mn2+, even when FD 
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was added to the incubation mixture. Similarly, only the Bb band of C3bBb was 
detected in the reaction with Mg2+ and FD. 
 
 
Figure 2-3. Detection of C3bB C3 proconvertase and C3bBb C3 convertase complex formation by 
ELISA and microplate/WB assays. 
A. Detection of Ni2+-dependent C3bB and C3bBb. C3b-coated microtiter wells were incubated with 
increasing amounts of FB (0–500 ng/ml) and 2 mM NiCl2 in the absence or in the presence of 25 ng/ml 
FD and analyzed by ELISA by using an anti-FB antibody (left side). The product of the reaction with 
500 ng/ml FB, once detached from the wells, was also analyzed by WB with an anti-FB antibody (right 
side). B and C. Selective formation of C3bB and C3bBb with Mn2+ and Mg2+, respectively. 
C3b-coated wells were incubated with 500 ng/ml FB in the absence or in the presence of 25 ng/ml FD, 2 
mM MnCl2, or 10 mM MgCl2 to obtain C3bB(Mn2+) and C3bBb(Mg2+), respectively. Complexes were 
detected both by ELISA (left side) and WB (right side). C3bB and C3bBb formation was evaluated by 
the visualization of the B band (93 kDa) and the Bb band (60 kDa), respectively. One representative 
experiment of three is shown. 
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Then, time course of C3bB(Mn2+) and C3bBb(Mg2+) complexes formation was 
analyzed, and the two novel microplate/WB procedures were optimized. Microplates 
were coated with C3b, blocked and washed as above. C3bB(Mn2+) complexes were 
assembled by incubating C3b-coated wells at 37 °C for 1, 2, 4 and 8hr with FB (1000 
ng/ml, 10.8 nM), diluted in assay buffer containing 2 mM MnCl2 and 4 % BSA. 
C3bBb(Mg2+) complexes were formed by incubating C3b-coated wells at 25 °C for 5, 
10, 30 and 45 min with FB (1000 ng/ml, 10.8 nM) and FD (5 ng/ml, 0.22 nM; 
physiological FB/FD molar ratio of 50:1), in assay buffer with 10 mM MgCl2 and 0.5 % 
BSA. After washes, the complexes were detached from microtiter wells and analyzed 
on WB as described in the previous section. C3bB and C3bBb formation was evaluated 
by the visualization on WB of the B (93 KDa) and Bb (60 KDa) bands, respectively, 
and estimated by densitometry using NIH Software ImageJ (NIH, USA). As shown in 
Fig. 2-4A, the B band of C3bB(Mn2+) was clearly detected after 2hr of incubation and 
was still evident at 8hr independently of the presence of FD, further confirming the 
specificity of the test for C3bB assembly. The kinetics of C3bBb(Mg2+) (Fig. 2-4B) 
formation was faster than that of C3bB(Mn2+), and indeed the Bb band was already well 
detected after 10 min of incubation and the intensity further increased at 45 min of 
incubation.  
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In the attempt to evaluate ADAMTS13 effect on C3bB C3 proconvertase and C3bBb 
C3 convertase formation, these two novel microplate/WB assays were used. Microtiter 
wells were coated with 3 µg/ml C3b in PBS by overnight incubation at 4°C, blocked 
with 1 % BSA, 0.1 % Tween20 in PBS for 1h at 37 °C, and washed with wash buffer 
supplemented with 2 mM MnCl2 or 10 mM MgCl2. C3bB(Mn2+) complexes were 
formed by incubating C3b-coated wells at 37 °C for 2hr with FB (1000 ng/ml, 10.8 
nM), in the absence or in the presence of rADAMTS13 (R&D Systems; 0.04 nM, 6.6 
ng/ml; 0.11 nM, 19.8 ng/ml; 0.55 nM, 99 ng/ml), diluted in the assay buffer containing 
2 mM MnCl2 and 4 % BSA. C3bBb(Mg2+) complexes were formed by incubating C3b-
coated wells at 25 °C for 10 min with FB (1000 ng/ml, 10.8 mM) and FD (5 ng/ml, 0.22 
mM), in the absence or in the presence of rADAMTS13 (0.04 nM, 6.6 ng/ml; 0.11 nM, 
19.8 ng/ml; 0.55 nM, 99 ng/ml), both diluted in the assay buffer with 10 mM MgCl2 and 
0.5 % BSA. After washes, the protein complexes were detached from microtiter wells 
and analysed by WB as above. 
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Figure 2-4. Time course of selective C3bB(Mn2+) C3 proconvertase assembly (A) and C3bBb(Mg2+) 
C3 convertase formation (B) detected by microplate/WB assays.  
C3bB(Mn2+) and C3bBb(Mg2+) complexes were obtained by incubating C3b-coated wells at time points 
indicated with 1000 ng/ml FB in the presence or in the absence of 5 ng/ml FD and 2 mM MnCl2 at 37 °C 
or 10 mM MgCl2 at 25 °C, respectively. The amount of C3bB assembled and of C3bBb formed was 
calculated as the intensity of B (93 kDa) and Bb (60 kDa) bands, respectively, and results are reported in 
the bottom graphs as pixel2*106. Results of a representative microplate/WB experiment of n = 3 are 
shown. 
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2.10.2 Spontaneous and FH-mediated decay of 
C3bBb(Mn2+) C3 proconvertase and C3bBb(Mg2+) C3 
convertase in microplate/WB assays 
In order to study spontaneous or FH-mediated decay of C3 proconvertase and C3 
convertase over time, C3bB(Mn2+) and C3bBb(Mg2+) were allowed to form for 2hr at 
37°C and 10 min at 25°C, respectively as described above, then were washed and 
incubated with selective assay buffers in the presence or in the absence of FH (2640 
ng/ml; molar ratio FB:FH=1:1.6) for the following time periods: C3bB(Mn2+), 30, 60 
120 and 240 min; C3bBb(Mg2+), 2, 4, 8 and 16 min.  
The intensity of the B bands of C3bB(Mn2+) did not change over 240 min decay vs. 
baseline, either in the absence or in the presence of FH, indicating that in these 
conditions FH did not displace FB from C3b (Fig. 2-5A). Conversely, Bb bands of 
C3bBb(Mg2+) disappeared in a time-dependent manner, and faster in the presence of FH 
(Fig. 2-5B) confirming that FH is very efficient in Bb displacement from C3b. 
To investigate the effect of VWF on FH decay accellerating activity on C3 convertase, 
rVWF-A1A2A3 was tested in this new microplate/WB assay. C3bBb(Mg2+) complexes 
were obtained as described above by incubating C3b-coated wells at 25 °C for 10 min 
with FB (1000 ng/ml, 10.8 mM) and FD (5 ng/ml, 0.22 mM), in the absence or in the 
presence of rVWF-A1A2A3 (17.6 nM, 1408 ng/ml; 0.176  nM, 14.08 ng/ml), diluted in 
the assay buffer with 10 mM MgCl2 and 0.5 % BSA. After washes, the protein 
complexes were incubated at 25 °C for 4 min with assay buffer alone in the presence or 
in the absence of FH (17.6 nM, 2640 ng/ml) and rVWF-A1A2A3 (17.6 nM, 1408 
ng/ml). At the end of incubation, the complexes were detached from microtiter wells 
and analysed by WB as above. 
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2.10.3 C3 proconvertase and C3 convertase formation in 
SPR assays 
SPR experiments were carried out in collaboration with Dr. Marco Gobbi, as mentioned 
before, by using BIAcore 2000 (Biorad). Purified human C3b (Complement 
Technology Inc.) was diluted to 30 µg/ml in sodium acetate pH 5.0 and immobilized 
using amine coupling chemistry over a surface of a GLC sensor chip (Biorad), as 
previously described (Jokiranta et al. 2001; Harris et al. 2005), to obtain a final 
immobilization level of about 7000 RU (1RU= 1 pg/mm2). A reference surface was 
always prepared in parallel by performing the same immobilization procedure but 
without the addition of any protein. The signal observed in the surfaces immobilizing 
the protein was corrected by subtracting the nonspecific response observed in the 
Figure 2-5. Spontaneous and FH-mediated decay of selective C3bB(Mn2+) C3 proconvertase (A) 
and C3bBb(Mg2+) C3 convertase (B) detected by microplate/WB assays. 
C3bB(Mn2+) and C3bBb(Mg2+) complexes were obtained by incubating C3b-coated wells with 1000 
ng/ml FB in the absence or in the presence of 5 ng/ml FD and 2 mM MnCl2 for 2 h at 37 °C or 10 mM 
MgCl2 for 10 min at 25 °C, respectively. Time-course of spontaneous and FH-mediated decay of 
C3bB(Mn2+)  or C3bBb(Mg2+) was evaluated by further incubation with buffer alone or with 2640 ng/ml 
FH for 30, 60, 120 and 240 min, or 2, 4, 8 and 16 min, respectively. The amount of C3bB and C3bBb 
formed was calculated as the densitometry of the B (93 kDa) and Bb (60 KDa) bands and results are 
reported in the bottom graphs as pixel2 * 106. The percentage of residual B and Bb bands was calculated 
as the ratio of the densities (in Pixel2) of each band after decay and the corresponding baseline band 
density before decay x 100. Results of a representative microplate/WB experiment of n = 3 are shown.  
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reference surface. After rotation of the microfluidic system, FB (200 nM, Complement 
Technology Inc.) was injected in the presence or in the absence of FD (4 nM, 
Complement Technology Inc.) and rADAMTS13 (1 nM, R&D Systems) over the 
immobilized C3b for 180 s at a flow rate of 30 ml/min. All of these assays were done at 
25°C. The sensorgrams were normalized to a base-line value of 0.  
 
2.11 FH cofactor activity for FI-mediated proteolysis of fluid 
phase C3b 
The fluid-phase cofactor activities of FH and VWF were determined in a C3b 
proteolytic assay using purified proteins. C3b and FI were from Complement 
Technology Inc.; FH was purchased from Merck; rVWF was a gift from Baxter; LFB-
VWF was from LFB Biotechnologies (Mazurier 1998); Emoclot-VWF was from 
Kedrion S.p.A. (Peyvandi et al. 2013); rA2-VWF was from R&Dsystems.  
In brief, C3b, FH, VWF and FI were mixed in 10 mM HEPES (pH 7.5), 150 mM NaCl, 
and 0.02 % Tween20. Final concentrations were: C3b 0.42 µM, FH 31.3 nM, FI 43 nM, 
and VWF 0.313 nM (1X, physiological molar ratio with FH) or 3.13 nM (10X) or 156.5 
nM (500X). Molarities were calculated using the following masses: C3b, 185 KDa; FH, 
155 KDa; FI, 88 KDa; VWF, 250 KDa; A2-VWF, 20 KDa. Mixtures were incubated at 
37°C in a water bath for 10 min or 1 min, in the absence or in the presence of FH 
respectively. The reactions were stopped by the addition of 4x Laemmli protein sample 
buffer for SDS-PAGE (Biorad) supplemented with 10% 2-mercaptoethanol (Sigma 
Aldrich srl). Samples were analyzed in 10% SDS-PAGE under reducing conditions. 
Gels were stained with ProteoSilver Stain Kit (Sigma Aldrich srl), and proteolysis of 
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C3b was determined by analyzing the disappearing of the α‘ chain (110 KDa) band and 
the appearance of the α65 KDa and α43 KDa bands. 
 
2.12 C3b-VWF interaction  
2.12.1 SPR binding assays 
SPR experiments were carried out in collaboration with Dr. Marco Gobbi, as mentioned 
before, by using BIAcore 2000. Recombinant multimeric human VWF (rVWF, kindly 
provided by Baxter) was reduced (20 min at 56 °C with 65 mM dithiothreitol, DTT) and 
then covalently  immobilized onto a flow channel surface of a Proteon GLC sensor chip 
(Biorad), using amine coupling chemistry. Three different concentrations (1µM, 500 
nM or 100 nM) of purified human C3b (Complement Technology Inc.) were injected 
over immobilized rVWF at the rate of 30 µl/min for 10 min (associating phase). The 
dissociating phase was evaluated in the following 10 min. The running buffer, also used 
to diluite analytes, was phosphate-buffered saline pH 7.4, 0.005% Tween20. A 
reference channel was always prepared in parallel by the same immobilization 
procedure without the addition of the ligand. The signal observed in the surfaces 
immobilizing the protein was corrected by subtracting the nonspecific response 
observed in the reference surface. All the assays were performed at 37 °C.  
 
2.12.2 ELISA binding assays 
Microtiter wells were coated with 5 µg/ml rVWF either multimeric or monomeric 
(reduced with DTT 30 mM) or purified rVWF-A1A2A3 domains (a kind gift of Prof. 
Z.M. Ruggeri, The Scripps Research Institute, La Jolla, Ca) rVWF-A1 (U-Protein 
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Express BV), rVWF-A2 (R&D Systems), rA3-VWF (U-Protein Express BV) in PBS by 
overnight incubation at 4°C. Then, coated wells were blocked with 1% BSA for 1hr at 
R.T., and washed with PBS supplemented with Tween20 0.1% and MgCl2 10 mM. 
Different amounts of C3b ranging from 0.16 µg/ml to 50 µg/ml were incubated with 
coated wells for 2hr at 37°C. Protein complexes were detected by mouse anti-human C3 
antibody (1:16000, Abbiotec) followed by HRP-conjugated anti-mouse antibody 
(1:10000, Zymed). Colour was developed using TMB substrate (Bethyl), stopped with 
H2SO4 2 M, and absorbance was measured at 450 nm. Each reaction was performed in 
duplicate and the OD values averaged. BSA was considered as an irrelevant-negative 
control. 
In additional experiments microtiter wells were coated with 5 µg/ml C3b (Calbiochem) 
in PBS by overnight incubation at 4°C, blocked with 1% BSA for 1hr at R.T., and 
washed with PBS supplemented with Tween20 0.1% and MgCl2 10 mM. Different 
amounts of purified rVWF-A1A2A3 domains of VWF ranging from 25 µg/ml to 0 
µg/ml (dilution 1:2 in PBS) were incubated with coated wells for 2hr at 37°C. Protein 
complexes were detected by HRP-conjugated anti-human VWF antibody (1:4000, 
Dako). Colour was developed using TMB substrate (Bethyl), stopped with H2SO4 2 M, 
and absorbance was measured at 450 nm. Each reaction was performed in duplicate and 
the OD values averaged. BSA was considered as an irrelevant-negative control. 
 
2.12.3 In silico prediction of C3b – VWF-A2  interaction 
The computational docking between protein structures of C3b and A2 domain of VWF 
was perfomed by ClusPro 2.0 as described above in Paragraph 4.7.3.  
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PDB codes of C3b (2IO7) and VWF-A2 (3ZQK:A) structures were uploaded through 
ClusPro's web interface, and results of protein-protein docking prediction are reported 
in Table 2-3. Since it is unknown of what forces govern C3b-VWF complex, docking 
results have been chosen by the balanced coefficients, which took into consideration 
electrostatic,  hydrophobic and  van der Waals forces concurrently. 
 
Table 2-3. List of putative C3b – VWF-A2 complexes. 
Cluster Members Representative Weighted Score 
0 119 
Center -727.8 
Lowest Energy -802.7 
1 50 
Center -682.6 
Lowest Energy -802.5 
2 43 
Center -693.3 
Lowest Energy -693.3 
3 41 
Center -709.5 
Lowest Energy -709.5 
4 35 
Center -643.5 
Lowest Energy -744.1 
5 34 
Center -641.7 
Lowest Energy -788.7 
6 34 
Center -711.4 
Lowest Energy -711.4 
7 33 
Center -689.4 
Lowest Energy -710.2 
8 26 
Center -682.9 
Lowest Energy -695.4 
9 25 
Center -672.8 
Lowest Energy -691.4 
10 19 
Center -679.6 
Lowest Energy -703.8 
11 19 
Center -775.8 
Lowest Energy -775.8 
12 18 
Center -733.0 
Lowest Energy -733.0 
13 18 
Center -716.2 
Lowest Energy -716.2 
14 17 
Center -662.2 
Lowest Energy -715.7 
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15 17 
Center -648.3 
Lowest Energy -701.3 
16 15 
Center -747.1 
Lowest Energy -780.1 
17 15 
Center -697.0 
Lowest Energy -697.0 
18 14 
Center -665.4 
Lowest Energy -716.2 
19 14 
Center -660.4 
Lowest Energy -689.3 
20 13 
Center -747.2 
Lowest Energy -747.2 
21 13 
Center -696.7 
Lowest Energy -714.5 
22 13 
Center -684.3 
Lowest Energy -684.3 
23 13 
Center -680.9 
Lowest Energy -685.4 
24 13 
Center -647.0 
Lowest Energy -721.3 
25 12 
Center -639.8 
Lowest Energy -678.9 
26 12 
Center -668.2 
Lowest Energy -686.4 
27 11 
Center -756.2 
Lowest Energy -756.2 
28 11 
Center -676.3 
Lowest Energy -676.3 
29 11 
Center -674.9 
Lowest Energy -674.9 
 
The models were manipulated using the Educational-use-only program PyMOL  
(https://www.pymol.org/, The PyMOL Molecular Graphics System, Version 1.2r3pre). 
PyMOL is a molecular visualization system on an open source foundation, maintained 
and distributed by Schrödinger. 
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2.13 AP C3 Convertase and C5b formation  
2.13.1 C3bBb(Mg2+) C3 convertase and C5b-9 terminal 
complex formation in the presence of normal human 
serum or serum from cTTP patients 
To obtain C3 convertase formation by using a physiological mixture of complement 
components, microtiter wells were coated with 5 µg/ml of purified rA1A2A3 wt or 
rA1A2A3 mutant (a kind gift of Prof. Z.M. Ruggeri, The Scripps Research Institute, La 
Jolla, Ca), properdin (Complement Technology Inc.) or rA2-VWF (R&D Systems) in 
PBS by overnight incubation at 4 °C, blocked with 0.5% BSA in PBS for 1hr at R.T., 
and washed with wash buffer supplemented with 5 mM MgCl2. C3bBb(Mg2+) 
complexes were formed by incubating coated wells at 37 °C for 30 min with 20% NHS 
(normal human serum, a pool obtained from 15 healthy volunteers) or cTTP serum 
diluted in PBS containing 5 mM MgCl2 in the presence or in the absence of 1 mM 
EGTA. After washes, formed C3bBb(Mg2+) complexes and bound FH and complement 
components were detached from wells by incubation with 10 mM EDTA and 1% SDS 
for 1hr at R.T., subjected to 10% SDS-PAGE, and transferred by electroblotting to a 
PVDF membrane (Biorad). Proteins were detected with polyclonal rabbit anti-human 
FB antibody (1:500, ATLAS) or rabbit anti-C3c antibody (1:12000, Dako) both 
followed by HRP-conjugated anti-rabbit antibody (1:30000, Vector Laboratories Inc.), 
or with goat anti-FH (1:1000, Calbiochem) followed by HRP-conjugated anti-goat 
antibody (1:15000, Sigma Aldrich srl) and the ECL chemiluminescence detection 
system (Amersham). C3bBb formation was evaluated by the visualization by WB of the 
Bb band (60 kDa) and C3b β chain (75 KDa). In addition, C5b formation was evaluated 
by using polyclonal rabbit anti-human C5/C5b (1:300, Abcam) antibody, followed by 
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HRP-conjugated anti-rabbit antibody (1:15000, Vector Laboratories Inc.). C5b was 
visualized as α’ chain C5b (104 kDa) band. C6 and  C9 were detected with rabbit 
polyclonal anti-C6 (1:1000, ABGENT) or goat-polyclonal anti-C9 (1:250, Origene) 
antibodies respectively, followed by HRP-conjugated anti-rabbit (1:30000, Vector 
Laboratories Inc.) and anti-goat (1:10000, Sigma Aldrich srl) antibodies, respectively.  
In additional experiments, properdin or C3b or rVWF-A2 -coated wells were incubated 
with NHS in the absence or in the presence of 1 mM EGTA or 150 µg/ml sCR1 or with 
PBS only. C5b-9 complexes were detected by HRP conjugated anti-C5b-9 antibody 
(1:100, Quidel) followed by TMB substrate (Bethyl). Color was stopped with H2SO4 2 
M, and absorbance was measured at 450 nm. Each reaction was performed in triplicate 
and the OD values averaged. 
 
2.13.2 Detection of rVWF-A2 coated on plastic wells 
The amount of rVWF-A2 that coated plastic wells after incubation with PBS in the 
absence or in the presence of 1 mM EGTA was detected by ELISA using a rabbit anti-
VWF antibody (1:4000, Dako), followed by HRP-conjugated anti-rabbit antibody 
(1:30000, Vector Laboratories Inc.) and the TMB substrate (Bethyl). Color was stopped 
with H2SO4 2 M, and absorbance was measured at 450 nm. Each reaction was 
performed in triplicate and the OD values averaged. 
 
2.14 Thrombus formation under flow condition  
The assay was performed as previously described (Morigi et al. 2011) and depicted in 
Fig. 2-6. HMEC-1 were plated on glass slides and used when confluent. Cells were 
activated with 10 µM ADP for 10 min and, after washes, exposed for 4hr to serum from 
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patients or healthy controls diluted 1:2 with test medium in static conditions. Perfusion 
of heparinized whole blood (10 UI/ml) obtained from healthy subjects (prelabelled with 
the fluorescent dye mepacrine 10 µM, that marks platelets) was then performed in a 
thermostatic flow chamber (37°C) in which one surface of the perfusion channel was a 
glass slide seeded with a monolayer of endothelial cells at a constant flow rate of 1500 
sec-
1
 (60 dynes/cm2). After 3 min, perfusion was stopped, and the slide with the 
endothelial cell monolayer was dehydrated and fixed in acetone for 20 min. In selected 
experiments the adhesion test was performed with patients’ sera added with sCR1 (150 
µg/ml, as positive control of complement inhibition), or a FH concentrate (230 µg/ml), 
eculizumab (100 µg/ml), or the C5aR antagonist (W-54011, 1 µM; Calbiochem), or 
rADAMTS13 (4 µg/ml), or a polyclonal rabbit anti-human VWF antibody (100 µg/ml), 
or an irrelevant antibody (100 µg/ml) before incubation with HMEC-1. Slides were 
examined under confocal inverted laser microscopy (LSM 510 Meta, Zeiss) as described 
above. Fifteen fields for each slide were systematically digitized along the surface and 
the area covered by thrombi was quantified by Image J (NIH, Bethesda, MD), and 
expressed as pixel
2 
per field analyzed. In each experiment, serum from one healthy 
control was tested in parallel to cTTP serum. For each sample the mean of fifteen fields 
(excluding the lowest and the highest values) was calculated. 
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2.15 Statistics 
Results are expressed as mean ± SE. Data were analyzed by ANOVA (two-tailed) or 
Kruskall-Wallis test. Statistical significance was set at P<0.05. 
 
 
control or cTTP serum
+/- inhibitors
Adhesion assay under flow 
(60 dynes/cm2, 3 min)
Parallel-plate flow chamber
h = 0.15 mm; w = 1 mm; l = 30 mm
Endothelial cells
Coverslip
HS inlet HS outlet
T = 37\C
Coverslip
whole blood
(+ mepacrine)
4 hours
ADP-activated HMEC-1
Images acquired by a confocal fluorescence microscope connected
to a computer
Figure 2-6. Schematic representation of thrombus formation studies. 
HMEC-1 were treated with ADP and exposed for 4 hr in static conditions to 50% serum from cTTP 
patients or controls diluted with test medium. Perfusion of heparinized whole blood from healthy subjects 
(added with mepacrine) was then performed in a thermostatic flow chamber in which one surface of the 
perfusion channel was a glass slide seeded with a monolayer of endothelial cells, at a constant flow rate of 
1500 sec-1 (60 dynes/cm2). After 3 min, perfusion was stopped, and the slide with the endothelial cell 
monolayer was dehydrated and fixed. 
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3.1 Circulating complement profile in cTTP 
20 TTP patients with congenital ADAMTS13 deficiency were recruited among those 
referred to the International Registry of HUS and TTP coordinated by the Clinical 
Research Centre for Rare Disease in Ranica (Bergamo) (Table 3-1). Inclusion criteria 
were: 1) diagnosis of cTTP; 2) homozygous or compound heterozygous ADAMTS13 
mutations; 3) availability of plasma and serum samples; 4) absence of genetic 
abnormalities in aHUS associated complement genes (see Methods 2.1). For each of 
these patients sex, diagnosis, mutations, phase disease and clinical parameters (platelets 
count, LDH, Hemoglobin and s-Creatinine levels) referred at the time of sampling were 
collected and reported in Table 3-1. Undetectable ADAMTS13 activity levels were 
observed by the collagen binding assay for all recruited patients except for F1518#728, 
who had 9% activity. Undetectable plasmatic ADAMTS13 antigen levels were observed 
for all recruited patients except for F48#002, who had 79 ng/ml. 
  
 
 
 
 
 
  
 
Table 3-1. Clinical parameters of cTTP patients.  
 
Rem, remission. For domain abbreviations see Introduction 1.1.6.1. 1This patient was not studied in remission since he was treated with eculizumab (Pecoraro et al. 2015); 2Limits of normal 
ranges; 3New mutation; 4At the time of sampling. 5Normal value of s-creatinine for children < 1-5 yrs, 0.3-0.5 mg/dl, children >10 yrs/adults, 0.55-1.25 mg/dl. Increased abnormal range are 
in bold. 6Renal impairment: acute kidney injury, need for dialysis and/or urinary abnormalities (hematuria and/or proteinuria) in patients without previous renal involvement.  
Patient's 
code Sex 
age of 
onset 
(years) 
ADAMTS13 mutation  
 (mutated domain) 
ADAMTS13 
activity (%) 
ADAMTS13 
(ng/ml) Disease phase 
Clinical parameters 4 Renal 
impairment6  platelets LDH Hemoglobin s-Creatinine 
on 1st allele on 2nd allele (CBA) (ELISA) (150-400*103/µl)2 (266-500 IU/l)2 (14-18 g/dl)2 (0.55-1.25 mg/dl)2 
F769#239 F 21 p.I143F (MP) p.I143F (MP) <6% <62.5  acute 26 931 10.5 normal No 
rem 389 145 13.6 0.83 
F1116#239 M 18 p.I143F (MP) p.I143F (MP) <6% <62.5  rem 267 320 13 0.94 No 
S1312 F 0.3 p.R257Afs*13 (MP) c.1786+1G>A (Spacer) <6% <62.5  rem 188 723 11.3 0.31 5 No 
 F908#226 F 28 p.W28Lfs*111 (SP) p.R1060W (TSP1-7) <6% <62.5  rem 202 n.a. 9.7 normal No 
F711#226 F 20 p.W28Lfs*111 (SP) p.R1060W (TSP1-7) <6% <62.5  rem 242 n.a. 11.7 0.59 No 
F1519#728 F 3.5 p.E1382Rfs*6 (CUB2) p.E1382Rfs*6 (CUB2) <6% <62.5  rem 150 149 13.3 0.8 5 Yes 
F1518#728 M 35 p.G761S (TSP1-3) p.E1382Rfs*6 (CUB2) 9% <62.5  acute 69 460 9 2.3 Yes 
9% n.a. rem 130 105 14.7 1.55 
F1057#403 M 7 p.E1382Rfs*6 (CUB2) p.E1382Rfs*6 (CUB2) <6% <62.5  acute 94 502 13.7 2.37 Yes 
rem 138 321 13.1 3.55 
F1209#403 F 8 p.E1382Rfs*6 (CUB2) p.E1382Rfs*6 (CUB2) <6% <62.5  rem 404 n.a. 14.6 0.76 No 
R002 F 0.25 p.Q429* (TSP1-1) p.R1095Q (TSP1-8) <6% <62.5  acute 135 n.a. 12.5 0.6 
5
 Yes 
rem 270 526 10.4 0.66 
R564 F 24 p.D235Y (MP) p.D235Y (MP) <6% <62.5  acute 55 537 11.4 0.8 No 
rem 207 335 13.3 0.7 
F1689#922 1 M 12 p.C1084Y (TSP1-8) p.E1351Rfs*9 (CUB2) <6% n.a. acute 9 1449 7.8 9.31 Yes 
F1628#873 M birth p.N1345Tfs*14 (CUB2) p.N1345Tfs*14 (CUB2) <6% n.a. rem 206 321 15 0.65 Yes 
F1627#873 F 1.83 p.N1345Tfs*14 (CUB2) p.N1345Tfs*14 (CUB2) <6% n.a. rem 254 456 12 0.45 Yes 
F1833#985 F 28 p.L120V 3 (MP) p.L120V 3 (MP) <6% n.a. acute 37 n.a. 9.5 normal No 
rem 173 265 10.7 normal 
F48#002 F 23 p.V88M (MP) p.G1239V (CUB1) <6% 79 rem 222 226 13.6 0.83 No 
R012 M 3 p.R1123C (TSP1-8) p.R1123C (TSP1-8) <6% <62.5  acute 83 424 13.5 2.8 Yes 
rem 156 n.a. 12.2 2.5 
F101#019 M 35 p.R1219W (CUB1) p.R1219W (CUB1) <6% <62.5  acute 69 675 15.2 1.07 Yes 
F102#019 M 28 p.R1219W (CUB1) p.R1219W (CUB1) <6% <62.5  rem 191 385 14.9 0.77 Yes 
R019 M 5.5 p.G236C (MP) p.W1016* (TSP1-7) <6% <62.5  acute 26 600 14.2 0.74 No 
rem 175 n.a. 15.1 0.92 
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Firstly, I attempted to characterize circulating complement profile of all available 
plasma/serum samples by measuring complement activation markers such as C3, C4 
and soluble terminal complement complex (SC5b-9) (Fig. 3-1 and Table 3-2).  
 
 
During the acute phase we found lower than normal serum C3 level in only 1 out of 9 
patients (11%). Lower than normal serum C3 levels were found in 2 out of 17 patients 
in remission (12%). C4 levels were normal in all patients both during the acute phase 
and at remission. During the acute phase, plasma levels of SC5b-9 were higher than 
normal in 57% of patients. At remission, increased SC5b-9 plasma levels were found in 
43% of patients. 
 Mean values of plasma SC5b-9 in cTTP patients both in acute and in remission phases 
were significantly higher than in healthy controls and comparable to values recorded in 
aHUS cohort patients referred to the International Registry of HUS and TTP (Fig. 3-2). 
 
 
 
Figure 3-1. Circulating complement profile of cTTP patients. 
The number of patients with normal and abnormal levels of complement markers are indicated with light 
grey and dark grey bars, respectively. Rem, remission. 
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3.2 cTTP serum induced C3 and C5b-9 deposition on 
microvascular endothelial cells 
To evaluate whether complement is activated at endothelial cell level in cTTP, resting 
or ADP-activated HMEC-1 were incubated with serum from cTTP patients or healthy 
subjects by using an ex vivo test that my Supervisors and I have recently set up for 
patients with aHUS (Noris et al. 2014). This new assay is based on the incubation of 
serum from aHUS patients on ADP-activated HMEC cells for 4hr at 37°C. After 
washes, C3 and C5b-9 complement deposits were evaluated and quantified by 
immunostaining with anti-human C3c and anti-human C5b-9 antibodies. In previous 
Figure 3-2. Plasma SC5b-9 levels in aHUS and cTTP patients. 
SC5b-9 levels in healthy subjects (CTR, n=50 ), acute phase cTTP patients (cTTP acute, n=7), remission 
phase cTTP patients (cTTP rem, n=14), acute phase aHUS patients (aHUS acute, n=57), and remission 
phase aHUS patients (aHUS rem, n=113). Data are represented in a box and whiskers plot. The middle line 
represents the medians. The boxes indicate the interquartile ranges containing middle 50 % of values. The 
errors bars (whiskers) represent the range including all data except outliers. Black circles indicate outliers , 
which have values 3/2 times higher than the upper quartile. Kruskal-Wallis test; *  p<0.05 vs CTR. 
*
*
*
*
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studies we documented that all sera from aHUS patients induced abnormal C3 and C5b-
9 deposits on ADP-activated endothelial cells ex vivo. ADP activation was used, before 
incubation with serum, to mimic an activated/perturbed endothelium (Moake et al. 
1988), resulting in exocytosis of P-selectin (Morigi et al. 2011), an adhesive molecule 
that can bind and activate C3, and VWF (Fig. 3-3). 
 
I found that sera from all cTTP patients studied during the acute phase (n=4; cTTP 
patients: F1518#728, F1057#403, R002, F1689#922) induced more C3 and C5b-9 
deposits (Table 3-2 and Fig. 3-4) than control sera both on resting and on ADP-
activated HMEC-1. On resting HMEC-1, C3 and C5b-9 deposits were comparable 
following exposure to serum from cTTP patients in remission (n=4; selected cTTP 
patients: F1518#728, F1057#403, R002, R564) or from controls (Fig. 3-4A and C), 
whereas on activated HMEC-1 cTTP sera taken both during the acute phase (n=4; cTTP 
Figure 3-3. ADP stimulation on endothelial cells (HMEC-1).  
VWF (red) and C3 (green) staining on unstimulated (resting) or ADP-activated HMEC-1 (nuclei: DAPI, 
blue), not exposed to serum. Original magnification 400x. White scale bar: 20 µm 
resting
HMEC-1
ADP-activated
HMEC-1
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patients as above) and in remission (n=11; cTTP patients: F769#239, F1116#239, 
F908#226, F711#226, F1518#728, F1057#403, F1209#403, R002, R564, F1833#985, 
F48#002) induced more C3 and C5b-9 deposits than control sera run in parallel, further 
documenting that activation of complement proceeded till the terminal pathway (Table 
3-2 and Fig. 3-4B and D). 
 
Notably, the intensities of complement deposits on HMEC-1 exposed to cTTP sera were 
comparable to those on cells incubated with aHUS sera (Fig. 3-4B-D) (Noris et al. 
Figure 3-4. C3 and C5b-9 deposition on microvascular endothelial cells (HMEC-1). 
Endothelial surface area covered by C3 (A-B) and C5b-9 (C-D) staining after incubation for 4 hr of 
resting (A and C) or ADP-activated HMEC-1 (B and D) with 50% serum from healthy subjects (ctr, 
n=15) or cTTP patients (cTTP), studied both during the acute phase (n=4; acute) and at remission (A and 
C, n=4; B and D, n=11; rem), or from aHUS patients (acute n=3; remission, rem n=4), with or without 
sCR1 (150 µg/ml). Thereafter, cells were stained with anti-human C3c or anti-human C5b-9 antibodies 
and complement deposits were analyzed by confocal microscopy. Data are expressed as mean ± SE of 
area covered by C3 or C5b-9 deposits. °P<0.01, °°P<0.05 vs ctr; *P<0.01, **P<0.05  vs cTTP untreated, 
ANOVA. 
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2014). HMEC-1 exposed to ADP alone, without serum, showed no C3 staining (Fig. 3-
3). C3 and C5b-9 deposits were blocked by adding the pan complement inhibitor, 
soluble complement receptor 1 (sCR1) to cTTP serum (Fig. 3-4).   
 
 
In addition, the AP inhibitors CR2FH (Risitano et al. 2012), and FH (230 µg/ml, which 
approximately doubled the FH serum concentration (Noris et al. 2014)) significantly 
reduced cTTP serum-induced C3 deposits (Fig. 3-5A, n=4; selected cTTP patients: 
F1116#239; F1209#403; R564; F48#002). These findings, together with the observation 
that sera from cTTP patients, studied during remission phase, and healthy subjects 
induced comparable C4 staining on ADP-activated HMEC-1 (Fig. 3-5B, n=3; selected 
cTTP patients: F1116#239; F1057#403; R564), confirm selective activation of the 
alternative pathway of the complement system by cTTP serum on endothelial cells.  
Figure 3-5. C3 and C4 deposition on endothelial cells (HMEC-1), and the effect of some complement 
inhibitors. 
A Effect of inhibitors of the complement alternative pathway on cTTP serum-induced C3 deposits on 
ADP-activated HMEC-1. Cells were exposed to 50% serum from healthy subjects (ctr, n=4), or from 
cTTP patients in remission (cTTP, n=4) with or without CR2FH (150 µg/ml) or exogenous FH (230 
µg/ml). B. Endothelial surface area covered by C4 staining after incubation of ADP-activated HMEC-1 
with 50% serum from healthy subjects (ctr, n=3) or cTTP patients (cTTP, n=3), studied at remission, with 
or without sCR1 (150 µg/ml). Data are mean ± standard error (SE). ° p<0.0001 vs ctr; * p<0.0001 vs TTP. 
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3.3 Restoration of  ADAMTS13 activity prevented cTTP 
serum-induced C3 and C5b-9 deposition on 
microvascular endothelial cells 
To investigate whether cTTP serum-induced complement activation was related to 
ADAMTS13 deficiency,  recombinant ADAMTS13 (rADAMTS13, at the concentration 
of 4 µg/ml, which restored ADAMTS13 activity to 100% normal levels, as measured by 
collagen binding assay, CBA, in cTTP serum) was added to cTTP serum taken in 
remission. Recombinant ADAMTS13 fully normalized cTTP serum-induced C3 and 
C5b-9 endothelial deposits (Fig. 3-6, n=3; selected cTTP patients for C3 deposits: 
F1209#403; R564; F48#002; selected cTTP patients for C5b-9 deposits: F711#226; 
F1029#403; R564). At variance the same amount of rADAMTS13 did not affect 
complement deposits in sera from an healthy subject (control serum). Interestingly, 
rADAMTS13 blocked both C3 and C5b-9 deposition on endothelial cells at the same 
level of what can be observed with a complement inhibitor.  
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Together, these findings strongly suggest an important role for ADAMTS13 in the 
regulation of the alternative pathway of the complement system.  
 
Figure 3-6. Effects of rADAMTS13 on C3 and C5b-9 deposition on endothelial cells. 
rADAMTS13 added to cTTP serum normalized C3 and C5b-9 deposits on HMEC-1. ADP-activated 
HMEC-1 were exposed to 50% serum from healthy subjects (ctr, n=3) or cTTP patients in remission 
(cTTP, n=3) in the absence or in the presence of rADAMTS13 (4 µg/ml).  
For each patient’s sample a serum from an healthy subject was run in parallel to correct for assay 
variability. Data are expressed as mean ± SE of area covered by C3 or C5b-9 deposits. °P<0.01, vs ctr; 
*P<0.01 vs cTTP untreated, ANOVA. 
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Table 3-2. Complement activation markers of cTTP patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N.a., not available; n.d., not done; rem, remission. For domain abbreviations see Introduction 1.1.6.1. 1This patient was not studied in remission since he was 
treated with eculizumab (Pecoraro et al. 2015); 2Limits of normal ranges (see Methods 2.5); 3New mutation; 4At the time of sampling. 5On ADP-activated 
HMEC-1. 6P< 0.05 vs control (statistical comparisons were made for each patient by comparing deposits in pixel2 recorded in the 15 fields analyzed for the 
patient and for the corresponding control run in parallel). 
Patient's code Sex 
ADAMTS13 mutation  
 (mutated domain) Disease phase 
Complement parameters4 Endothelial complement deposits 4 
serum C3 serum C4 plasma SC5b-9 C3 deposits C5b-9 deposits 
on 1st allele on 2nd allele (83-180 mg/dl)2 (15-40 mg/dl)2 (127-400 ng/ml)2 (% of control)5 (% of control)5 
F769#239 F p.I143F (MP) p.I143F (MP) acute 205 48 2602 n.d. n.d. 
rem 139 26 198 184% 6 287% 6 
F1116#239 M p.I143F (MP) p.I143F (MP) rem 99 16 770 486% 6 206% 6 
S1312 F p.R257Afs*13 (MP) c.1786+1G>A (Spacer) rem 89 15 126 n.d. n.d. 
 F908#226 F p.W28Lfs*111 (SP) p.R1060W (TSP1-7) rem 118 37 1218 176% 6 228% 6 
F711#226 F p.W28Lfs*111 (SP) p.R1060W (TSP1-7) rem 182 33 1044 199% 6 262% 6 
F1519#728 F p.E1382Rfs*6 (CUB2) p.E1382Rfs*6 (CUB2) rem 90 30 124 n.d. n.d. 
F1518#728 M p.G761S (TSP1-3) p.E1382Rfs*6 (CUB2) acute 133 27 101 205% 
6
 668% 6 
rem n.a. n.a. n.a. 363% 6 259% 6 
F1057#403 M p.E1382Rfs*6 (CUB2) p.E1382Rfs*6 (CUB2) acute 224 83 1688 224% 
6
 1016% 6 
rem 130 25 263 158% 6 245% 6 
F1209#403 F p.E1382Rfs*6 (CUB2) p.E1382Rfs*6 (CUB2) rem 141 30 168 355% 6 216% 6 
R002 F p.Q429* (TSP1-1) p.R1095Q (TSP1-8) acute 97 23 315 287% 
6
 403% 6 
rem 103 22 186 362% 6 316% 6 
R564 F p.D235Y (MP) p.D235Y (MP) acute n.a. n.a. 482 n.d. n.d. 
rem 107 30 142 424% 6 215% 6 
F1689#922 1 M p.C1084Y (TSP1-8) p.E1351Rfs*9 (CUB2) acute 156 29 520 244% 6 159% 6 
F1628#873 M p.N1345Tfs*14 (CUB2) p.N1345Tfs*14 (CUB2) rem 230 42 1259 n.d. n.d. 
F1627#873 F p.N1345Tfs*14 (CUB2) p.N1345Tfs*14 (CUB2) rem 238 19 869 n.d. n.d. 
F1833#985 F p.L120V 3 (MP) p.L120V 3 (MP) acute 164 59 398 n.d. n.d. 
rem 119 37 679 165% 6 234% 6 
F48#002 F p.V88M (MP) p.G1239V (CUB1) rem 82 19 n.a. 305% 6 224% 6 
R012 M p.R1123C (TSP1-8) p.R1123C (TSP1-8) acute 109 44 n.a. n.d. n.d. 
rem 79 24 n.a. n.d. n.d. 
F101#019 M p.R1219W (CUB1) p.R1219W (CUB1) acute 80 16 n.a. n.d. n.d. 
F102#019 M p.R1219W (CUB1) p.R1219W (CUB1) rem 97 20 n.a. n.d. n.d. 
R019 M p.G236C (MP) p.W1016* (TSP1-7) acute 107 18 n.a. n.d. n.d. 
rem 99 18 205 n.d. n.d. 
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3.4 ADAMTS13-FB interaction 
3.4.1 Structural homology between FB and VWF 
The Bb proteolytic fragment of FB contains a von Willebrand type A (VWA) domain 
structurally homologous with A2 domain in VWF (VWF-A2), which contains 
ADAMTS13 binding and cleavage sites. In silico comparison between VWA-FB and 
VWF-A2 reveals a similar overall folding of their crystal structures (Fig. 3-7A).  
Figure 3-7. In silico comparison between von willebrand type A domain of Factor B (VWA-FB) 
and A2 domain of VWF (VWF-A2).  
A. Top, Primary sequences of FB (Milder et al. 2007) and VWF (Haberichter 2015). Bottom, crystal 
structures of VWA-FB  (1Q0P) and VWF-A2 (3ZQK) domains. B. Results of aminoacidic sequence 
alignment obtained by UNIPROT. CS: Cleavage Site for ADMATS13. Numbers indicate exosites. 
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Furthermore, aminoacid sequence alignment of the two domains shows 18.5% identity 
(UNIPROT, Fig. 3-7B), with conservation of the peculiar exosites regions (in Fig. 3-7B 
as numbers) that are important for the recognition and interaction with ADAMTS13: 
- exosite 1,  Asp1614-Glu1615 (DE),  is complementary to a functional exosite on the 
ADAMTS13 disintegrin-like domain, and helps orientating the scissible bond toward 
the active center of the protease (de Groot et al. 2009); 
- exosite 2, Gln1624-Arg1668 (depicted as an α-helix, α6), is referred as the VWF A2 
domain exosites for the binding with spacer domain of ADAMTS13 (Gao et al. 2008); 
- exosite 3, residues 1596-1668, together with exosite-1 and exosites-2, is reported to 
make cooperative and modular contacts with the catalytic cleft of ADAMTS13 (Gao et 
al. 2008; Akiyama et al. 2009).  
Of note, the cleavage site (CS) Tyr1605-Met1606 of VWF-A2 is replaced by Leu-Met 
in VWA of FB (Fig. 3-7B).  
 
3.4.2 Protein structure prediction of ADAMTS13 
Since the crystal structure of whole ADAMTS13 molecule has not been obtained yet, it 
was modeled by I-TASSER. The software provided an high-quality structural model, 
since C-score (-0.73) is higher than -1.5, meaning a correct fold based on availability of 
good threading templates in protein library, and TM-score (0.62) is higher than 0.5, 
meaning correct topology for all sizes of protein. This model was then analyzed in 
details by PyMOL (Fig. 3-8).  
The proposed three dimensional  model shows that ADAMTS13 undertakes an 
elongated structure like a “big scissor”, without buried regions. (Fig. 3-8A). 
Thrombospondin  repeat modules (T) fold back on themselves, providing the approach 
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between CUB (CUB) and Spacer (S) domains, both important for the binding to its 
physiological substrate, VWF. According to the multiple interaction model proposed by 
Crawley and co-workers for ADAMTS13-VWF binding (Fig. 1-4) (Crawley et al. 
2011), it could be speculated that the domains of the protease could have great mobility. 
This is also supported by the difficulty in obtaining a crystal structure of the entire 
ADAMTS13 molecule, suggesting that a spectrum of ADAMTS13 conformations 
exists, with different spatial alignments of the exosites (Akiyama et al. 2009). This 
mobility could in turn increase the possibility of ADAMTS13 to interact with partially 
unfolded VWF molecules, which also present a wide spectrum of conformations under 
shear-stress conditions in the circulation, and with other proteins carrying VWA domain 
such as FB.  
Figure 3-8. ADAMTS13 structural model generated by I-TASSER and manipulated with 
PyMOL. 
A. The image corresponds to the predicted model of ADAMTS13 obtained by submitting 75-1427 
aminoacidic sequence of ADAMTS13 to I-TASSER software. B. Cartoon representing domain 
organization of ADAMTS13 with color correspondence in A. M, metalloprotease domain; D, 
Disintegrin-like domain; T1-8, Thrombospondin  repeat modules; C, Cysteine-rich domain; S, Spacer 
domain; CUB1-2, CUB domains. 
M D T1 C S T2 T3 T4 T5 T6 T7 T8 CUB1 CUB2
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3.4.3 In silico interaction between ADAMTS13 and FB 
The predicted three dimensional  model of ADAMTS13 structure (Fig. 3-8) was then 
used to assess the predicted in silico interaction between the protease and FB, by using 
the free open-source ClusPro software available on the net. In this study, the model 
referred to the most populated cluster (Model 0, the first cluster in Table 2-2) was 
chosen and analyzed in details by PyMOL and the results are reported in Fig. 3-9. 
The docking interface of the predicted complex reveals that, in contrast to what was 
expected, FB binding sites are mostly restricted to Ba fragment (26-259 aa), while 
VWA domain seems not to be involved in the binding, remaining on the back of the 
docking interface (Fig. 3-9B). Interestingly, in this model ADAMTS13 interacts with 
FB through its MP domain (Fig. 3-9C). Nevertheless, the analysis of the other 1-4 
models, corresponding to the subsequent most populated clusters 1-4 generated by 
ClusPro (Table 2-2), indicates that the binding surface of ADAMTS13 involves Spacer 
and CUB domains (Fig. 3-10). This heterogeneity among the proposed models reflects 
the previous observation of the great mobility of ADAMTS13 structure, and further 
highlights the possibility of a multiple interaction mode between the protease and its 
binding partners. However, also in these models FB binds ADAMTS13 through its Ba 
fragment chain, while VWA domain remains exposed to the surface (Fig. 3-10).  
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Figure 3-9. ADAMTS13 - FB docking model generated by ClusPro and manipulated with PyMOL. 
A. The image corresponds to the complex, predicted by ClusPro web server, formed by ADAMTS13 
(light grey, I-TASSER model Fig. 3-8) with FB (dark grey PDB code: 2OK5). The binding interface is 
highlighted in red. B. Tridimensional structure of FB shown as surface distribution (upper panels) and in 
ribbon representation (bottom panels) with location of von Willebrand type A (VWA) domain in 
paleyellow in all structures prepared by PyMOL. The aminoacidic residues of FB contained in the binding 
interface are highlighted in red and indicated as numbers. C. Tridimensional structure of ADAMTS13 
shown as surface distribution (upper panels) and in ribbon representation (bottom panel) with location of 
MetalloProtease (MP) domain (boxed) in the structure model from PyMOL. The aminoacidic residues of 
ADAMTS13 contained in the binding interface are highlighted in red and indicated as numbers. 
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Figure 3-10. Other ADAMTS13 - FB docking models generated by ClusPro and manipulated with 
PyMOL.  
The images correspond to the Models 1-4 predicted by ClusPro web server for the complex formed by 
ADAMTS13 (light grey, I-TASSER model Fig. 3-8) and FB (dark grey PDB code: 2OK5). 
Tridimensional structure of both proteins are shown as surface distribution. The binding interface is 
highlighted in red. The clusters corresponding to each model are reported in Table 2. 
Model 1
Model 3 Model 4
Model 2
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3.4.4 ADAMTS13 interacts with FB in SPR and ELISA 
I then investigated ADAMTS13-FB binding by in vitro assays. SPR experiments were 
performed by flowing FB on immobilized recombinant human ADAMTS13. The 
protein complex assembly results in an increase of light refraction expressed as 
resonance units (RU), in the first step of FB perfusion, followed by a second 
dissociation step evidenced by the decrease of the signal, due to buffer perfusion over 
the chip. The sensorgrams reported in Fig. 3-11ATop show that FB bind immobilized 
rADAMTS13. The calculated dissociation constant (KD) is 1.89 x 10-6 M at room 
temperature, and 1.88 x 10-7 M at 30 °C, suggesting that ADAMTS13-FB binding is 
dependent on temperature. To evaluate the binding specificity, a single concentration of 
purified human C3b or C3 was flowed over immobilized rADAMTS13, showing no 
binding in both conditions (Fig. 3-11ABottom). In this assay, the dissociation phase was 
then monitored until 900 sec, and the RU values of these curves became negative. Since 
RU value indicates the total mass on the chip, it can be speculated that the continuous 
perfusion of the buffer alone on the chip might induce the detachment of the 
immobilized rADAMTS13 protein, resulting in the decrease of RU under the zero, 
previously set as background. The meaning of this event could be correlated to the 
instability of the protein on the surface of the chip.   
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These results were confirmed by ELISA experiments, where it was documented a dose-
response interaction of FB with coated rADAMTS13 (Fig. 3-11B).  
To better characterize the binding site of FB involved in the interaction with 
ADAMTS13, the same SPR and ELISA experiments could be repeated by using Ba or 
Bb fragments chains. 
 
 
 
 
 
Figure 3-11. Specific interaction between FB and ADAMTS13. 
A. SPR experiments. Top, three different concentrations (1, 2 and 4 µM) of FB were flowed over 
immobilized rADAMTS13. Bottom, a single concentration (1µM) of FB or C3b or C3 was injected over 
immobilized rADAMTS13. The binding was estimated as the increment of Resonance Unit (RU). B.  
ELISA experiments. Different amounts of FB 50-0 nM (1:2) were incubated over rADAMTS13 coated 
wells (2.5 ug/mL), and the ADAMTS13-FB complexes were detected by goat anti-human FB antibody 
followed by HRP-conjugated secondary antibody and TMB substrate. Each reaction was performed in 
duplicate and the OD values averaged. BSA and HSA were considered as irrelevant negative controls. 
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3.5 ADAMTS13 does not cleave neither FB, nor C3b nor 
FD 
ADAMTS13 physiologically works as a protease by cleaving VWF, regulating its 
multimeric length. In order to investigate the mechanism(s) through which ADAMTS13 
deficiency in cTTP may result in complement AP activation, rADAMTS13 cleavage 
activity was tested on complement proteins such as FB, C3b and FD. It was speculated 
that ADAMTS13 could modulate complement cascade reducing protein availability for 
complement activation. 
Figure 3-12. rADAMTS13 proteolytic activity on rVWF-A1A2A3, FB, C3b and FD. 
A. rVWF-A1A2A3 was incubated with rADAMTS13 in the presence of urea and BaCl2. The cleavage 
product was visualized by WB with a monoclonal antibody anti-rVWF-A1A2A3 carboxy-terminal. At 
the end of the incubation the band corresponding to rVWF-A1A2A3 (80 kDa) disappeared, while the 30 
kDa rVWF-A1A2A3 cleavage product appears. B and C. FB was incubated with different concentration 
of rADAMTS13 in the presence of urea and BaCl2. rADAMTS13 and FB were visualized by silver 
stained SDS-PAGE (B) and WB (C) with an anti-ADAMTS13 antibody (upper image) or an anti-FB 
antibody (lower image). The two last lines on the right show the bands of purified FB and Bb for 
comparison. D and E. C3b or FD was incubated with different concentration of ADAMTS13, starting 
from the one that provides the cleavage of 100 ng of the VWF, in the presence of urea and BaCl2. The 
reactions were evaluated by silver stained SDS-PAGE. The physiological molar ratios between FB or FD 
and rADAMTS13 are squared. The molar ratio between C3b and rADAMTS13 is almost 30 fold lower 
than the physiological condition. Results of representative experiments of n=3 are shown. 
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In the presence of urea and BaCl2,  rADAMTS13 efficiently cleaved rVWF-A1A2A3 
fragment (Fig. 3-12A) but had no effect on either FB, both in silver stained SDS-PAGE 
and WB (Fig. 3-12B and C), or C3b (Fig. 3-12D) or FD (Fig. 3-12E) since no cleavage 
fragments could be visualized on the gels. 
In normal circulation VWF is unfolded due to shear stress allowing A2 cleavage site 
exposure to ADAMTS13 proteolysis. In in vitro fluid phase experiments in static 
condition this phenomenon is reproduced by urea, which was used also in the reactions 
cointaining FB or C3b and FD. However, other denaturating agents could also have 
been considered.  
 
 
3.6 ADAMTS13 does not inhibit the formation of C3 
proconvertase and C3 convertase complexes   
Relying on the previous evidence that ADAMTS13 binds FB, I hypothesized that 
ADAMTS13 could modulate complement activation by interacting with FB during the 
formation of the proenzyme AP C3 proconvertase or the central enzyme C3 convertase 
complex (Fig. 3-13).  
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In the attempt to evaluate ADAMTS13 effect on the assembly of C3 proconvertase and 
the formation of C3 convertase, the recombinant protease was tested in microplate/WB 
methods, which selectively generate and detect C3bB(Mn2+) and C3bBb(Mg2+) 
complexes (see Methods 2.10) (Fig. 3-14A). 
C3b +   FB  
ADAMTS13
Mg2+
C3bB
proconvertase
C3b +   FB
ADAMTS13
Mg2+
C3bB  +  FD C3bBb
convertase
Ba
B
A
Figure 3-13. Working hypotheses to investigate ADAMTS13 effect on C3bB C3 proconvertase and 
C3bBb C3 convertase.  
A. ADAMTS13 inhibits C3bB C3 proconvertase assembly by binding to FB, thus preventing its 
association with C3b. B. ADAMTS13 inhibits C3bBb C3 convertase formation by interacting with FB 
bound to C3b (in proconvertase complex), hindering FD cleavage activity on FB. 
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Figure 3-14. ADAMTS13 does not affect C3bB proconvertase and C3bBb C3 convertase formation. 
A. Experimental design of the assay for testing the effect of rADAMTS13 on C3bB(Mn2+) proconvertase 
and C3bBb(Mg2+) convertase formation by microplate/WB. 
B. Effect of rADAMTS13 on C3bB(Mn2+) proconvertase assembly. C3bB(Mn2+) complexes were formed 
by incubating C3b-coated wells with FB, in the absence or in the presence of increasing concentrations of 
rADAMTS13. C3 proconvertase was detected as a FB band (93 kDa) visualized by WB with an anti-FB 
antibody. C. Effect of rADAMTS13 on C3bBb(Mg2+) convertase formation. C3bBb(Mg2+) complexes 
were formed by incubating C3b-coated wells with FB and FD, with or without rADAMTS13. C3-
convertase formation was evaluated by the visualization of the Bb band (60 kDa) by WB with an anti-FB 
antibody. ADAMTS13 buffer (right side) was the negative control. The physiological molar ratios 
between FB or FD and rADAMTS13 are squared. Results of representative experiments of n=3 are 
shown. 
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No difference either in C3bB(Mn2+) assembly (Fig. 3-14B) or in C3bBb(Mg2+) 
formation (Fig. 3-14C) was observed in the presence of rADAMTS13, either at 
physiological or at molar excess ratios with FB and FD.  
These results indicate that ADAMTS13 does not affect the formation of both C3bB and 
C3bBb complexes in static conditions. With the aim to reproduce the physiological fluid 
shear stress, C3 proconvertase and C3 convertase were allowed to form in SPR 
experiments, thanks to the collaboration with the laboratory of Dr. Marco Gobbi in 
Mario Negri Institute in Milano. C3bB and C3bBb complexes were obtained by flowing 
FB over immobilized C3b in the absence or in the presence of FD, respectively (Fig. 3-
15). ADAMTS13 effect was evaluated by flowing the recombinant protein together 
with FB and/or FD over C3b-coated chip.  
 
Figure 3-15. ADAMTS13 does not affect C3bB C3 proconvertase assembly and C3bBb C3 
convertase formation in SPR.  
C3b was immobilized by amine coupling on sensor  chip.  FB (200 nM) was injected in the presence or in 
the absence of FD (4 nM) and rADAMTS13 (1 nM ) or its buffer (buffer) over the immobilized C3b. The 
binding was estimated as the increment of Resonance Unit (RU). Buffer was considered as irrelevant 
negative control. 
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As reported in Fig. 3-15, rADAMTS13 modestly affected C3 proconvertase assembly 
by reducing the total amount of C3bB complexes generated on chip (violet vs orange 
curves), suggesting a possible competition among C3b and ADAMTS13 for the binding 
to FB. However, rADAMTS13 did not influence C3 proconvertase decay, since the 
dissociation curves of C3bB complexes in the presence or in the absence of the protease 
have the same slope (Fig. 3-15; violet vs orange curves). On the other hand, 
rADAMTS13 had no effect on the formation of C3 convertase, while it midly 
accellerated C3bBb dissociation (Fig. 3-15; blue vs green curves). The latter indicates 
that ADAMTS13 may promote C3 convertase decay, which in turn could results in 
reducing the stability of C3bBb complexes and promoting complement regulation. 
Notably, these observations alone could not explain the previous results obtained on 
cells, where the presence of ADAMTS13 completely abolished the complement 
deposition mediated by serum from cTTP patient. Thus, at this point, the regulatory role 
for ADAMTS13 in complement cascade remains still unexplained. However, the very 
modest effect of ADAMTS13 on both complexes obtained in SPR should be confirmed 
with additional experiments. 
In summary, altogether these results indicate that the binding between ADAMTS13 and 
FB is very weak and this interaction does not substantially impact FB activity in C3bB 
proconvertase assembly and C3bBb convertase formation. Nevertheless, a limited 
modulation of complexes formation and decay could be observed only in fluid phase, 
which could properly emulate the physiological condition in blood circulation. Effects 
of ADAMTS13 on C3 convertase activity could not be excluded and further 
experiments are needed. 
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3.7 VWF does not modulate complement regulatory 
activities of FH 
3.7.1 Neither ULVWF multimers nor normal plasma VWF 
multimers inactivate C3b  
Since VWF is the physiological substrate of ADAMTS13, and in TTP the deficiency of 
the protease results in the VWF accumulation into blood of the patients, it was then 
hypothesized that VWF could also interact with complement proteins and in turn affect 
the complement system. Different groups have recently reported that VWF binds FH, 
the major negative regulator of the alternative pathway of the complement cascade, and 
together with or without FH it modulates the complement activation (Rayes et al. 2014; 
Feng et al. 2015). With the aim to verify whether VWF had any effect on complement 
system, I tested different VWF preparations in the FH-cofactor assay for FI-mediated 
C3b degradation, as suggested by previous studies.  
As reported in Fig. 3-16, neither normal plasma-derived VWF from two different 
commercial sources (LFB-VWF or Emoclot-VWF), nor rVWF (which includes 
ULVWF multimers) nor the rVWF-A2 domain, either alone or in the presence of FH, 
had any effect on C3b cleavage, when tested both at physiological molar ratios with FH 
and FI and in large excess. Faint bands of iC3b products were only observed with 500 
molar excess of plasma VWF (Emoclot-VWF), which however also contained small 
amounts of contaminating FH, as shown by a faint 150 kDa band in Fig. 3-16C. FH 
contamination was determined by analysing Emoclot-VWF, LFB-VWF and rVWF on 
WB with a goat anti-FH antibody. The presence of FH in Emoclot-VWF was 
demonstrated by the visualization of the FH 150 kDa band, while no 150 kDa band 
could be visualized for both LFB-VWF and rVWF (Fig 3-16D).   
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Notably, LFB-VWF concentrate reflects the “physiological state” of VWF in normal 
human plasma (the presence of intermediate and high molecular forms of VWF), indeed 
it has been shown to have a multimeric pattern similar to plasma VWF giving evidence 
that this preparation strongly preserves physiological functions of plasma VWF 
(Mazurier 1998). The other concentrate, Emoclot-VWF has been shown to exhibit a 
lower content of high molecular weight VWF multimers than normal plasma (Peyvandi 
et al. 2013), while the rVWF contains also UL-multimers (Turecek et al. 2009) and has 
been used to mimic the multimers pattern in TTP plasma that lacks ADAMTS13 
activity. 
 
3. RESULTS 
 
151 
 
 
 
Figure 3-16. VWF does not exert cofactor activity in FI-mediated C3b cleavage.  
C3b was incubated with FI, in the absence (A and C) or in the presence (B) of FH  for 10 min (A and C) 
or 1 min (B), respectively. Different preparations of VWF were tested in the assays at 1X (0.313 nM, 
physiological molar ratio with FH), 10X (3.13 nM) or 500X (156.5 nM) molar concentrations: rVWF and 
LFB-VWF (A-B); Emoclot-VWF and rVWF-A2 (C). The reactions were analyzed on SDS-PAGE with 
Silver staining detection. C3b was detected as α’-chain (110 kDa) and β-chain (76 kDa) bands. FH was 
visualized as 150 kDa band. C3b cleavage products were detected as α65 kDa and α43 kDa bands. VWF 
full length (rVWF, LFB-VWF and Emoclot-VWF) was detected as 250 kDa band. rVWF-A2 was not 
visualized on SDS-PAGE since it run out the lower limit of the gel. The second lane in panel B (0 min) 
shows the reaction baseline. Results of a representative assay of n=3 are shown. D. Western Blot for FH 
contamination in Emoclot-VWF, LFB-VWF or rVWF preparations. The colors and numbers (200, 400 or 
800) indicate VWF source and ng of the protein loaded on gel; 200 ng correspond to VWF amount 
presents in the 500X reaction.  
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3.7.2 VWF does not affect FH decay accelerating activity on 
C3 convertase 
It is well known that FH regulates complement activation by promoting C3 convertase 
decay (Rodriguez de Cordoba et al. 2004; Makou et al. 2013). In order to investigate 
whether VWF-FH interaction could affect FH activity in dissociating C3 convertase, 
VWF fragments were tested in the new microplate/WB assay, which selectively 
generate and detect C3bBb(Mg2+) convertase complexes (Marinozzi et al. 2014) (see 
Methods 2.10). 
As shown in Fig. 3-17A, the presence of rVWF-A1A2A3 at two different 
concentrations during the formation of C3bBb(Mg2+) complexes did not modulate FH-
mediated C3 convertase decay, indicating that VWF does not affect FH activity on C3 
convertase. 
Also when rVWF-A1A2A3 fragments were added both during formation and decay of 
C3 convertase complexes, no effect was observed on FH accelerating activity on C3bBb 
dissociation (Fig. 3-17B), suggesting that also the direct VWF-FH interaction, if it 
occurs, does not influence FH regulatory activity in this static condition.  
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Figure 3-17. rVWF-A1A2A3 does not prevent both spontaneous and FH-mediated decay of C3 
C3bBb(Mg2+) convertase. 
C3bBb(Mg2+) complexes were formed by incubating C3b-coated wells with FB and FD, in the absence or 
in the presence of rVWF-A1A2A3. Spontaneous and FH-mediated decay of C3bBb(Mg2+) was evaluated 
by further incubation with buffer alone or with 2640 ng/ml FH in the absence (A) or in the presence (B) 
of rVWF-A1A2A3 for 4 minutes at 25 °C. The amount of C3bBb formed and remained on well after 
decay incubation was evaluated by the visualization of the Bb band (60 kDa) by WB with an anti-FB 
antibody. Molar ratios between FH and rVWF-A1A2A3 are indicated. Results of representative 
experiments of n=3 are shown. 
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3.8 VWF-C3 interaction 
3.8.1 VWF accumulation on ADP-activated microvascular 
endothelial cells exposed to cTTP serum favors C3 
deposition 
 ULVWF multimeric strings secreted by, and anchored to, activated endothelial cells 
were found to bind C3b, other components of the AP (FB, FD, properdin), and C5 
(Turner and Moake 2013). Moreover, the evidence that VWF possesses A2 domain that 
shares a high homology with typeA domain of FB (see Results 3.4.1), the natural C3b 
binding protein, highlights the possibility of a direct interaction between C3b and VWF.  
 
Figure 3-18. VWF interacts with C3b and favors C3 deposition on cell surface. 
A. Representative confocal microscopy images of co-localization of C3 (green) and VWF (red) on ADP-
activated HMEC-1 (nuclei: DAPI, blue) exposed to 50% serum from a healthy subject (ctr) or a cTTP 
patient (cTTP). Cells were immunostained with an anti-C3 antibody, and with an anti-VWF antibody. 
Original magnification 630x, white scale bar: 20 µm. B. ADP-activated HMEC-1 were exposed to serum 
from healthy subjects (ctr, n=3) or from cTTP patients in remission (cTTP, n=3), the latter with or 
without a polyclonal anti-human VWF antibody (anti-VWF) or an irrelevant antibody (irrel), or sCR1 
(negative control). Data are expressed as mean ± SE of area covered by C3 deposits. °P<0.01 vs ctr, 
*P<0.01 vs cTTP, ^P<0.01 vs cTTP+irrel, ANOVA. 
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Based on the above considerations, I then investigated whether the severe ADAMTS13 
deficiency in cTTP patients leads to VWF accumulation on endothelial cell surface and 
whether VWF deposits may act as nuclei for C3 deposition. Incubation with cTTP 
serum taken during remission resulted in intense VWF staining on ADP-activated 
HMEC-1 (Fig. 3-18), as expected since VWF multimers could not be cleaved by 
ADAMTS13 which is deficient. Interestingly, VWF deposition partially colocalized 
with C3 (Fig. 3-18A), suggesting active interaction between VWF and C3 activation 
products on endothelial cell surface.  
The addition of an anti-VWF antibody to cTTP serum during incubation with HMEC-1 
completely prevented the excessive C3 deposition on ADP-activated HMEC-1 as the 
complement inhibitor sCR1 did, while an irrelevant antibody had no effect (n=3, Fig. 3-
18B).  
Altogether these results indicate that in cTTP, VWF strings accumulating on endothelial 
cells due to severe ADAMTS13 deficiency participate in complement activation 
through C3b binding. 
 
3.8.2 VWF interacts with C3 in SPR and ELISA 
Through SPR Feng et al (Feng et al. 2015) documented that C3b binds VWF with high 
affinity under flow; the C3b-VWF interaction was reversible, with a dissociation 
constant of 218 nM. In order to verify and characterize VWF-C3b interaction, different 
fragments of VWF were tested for C3b binding in SPR and ELISA experiments (Fig. 3-
19). Thanks to the collaboration with the laboratory of Dr. Marco Gobbi in Mario Negri 
Institute in Milano, we firstly tried to immobilized rVWF on SPR chip in order to 
evaluate the binding between the multimeric form of VWF and C3b in a condition that 
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reproduce physiological shear flow. However, we observed that multimeric rVWF was 
not able to covalently bind the chip. Thus, rVWF was reduced with DTT, immobilized 
on the chip and subsequently used to binding assays in SPR. In Fig. 3-19A is reported 
the sensorgrams (time-course of SPR signal) obtained when flowing different 
concentrations of soluble C3b over monomeric rVWF immobilized on the sensor chip. 
A dose-dependent binding signal was detected, with a very slow dissociation rate (Kd = 
2x10-4 s-1, on average) suggesting a stable binding between VWF and C3b. The 
association rate constant (Ka) and the equilibrium dissociation constant (KD) could not 
be determined in a reliable manner since, in these conditions, binding saturation was not 
reached. However, these sensorgrams are consistent with KD values ranging 50-2000 
nM, suggesting a specific interaction between monomeric rVWF and C3b. 
Then, VWF-C3b interaction was studied in static conditions using ELISA. Recombinant 
multimeric VWF did not interact with C3b (Fig. 3-19B), possibly due to its non-
permissive close conformation, while dose-response interaction of C3b with coated 
VWF monomer was observed (Fig. 3-19B). To examine whether VWF binds C3b 
through its typeA region, ELISA experiments were performed using either rA1A2A3-
VWF or rA2-VWF coated onto the solid phase. Recombinant VWF-A1A2A3 and C3b 
dose-dependently interacted with each other (Fig. 3-19C and D) and the same was 
observed between rVWF-A2 and C3b (Fig. 3-19E and F). In competition studies, 
addition of rVWF-A2 (at equimolar concentration with C3b) to the C3b solution, 
inhibited C3b binding to coated rVWF-A2, confirming the specificity of the observed 
interaction (Fig. 3-19E, black circle). In contrast, rVWF-A1 and rVWF-A3 domains did 
not bind C3b (Fig. 3-19G). No binding was found between the rVWF-A2 domain and 
C4b (Fig. 3-19H). 
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Figure 3-19. VWF interacts with C3b in SPR and ELISA experiments. 
A. High-affinity binding of C3b to rVWF by SPR. The graph shows the sensorgram (time course of the 
SPR signal in resonance unit, RU) obtained by simultaneously injecting three concentrations of C3b (1 
µM, 500 nM or 100 nM) over sensor surface immobilizing rVWF  
B-H. ELISA assays of the interaction between VWF and C3b or C4b. B. C3b was added at increasing 
concentrations to either multimeric rVWF- (rVWF) or monomeric rVWF- (rVWF monomer) coated 
wells. C. C3b was added at increasing concentrations to rVWF-A1A2A3-coated wells. D. rVWF-
A1A2A3 was added at increasing concentrations to C3b-coated wells. E. C3b was added at increasing 
concentrations to rVWF-A2-coated wells. In separate wells C3b (5 µg/ml) was mixed with an equimolar 
amount (black circle) of rVWF-A2 F. rVWF-A2 was added at increasing concentrations to C3b-coated 
wells. G. C3b was added at increasing concentrations to either rVWF-A1- or rVWF-A3- coated wells. 
C3b binding was detected with a mouse anti-human C3 antibody followed by HRP-conjugated anti-
mouse antibody; rVWF-A1A2A3 or rVWF-A2 binding was detected with an HRP-conjugated anti-human 
VWF antibody.  H. C4b was added at increasing concentrations to either rVWF-A1- or rVWF-A2- or 
rVWF-A3- coated wells. Binding was detected with an anti-C4α antibody.  
B-H. The open circles show the background binding with the corresponding amounts of BSA. 
The graphs show the mean of triplicate measurements from a representative experiment of n=3. 
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In summary, SPR and ELISA experiments documented that VWF binds C3b in a 
conformation dependent manner, where fluid phase act as an important VWF-activating 
factor by exposing important binding exosites contained in the A2 domain.  
 
3.8.3 In silico interaction between C3b and VWF-A2 domain 
The three dimensional  structures of C3b (2I07) and VWF-A2 domain (3ZQK:A) were 
docked by ClusPro software to investigate the molecular binding sites between VWF 
and C3b. ClusPro output provided 29 models for C3b - VWF-A2 docking prediction 
(see Methods 2.12.3). In this study, the model referred to the most populated cluster (the 
first cluster in Table 2-3) was chosen and analyzed in details by PyMOL (Fig. 3-20).  
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The docking interface of the predicted model reveals that C3b interacts with C-terminal 
of A2 domain of VWF through its TED domain (Fig. 3-20A-B). Interestingly, thioester 
moiety, contained in TED domain of C3b, seems to be involved in the binding, while 
the cleavage site Tyr1605-Met1606 of VWF remains buried inside the closed 
conformation of A2 domain (Fig. 3-20C). 
 
 
 
Figure 3-20. C3b - VWF-A2 docking model generated by ClusPro and manipulated with PyMOL. 
A. The image corresponds to the complex, predicted by ClusPro web server, formed by C3b (light grey, 
PDB code:2I07) with the A2 domain of the VWF (dark grey PDB code: 3ZQK:A). The binding interface 
is highlighted in red. B. Tridimensional structure of C3b shown as surface distribution (left panels) and in 
ribbon representation (right panels) with location of TED domain (boxed) in the structure model from 
PyMOL. The aminoacidic residues of C3b contained in the binding interface are highlighted in red and 
indicated as numbers. The thioester moiety is shown as red spheres. C. Tridimensional structure of A2 
domain of VWF shown as surface distribution (left panels) and in ribbon representation (right panel) 
from PyMOL. The aminoacidic residues of VWF-A2 contained in the binding interface are highlighted in 
red and indicated as numbers. The cleavage site Tyr1605-Met1606 of A2 domain is shown as yellow 
sticks.   
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3.9 VWF, interacting with C3b through its A2 domain, 
favors the formation of the alternative pathway C3 
convertase  
In order to investigate the effect of VWF-C3b interaction on complement activation, I 
then studied whether the binding between VWF and C3b results in the formation of the 
C3bBb AP C3 convertase. Recombinant VWF-A1A2A3-coated wells were incubated 
with 20% normal human serum (NHS) as a source of complement. The products were 
detached from wells and analyzed by WB (Fig. 3-21A). C3bBb formation occurred on 
rVWF-A1A2A3-coated wells, as documented by specific C3b β-chain and Bb bands, 
respectively (Fig. 3-21B). Notably, the C3b and Bb bands of C3bBb were more intense 
when the reaction was performed on coated mutant rVWF-A1A2A3 (180-200% and 
150-171% of the C3b and Bb bands on wild-type rVWF-A1A2A3, respectively, Fig. 3-
21B), which could not be cleaved by ADAMTS13 present in NHS since the Tyr1605-
Met1606 at the cleavage site have been replaced by two Alanines. C3bBb formation 
was observed in positive control wells coated with properdin (Fig. 3-21B) (Lesher et al. 
2013).  No C3 convertase was formed on rVWF-A1A2A3- or properdin-coated wells 
incubated with NHS pre-treated with EDTA or sCR1 (Fig. 3-21B), which both block 
complement activation.   
The C3 convertase assay was repeated on rVWF-A2-coated wells. Results showed 
specific bands of C3b and Bb that were fully abolished by EDTA (Fig. 3-21C).  FH 
added in excess (higher than the physiological concentration) to NHS dose-dependently 
reduced the amount of Bb recovered from rVWF-A2-coated wells (Fig. 3-21D), 
confirming the specific formation of the AP C3 convertase on rVWF-A2 coated surface.  
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The addition of EGTA to NHS greatly reduced the C3b and Bb bands from rVWF-A2-
coated wells (Fig. 3-21C-D), without altering the amount of rVWF-A2 coated on wells 
(Fig. 3-216E). While EDTA chelates all divalent cations, EGTA binds Ca2+ with a 
greater affinity than Mg2+ and the other divalent cations, and at the concentration we 
used should not affect the formation of the Mg2+-dependent AP C3 convertase 
(Fishelson and Muller-Eberhard 1982). Indeed EGTA did not affect the C3b and Bb 
bands recovered from properdin-coated wells (Fig. 3-21C). Conversely, limited amount 
of C3b was recovered from rVWF-A2-coated wells in the presence of EGTA. Thus, it is 
likely that EGTA treatment inhibited C3b binding to coated rVWF-A2, suggesting a 
Ca2+-dependent interaction between the two molecules.  
Altogether these results indicate that rVWF-A2 binds C3b and acts as a platform for the 
formation of the AP C3 convertase.   
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3.10 VWF-C3b interaction forms the alternative pathway C5 
convertase and activates the terminal pathway 
I previously documented that immobilized C3b in the microplate/WB assay formed an 
active C5 convertase in the presence of NHS. To evaluate the impact of VWF-C3b 
interaction on the terminal complement pathway, the products recovered from rVWF-
A2-coated wells after incubation with NHS were analyzed on WB with anti-C5, anti-
C6, or anti-C9 antibodies (Fig. 3-22A). Bands corresponding to the C5b α’-chain, C6 
Figure 3-21. Formation of C3 alternative pathway convertase on VWF. 
A. Experimental design of the assay for testing the formation of the C3 convertase by microplate/WB. B. 
Microtiter wells were coated with wild-type rVWF-A1A2A3 or rVWF-A1A2A3, mutated at the 
ADAMTS13 cleavage site (YM>AA), or PBS or properdin, and incubated with 20% normal human 
serum (NHS) with or without EDTA 5 mM or sCR1 150 µg/ml. C. Microtiter wells were coated with 
rVWF-A2 or properdin, and incubated with 20% NHS with or without EGTA 1 mM or EDTA 5 mM. D. 
Microtiter wells were coated with rVWF-A2, and incubated with 20% NHS with or without EGTA 1 mM 
or increasing amounts of exogenous FH (100 and 200 µg/ml). FH was visualized as a 150 kDa band by 
WB. In B, C and D C3bBb formation was detected by C3b β-chain (76 kDa) and Bb (60 kDa) bands by 
WB. Results of a representative experiment of n=3 are shown. E. Absorbance values of the staining of 
rVWF-A2 coated on microplate wells in the absence or in the presence of EGTA 1 mM, by using a rabbit 
anti-human VWF antibody followed by an HRP-conjugated anti-rabbit  antibody. 
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and C9 were observed in samples recovered from wells coated with rVWF-A2 or with 
properdin (Fig. 3-22B). No C5b, C6 or C9 bands could be recovered from rVWF-A2-
coated wells exposed to EGTA-treated NHS (Fig. 3-22B). No activation products of C3 
and C5 convertases could be recovered following the incubation of NHS in wells coated 
with fibrinogen, a protein that does not bind C3b (Andersson et al. 2005), supporting the 
specificity of these findings. Finally, labeling the products on rVWF-A2-coated wells, 
after incubation with NHS, with an anti-C5b-9 antibody in an ELISA assay, showed the 
formation of C5b-9 complexes (Fig. 3-22C). Notably, the absorbance values of C5b-9 
formed in rVWF-A2-coated wells were comparable to absorbance values in C3b- or 
properdin-coated wells. The addition of sCR1 reduced the absorbance values in all three 
conditions, while EGTA only reduced the C5b-9 signal in rVWF-A2-coated wells (Fig. 
3-22C). 
These results indicate that rVWF-A2 domain favors the assembly of an active C5 
convertase, the formation of C5b and the activation of the terminal complex (Fig. 3-
22D).  
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Figure 3-22. Formation of C3 and C5 alternative pathway convertases on VWF. 
A. Experimental design of the assay for testing the formation of the C3 and C5 convertases by 
microplate/WB. B. Microtiter wells were coated with properdin or C3b or rVWF-A2 or fibrinogen, and 
incubated with 20% NHS with or without EGTA 1 mM. C3bBb and C5b formation, and C6 and C9 
binding were detected by the bands of C3b β-chain (76 kDa), Bb (60 kDa) and C5b α’-chain (104 kDa), 
C6 (105 kDa) and C9 (66 kDa), respectively, with specific antibodies. FH was visualized as a 150 kDa 
band. Results of a representative experiment of n=3 are shown. C. ELISA-based detection of C5b-9 
deposits formed on properdin or C3b or rVWF-A2 in the presence of NHS, or NHS plus EGTA 1 mM, or 
NHS plus sCR1 150 µg/ml, by using an HRP-conjugated anti-C5b-9 antibody. PBS was used as negative 
control. The graphs show the mean of triplicate measurements from a representative experiment of n=3. 
D. Drawing describing C3, C5 convertases and C5b-9 complex formation on rVWF-A2 coated wells in 
the presence of NHS. 
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3.11 cTTP serum exerts a pro-thrombogenic effect on 
endothelial cells 
3.11.1 cTTP serum induces VWF deposition and 
thrombomodulin shedding mediated by complement 
terminal pathway products 
To investigate whether in the presence of ADAMTS13 deficiency, VWF-induced 
complement activation perturbed the thromboresistant endothelial phenotype, I then 
tested cTTP serum for VWF staining and thrombomodulin expression on ADP-
activated HMEC-1, in the absence and in the presence of complement inhibitors. 
HMEC-1 incubated with cTTP serum (taken in remission, n=5) showed more intense 
VWF staining than cells incubated with control serum (Fig. 3-23A). The VWF staining 
intensity was normalized through supplementation of cTTP serum with ADAMTS13 (4 
µg/ml corresponding to 100% protease activity) that cleaved VWF strings on cell 
surface (Fig. 3-23A). Blocking either the entire complement cascade with sCR1 or the 
terminal pathway alone with eculizumab significantly limited the excessive VWF 
staining induced by cTTP serum (Fig. 3-23A). Following exposure of ADP-activated 
HMEC-1 to cTTP serum the intensity of thrombomodulin staining was significantly 
reduced relative to HMEC-1 exposed to control serum (Fig. 3-23B, n=5). Because the 
cleavage of THBD from the plasma membrane is thought to be dependent on serine 
protease activity, we examined t-PA, a serine protease present in endothelial Weibel-
Palade bodies possibly released upon stimulation by anaphilatoxins. Blockade of t-PA 
activity by treatment of HMEC-1 with the serine protease inhibitor aprotinin prevented 
THBD shedding in response to exogenous C3a. (Morigi et al. 2011). Addition of 
aprotinin to cTTP serum significantly limited the loss of thrombomodulin staining, 
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suggesting that cTTP serum induced thrombomodulin shedding from HMEC-1 (Fig. 3-
23B). Also eculizumab antagonized the effect of cTTP serum on thrombomodulin loss 
(Fig. 3-23B).  
Together the above results indicated that C5 activation products have a role in cTTP 
serum-induced VWF accumulation on HMEC-1 and in thrombomodulin loss from 
HMEC-1 cell surface. 
Human umbilical vein and human microvascular endothelial cells have been reported to 
express the receptors for the C5 cleavage product C5a (C5aR) (Schraufstatter et al. 
2002). Here we also found that HMEC-1 also express C5aR, and C5aR expression 
levels increased after stimulation with ADP (Fig. 3-23C). 
To investigate whether C5a mimicked the effects of cTTP serum on HMEC-1, HMEC-1 
were exposed to C5a in test medium, in the absence of serum (Fig. 3-23D-E). HMEC-1 
incubation with C5a resulted in intense VWF staining compared with cells incubated 
with test medium alone. C5a also caused loss of thrombomodulin staining on the 
HMEC-1 cell surface (Fig. 3-23D-E).   
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Figure 3-23. cTTP serum-induced activation of the terminal complement pathway alters the 
thromboresistant phenotype of microvascular endothelial cells.  
A. ADP-activated HMEC-1 were incubated with 50% serum from healthy subjects (ctr, n=5) or from 
cTTP patients in remission (cTTP, n=5), the latter in the absence or in the presence of sCR1 or 
rADAMST13 or eculizumab (ecu). VWF deposits were evaluated by staining with an anti-VWF antibody, 
and the surface area covered by VWF staining was quantified on images from 15 high power fields 
acquired by confocal fluorescence microscopy. Data are expressed as mean ± SE of area covered by VWF 
deposits. °P<0.01 vs ctr, *P<0.01 vs cTTP untreated, ANOVA. B. Left panel. Thrombomodulin 
expression on ADP-activated HMEC-1 incubated with serum from healthy subjects (ctr, n=5) or from 
cTTP patients in remission (cTTP, n=5), with or without eculizumab (ecu) or aprotinin. Thrombomodulin 
(THBD) expression was evaluated by staining with an anti-thrombomodulin antibody, and the surface 
area with THBD staining was quantified on images from 15 high power fields acquired by confocal 
fluorescence microscopy. Results were expressed as mean ± SE. °P<0.01 vs ctr, *P<0.01 vs cTTP 
untreated, ANOVA. Right panel. Representative confocal microscopy images of thrombomodulin (red) 
staining on ADP-activated HMEC-1 (nuclei: DAPI, blue) exposed to serum from healthy subjects (ctr) or 
cTTP patients (cTTP). Original magnification 400x, white scale bar: 20 µm. C. C5aR expression (red) on 
resting and ADP-activated HMEC-1 (nuclei: DAPI, blue). HMEC-1 were incubated for 10 min with 
medium alone or added with 10 µM ADP, then C5aR were labeled with an anti-human CD88 antibody 
(or isotype control antibody, negative). Magnification 400x, white scale bar: 20 µm. D.  Effect of C5a on 
VWF and thrombomodulin expression on endothelial cells. HMEC-1 were incubated (10 min) with 200 
ng/ml C5a added to test medium. Staining of VWF and thrombomodulin was evaluated by confocal 
microscopy. Results were expressed as mean ± SE of  15 high power fields. #P<0.01 vs resting HMEC-1, 
ANOVA. E. Representative images of VWF (red) and thrombomodulin (red) staining on HMEC-1 
(nuclei: DAPI, blue), either resting or exposed to 200 ng/ml C5a. Magnification 400x. White scale bar: 20 
µm. 
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3.11.2 cTTP serum induces microvascular thrombosis 
Finally, to evalute whether the above abnormalities contributed to microvascular 
thrombosis of cTTP, ADP-activated HMEC-1 were pre-incubated with cTTP serum 
(n=11, in remission) and then perfused with normal heparinized whole blood (added 
with mepacrine, Fig. 3-24A, see Methods 2.14) at a shear stress encountered into the 
microcirculation (60 dynes/cm2). In these experimental conditions blood did not clot 
and platelet thrombi could be evaluated as green fluorescence signal on HMEC-1. A 
much wider surface area covered by thrombi was observed upon blood perfusion on 
HMEC-1 pre-treated with cTTP serum, compared to cells exposed to control serum 
(Fig. 3-24B-C). The thrombus area was completely normalized by the addition of sCR1, 
or FH, or eculizumab (Fig. 3-24B-C) during preincubation with cTTP serum. A C5aR 
antagonist significantly reduced but did not fully normalize the thrombus area (Fig. 3-
24B-C), indicating that both terminal complement products, C5a and C5b-9, have a role 
in the prothrombogenic effect of cTTP serum. cTTP serum-induced thrombus formation 
was also inhibited by rADAMTS13 (Fig. 3-24B-C) that prevented VWF accumulation 
on HMEC-1 (Fig. 3-23A), and by an anti-VWF antibody (Fig. 3-24B-C).  
Together these data indicate that VWF accumulation and complement activation on 
endothelium might play a cooperative role in the insorgence of microvascular 
thrombosis in conditions of ADAMTS13 deficiency. 
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Figure 3-24. cTTP serum exerts a prothrombogenic effect on microvascular endothelial cells  
mediated by VWF and terminal complement pathway. 
A. Experimental design. 
B. ADP-activated HMEC-1 were exposed to serum from healthy subjects (ctr, n=11) or cTTP patients in 
remission (cTTP, n=11) with or without sCR1 (n=11) or FH (n=8) or eculizumab (ecu, n=8), or a C5aR 
antagonist (C5aRA, n=3), or rADAMT13 (rA13, n=8), or a polyclonal anti-human VWF antibody (anti-
VWF, n=8) or an irrelevant antibody (irrel, n=8); then cells were perfused with whole blood. The area 
occupied by thrombi was measured on images from 15 high power fields acquired by confocal 
fluorescence microscopy and data were expressed as mean ± SE. °P<0.01 vs ctr, *P<0.01 vs cTTP 
untreated, ^P<0.01 vs cTTP+irrel, ANOVA. C. Representative confocal microscopy images of thrombi 
(platelet deposition, green) formed on ADP-activated HMEC-1 after exposure to serum from an healthy 
subject (ctr) or from a cTTP patient (cTTP) with or without sCR1 or FH or eculizumab (ecu) or a C5aRA, 
or rADAMTS13 (rA13) or a rabbit anti-VWF antibody (anti-VWF) or an irrelevant rabbit antibody 
(irrel). Original magnification 200x. White scale bar: 50 µm. 
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In this study I demonstrated that severe ADAMTS13 deficiency, which results in the 
accumulation of ULVWF multimers, is associated with activation of the complement 
AP and hence the terminal pathway on endothelial cell surface.  
This is supported by the following findings: 1) sera from all patients with cTTP and 
ADAMTS13 mutations induced abnormal C3 and C5b-9 deposits on ADP-activated 
endothelial cells, which were prevented by selective AP inhibitors; 2) abnormal C3 
deposits induced by cTTP serum colocalized with VWF; 3) the effect of cTTP serum on 
C3 and C5b-9 deposition was completely prevented by rADAMTS13 supplementation 
or by treatment with an anti-VWF antibody; 4) VWF interacted with C3b and provided 
a platform for the formation of active C3 and C5 convertases of the AP. Notably, 
circulating C3 and SC5b-9 levels were altered in only a fraction of patients, indicating 
that complement activation in cTTP occurs at cell surface rather than in the fluid phase. 
Altogether these results match the condition of endothelial-restricted complement 
activation of patients with aHUS (Goicoechea de Jorge et al. 2007; Noris et al. 2014), 
and support the existence of a cross-talk between ADAMTS13/VWF and the 
complement system.  
Previous studies suggested that complement is activated during acute episodes of 
acquired TTP. High plasma levels of C3a and SC5b-9 were reported in patients with 
anti-ADAMTS13 antibodies (Reti et al. 2012), however chronic high levels of C4d 
indicated secondary activation of the classical complement pathway by autoantibodies 
(Reti et al. 2012). There are also data suggesting that complement activation may occur 
in cTTP, as documented by complement-induced hemolysis of sheep erythrocytes in the 
presence of cTTP plasma (Feng et al. 2013)b, and by C3 and C5b-9 deposition on 
endothelial cells following exposure to cTTP sera (Ruiz-Torres et al. 2005). In the 
above reports the diagnosis of cTTP could not be confirmed since no genetic data were 
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provided; in addition, samples were taken during an acute episode (Ruiz-Torres et al. 
2005; Feng et al. 2013)b, so the possibility that complement activation was a secondary 
phenomenon triggered by extensive platelet activation and ischemic tissue injury could 
not be ruled out. Tati et al (Tati et al. 2013) found that plasma from patients with cTTP 
and ADAMTS13 mutations contained higher levels of complement-coated endothelial 
microparticles than control plasma. Exposure of histamine-stimulated glomerular 
endothelial cells to cTTP plasma caused deposition of C3 on VWF-platelet strings (Tati 
et al. 2013). Notably, all patients in the above study had renal involvement, a clinical 
feature that is observed only in a subgroup of cTTP patients, while it is prototypical of 
aHUS (Noris and Remuzzi 2009). Moreover, the Authors did not investigate the 
concomitant presence of any aHUS-associated complement abnormalities that could 
account for the renal phenotype and complement activation (Noris et al. 2005; Chapin et 
al. 2013; Tsai et al. 2013).  
Unlike in the above studies, Gavriilaki et al (Gavriilaki et al. 2015) failed to find 
increased C5b-9 deposits and complement-mediated killing in cells exposed to TTP 
serum, however a large majority of patients had acquired TTP and only three of them 
were studied during the acute phase of the disease. In addition, the tests were done on 
cell lines (human endothelial hybrid and human erythroblast cell lines) made artificially 
deficient for glycosylphosphatidylinositol-anchored complement regulatory proteins 
(CD55 and CD59), an experimental setting that was far from reproducing the conditions 
of human vascular endothelium. In this regard, and unlike in other studies (Noris et al. 
2014), the above tests could not distinguish aHUS patients with active disease from 
aHUS patients in remission under terminal complement blockade through eculizumab 
treatment, because of both  groups causing the same complement-mediated cell killing.  
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The aim of the present study was to clarify whether a direct link exists between 
impaired VWF cleavage due to ADAMTS13 deficiency and complement activation. For 
this purpose only cTTP patients with identified ADAMTS13 mutations and without 
mutations in complement genes were studied. It is relevant that all but two ADAMTS13 
mutations have been functionally characterized previously and cause a severe reduction 
in protein secretion and/or activity or result in protein interruption (Donadelli et al. 
2006; Lotta et al. 2012; Pecoraro et al. 2015; Rurali et al. 2015). In addition, to separate 
the relative contribution of ongoing thrombotic microangiopathy from that of 
ADAMTS13 deficiency per se to complement activation, cTTP patients were studied 
both during acute episodes and at remission.  
Although plasma SC5b-9 is considered a surrogate marker of complement activation  
(Cataland et al. 2014), it is documented to be unreliable in TMA patients, since most 
patients in remission continued to have elevated SC5b-9 levels, also after eculizumab 
therapy that blocks C5 cleavage (Noris et al. 2014). Also in cTTP cohort here 
considered high SC5b-9 levels detected during acute phase remained elevated in 
remission. Recent studies reported that SC5b-9 complex could originate also after C5 
cleavage mediated by thrombin and plasmin, which act as “alternative” potent C5 
convertases (Huber-Lang et al. 2006; Foley et al. 2016). Evidence that thrombin and 
plasmin generation increases in blood of patients suffering from thrombotic disorders 
(Wada et al. 1989; Grabowski 2002), where coagulation cascade is activated, suggests 
that the total amount of SC5b-9 complexes could be the sum of the “alternative” and the 
canonical C5 cleavage. To address above considerations, other experiments are needed 
to discriminate the contribution of thrombin- and plasmin- mediated C5 proteolysis in 
the complement cascade. 
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To evaluate whether complement is activated at endothelial cell level, we used the new 
ex vivo assay set up for monitoring eculizumab therapy in aHUS patients (Noris et al. 
2014) for cTTP cohort here described. Serum from acute cTTP caused C3 and C5b-9 
deposits on resting endothelial cells, which could reflect in vivo complement activation 
triggered by widespread platelet thrombi and coagulation (Huber-Lang et al. 2006; 
Amara et al. 2008; Speth et al. 2015). In contrast, cTTP serum taken in remission 
induced excessive complement deposition only on activated endothelial cells. These 
data fit with the observation that cTTP onset or relapses may occur in concomitance 
with a triggering event (infections, drugs, pregnancy) that perturbs microvascular 
endothelium (Galbusera et al. 2006), and suggest that ADAMTS13 deficiency 
predisposes to AP dysregulation on cell surface. The observation that supplementing 
cTTP serum with rADAMTS13 fully prevented C3 and C5b-9 deposits supported the 
above hypothesis. However, mechanistic studies did not reveal any direct regulatory 
activity of ADAMTS13 on the complement AP. Indeed, rADAMTS13 failed to 
proteolyse FB and did not alter the assembly of the AP C3 convertase. Some structural 
homology exists between the A2 domain of VWF that contains the ADAMTS13 
cleavage site (Akiyama et al. 2009; Crawley et al. 2011), and the VWA domain of FB 
that is involved in its binding with C3b (Milder et al. 2007; Torreira et al. 2009). 
However, the Tyrosine1605 in the ADAMTS13 cleavage site is replaced by Leucine in 
the VWA FB domain, which could explain failure of FB proteolysis by ADAMTS13. 
Nevertheless, this work provided for the first time experimental evidence that 
ADAMTS13 binds FB, and the results of ClusPro docking prediction suggested that Ba 
fragment chain of FB is responsible for this interaction. Since FB binding to C3b 
depends on elements contained in Ba chain (Milder et al. 2007), ADAMTS13 could 
hamper this interaction by competing with C3b for the same binding epitopes on FB, 
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and it could account for the little inhibition observed on C3 proconvertase assembly in 
SPR. However, ADAMTS13 did not substantially interfere in the formation of C3bBb 
convertase complexes, which originate after C3 proconvertase assembly. This 
consideration together with the evidence that physiological blood concentration of FB is 
largely higher than that of ADAMTS13 (FB = 2.15 uM, ADAMTS13 = 5.55 nM, 
FB:ADAMTS13 = 387:1) (Gerritsen et al. 2001; Waters and Licht 2011), could 
suggests that ADAMTS13 interacts with FB too weakly to efficiently antagonize the 
binding of FB with C3b in the C3bB and C3bBb complexes. Thus, the physiological 
meaning of this binding remains still unclear. Further studies will be necessary to better 
characterize the binding sites of ADAMTS13 and FB by using deletions mutants of both 
proteins in ELISA and SPR experiments similar to the ones here reported. Besides, any 
ADAMTS13 effect on C3 convertase activity could be not excluded and must be also 
investigated. 
Once established that ADAMTS13 does not directly modulate complement, I then 
investigated whether VWF interacted with C3b. Here I documented that a specific 
interaction between VWF and C3b exists, and that the binding site for C3b is localized 
in the A2 domain of VWF. ClusPro prediction revealed that C-terminal  of VWF-A2 
interacts with TED domain of C3b, containing the thioester moiety which is also 
involved in this binding.  
Activation of C3 into C3b in the complement pathway is a crucial step for complement 
response, since nascent C3b is able to bind covalently to cell and target surfaces via the 
exposed thioester (Janssen and Gros 2007). I would hypothesize that C3b molecules 
deposit on endothelial VWF in the same covalent manner in which they attach to 
stimulated surfaces. Indeed we observed in SPR experiments high affinity binding 
between VWF and C3b, and this interaction seems to be irreversible, in contrast with 
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published data by Feng and coworkers (Turner and Moake 2013; Feng et al. 2015). 
These results together with the observation that monomeric VWF was immobilized on 
the SPR chip after reduction with DTT, could properly suggest that thiol free groups of 
VWF could efficiently link to the exposed thioester group of C3b. However, these 
speculations should be confirmed by additional experiments. 
Nevertheless, of great relevance I confirmed VWF-C3b interaction at the endothelial 
cell level by colocalization of VWF and C3 deposits on HMEC-1 exposed to cTTP 
serum. Altogether these results are in line with published data showing the 
colocalization of C3/C3b with ULVWF on histamine-stimulated HUVEC (Turner and 
Moake 2013; Feng et al. 2015). I then found no C3 staining on ADP-activated HMEC-1 
before exposure to serum, despite the evidence of secreted/attached VWF on cell 
surface, indicating that the C3 deposited on HMEC-1 following incubation with cTTP 
serum mostly originated from serum.  
How the interaction between VWF and C3b impacts on the activation of the 
complement AP is a matter of debate. VWF has been shown to favor C3b inactivation 
by enhancing FH cofactor activity (Rayes et al. 2014). Another study proposed that 
normal plasma VWF multimers alone may exert cofactor activity, while ULVWF 
multimers lacked cofactor activity and did not inhibit the generation of C3b from C3 
(Feng et al. 2015). Here I documented no cofactor activity either for plasma-derived 
VWF or rVWF that includes ULVWF multimers, either in the absence or in the 
presence of FH. Discrepancies between the present and published results could be due 
to the largely supraphysiological molar ratios of VWF used in published studies, 
compared to FI and FH (Rayes et al. 2014; Feng et al. 2015). In addition, since FH 
binds to VWF, and VWF-FH complexes were detected in normal plasma, the 
contribution of contaminating FH in plasma-derived VWF preparation to the observed 
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cofactor activity cannot be excluded (Rayes et al. 2014). Furthermore, the interaction 
between VWF and the FH does not seem to modulate the activity of the FH even in C3 
convertase accelerating decay. Altogether these results documented that VWF does not 
directly affect FH activities on C3b and C3 convertase. 
Rather, finding here that the binding of rVWF-A1A2A3 or rVWF-A2 domains to C3b 
results in the formation of the C3 convertase, indicates that VWF may act as an initiator 
of the complement AP. This possibility is confirmed by data that either sCR1, or FH, 
which dissociates the AP C3 convertase (Jozsi and Zipfel 2008), inhibited C3 
convertase formation on rVWF, and normalized C3 deposits induced on HMEC-1 by 
cTTP serum.  
The current dogma states that while Ca2+ is required for the initiation of the complement 
classical pathway (Fishelson and Muller-Eberhard 1982; Major et al. 2010), the AP is 
Ca2+ independent. A major finding of the present study is the identification of a Ca2+-
dependent mechanism of AP activation that is mediated by VWF, as supported by data 
that EGTA prevented the formation of C3bBb on the rVWF-A2 domain. Calcium ions 
bind the VWF-A2 domain, and the calcium binding site and a vicinal disulphide bond 
act together to maintain the structural integrity of the VWF-A2 domain and to protect 
against ADAMTS13 proteolysis (Lynch et al. 2014). A plausible explanation of 
findings here reported could be that the Ca2+-stabilized conformation of the VWF-A2 
domain may favor the interaction between VWF and C3b, either by exposing a 
functional binding site or preventing cleavage of the subunit. Recent studies reported 
that single-particle electron microscopy (EM) could provide reliable and high resolution 
views of how domains of C3b could move and orientate during assembly with its 
binding partners (Torreira et al. 2009; Alcorlo et al. 2013). Considering all the 
observations here reported regarding the binding between C3b and VWF, EM 
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methodology could be an useful tool to describe and better characterize the C3b-VWF 
complex. On the other hand, it is important to note that rVWF-A2 domain used in this 
study is produced in bacteria (E.coli, provided by R&D Systems), while rVWF-A1 and 
rVWF-A3 domains are obtained from mammalian cells (HEK293E, Human Embryonic 
Kidney Cells; provided by U-Protein Express BV). So, I can not exclude that the results 
obtained here could be influenced by the non-human source of the recombinant 
proteins, which do not carry all the post-translational modifications present in 
mammalian cells. In this context, the expression of rVWF-A2 in human cells, such as 
HEK293 cells, is needed to confirm the results of this study and to understand the 
impact of mammalian modifications, such as glycosylation, in the interaction and 
function of this crucial domain of VWF.    
In contrast with our results,  Noone et al (Noone et al. 2016) recently suggested VWF 
has a role in protecting endothelial cells from complement, based on finding of 
increased C3c deposition on cultured blood outgrowth endothelial cells from patients 
with type 3 VWF disease that have severe deficiency of VWF. However in this study 
cells were treated with antibodies that artificially blocked all membrane-anchored 
complement regulators and induced complement fixation via the classical pathway. It 
would have been interesting that the Authors had analyzed whether serum of aHUS 
patients, in which alternative pathway cascade is selectively activated due to mutations 
in complement components, could induce the same response on the surface of these 
cells. Furthermore, the in vivo relevance of the above data is debatable since there is no 
published evidence indicating complement hyperactivation in patients with VWF 
disease. 
Another relevant finding of this study is the formation of C5b and C5b-9 on rVWF-A2 
domain, indicating that the AP C3 convertase assembled on VWF formed the C5 
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convertase that cleaved C5 to C5a and C5b and initiated the terminal pathway.  
Altogether these results provide a mechanistic explanation of the formation of C5b-9 
deposits on cTTP serum-exposed HMEC-1.  
C5a and C5b-9 cause profound perturbations of the physiologically thromboresistant 
endothelial phenotype, including upregulation of tissue factor, loss of thrombomodulin, 
and exocytosis of P-selectin and ULVWF (Hattori et al. 1989; Platt et al. 1991; Ikeda et 
al. 1997; Tedesco et al. 1997; Mori et al. 2001). Finding here that treatment with 
eculizumab prevented the loss of thrombomodulin and the VWF increase on endothelial 
cells exposed to cTTP serum, supports a role of terminal complement components in the 
loss of endothelial thromboresistant phenotype. The evidence that treating HMEC-1 
with C5a caused VWF exocytosis and thrombomodulin shedding points to C5a as a 
plausible major player in the cTTP serum-induced prothrombogenic endothelial 
abnormalities. The pathophysiological relevance of these data to microvascular 
thrombosis is highlighted by evidence that blocking complement with either sCR1, FH, 
eculizumab, or a C5aR antagonist consistently reduced the pro-thrombogenic effect of 
cTTP serum on microvascular endothelium. Besides, results here proposed further 
support the importance of C5a-C5aR axis in promoting thrombosis in a particular pro-
thombogenic condition (Romay-Penabad et al. 2007).  
Endothelial cells express functional C5aRs and delineates the intracellular signal 
transduction pathway by activating G-proteins and EGFR cascade (Schraufstatter et al. 
2002). It has been shown that various proinflammatory mediators can up-regulate C5aR 
expression (Gasque et al. 1997; Laudes et al. 2002), allowing C5a to directly potentiate 
proinflammatory events on the microvascular endothelium. Thus, it could be interesting 
to evaluate whether also cTTP serum stimulate endothelial C5aR expression by 
evaluating cellular C5aR mRNA levels after serum incubation. What still remains to 
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understand is the mechanisms by which C5a induces VWF secretion and THBD 
shedding during cTTP serum stimulation. Since C5a treatment of HMEC induced 
cytoskeletal changes, cell retraction and gap formation (Schraufstatter et al. 2002), it 
can be assumed that C5a could induce re-organization of intracellular vesicle trafficking 
of endothelial cells that results in exocytosis of VWF on cell surface. To evaluate this 
hypothesis, intracellular cytoskeletal markers such as actin and tubulin fibers could be 
analyzed in endothelial cells after incubation with cTTP serum. Finally, a novel 
anaphylatoxin receptor, named C5L2, has also been identified (Cain and Monk 2002) 
and its transduction signal could be further investigated. 
To summarize, the results presented here indicate that VWF multimer accumulation on 
endothelium, as occurs in cTTP, promotes the activation of the complement AP that 
proceeds until C5 cleavage with the formation of C5a and the terminal C5b-9 complex. 
In turn, the terminal complement components, cause the loss of the antithrombotic 
thrombomodulin and the increase in VWF multimers secreted/anchored on endothelial 
cells, thus creating a positive amplification loop that results in microvascular 
thrombosis (Fig. 4-1). Of note, VWF plasma levels and endothelial cells vary from one 
vascular bed to another and in particular cells may also have different responses to the 
same signals (Rosenberg and Aird 1999). In patients with TTP, accumulation of 
ULVWF multimers could have different effects on endothelial cells from different 
organs. These observations closely correlate with heterogeneous distribution of 
microthrombi in patients with TTP and suggest that the phenotype is governed by 
individualistic responses of endothelial cells to a stimulus. 
Altogether these findings link hemostasis-thrombosis with the complement AP and 
open potential therapeutic perspectives of complement-inhibitory drugs in cTTP and in 
general in thrombotic and inflammatory disorders, such as diabetes, autoimmune 
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disorders and cardiovascular diseases, associated with endothelium perturbation, VWF 
release and complement activation (Zhang et al. 2002; Bjerre et al. 2010; Verschoor and 
Langer 2013; Montoro-Garcia et al. 2014). Therapeutic strategies that include C5a and 
its receptor are considered an especially promising approach to complement inhibition 
(Reis et al. 2015). The observation that eculizumab given as sole treatment to a boy with 
cTTP resulted in prompt disease remission is in keeping with such a possibility 
(Pecoraro et al. 2015). 
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Figure 4-1. The interplay between VWF and the complement alternative pathway.  
C3 spontaneously undergoes cleavage to C3b at a slow rate, amplified by bacterial and viral products. 
Upon a trigger event that activates or injures endothelial cells, ULVWF multimers are exocytosed from 
Weibel-Palade bodies on endothelial cell surface, and by binding C3b may amplify the alternative 
pathway (AP) cascade by forming the C3 convertase complex. In normal subjects (upper panel) 
ADAMTS13 cleaves ULVWF multimers from cell surface and prevents AP activation maintaining 
homeostasis. The low amount of C3b formed is inactivated to iC3b by factor H (FH) and factor I (FI). 
Thrombomodulin (THBD), a surface protein expressed on all endothelial cells, provides additional 
protection: by binding to thrombin blocks its ability to activate coagulation and platelets and redirects the 
activity of thrombin toward the generation of carboxypeptidase B (TAFIa), which inactivates C3a and 
C5a.  
 In patients with cTTP and severe ADAMTS13 deficiency (lower panel), ULVWF multimers can not be 
cleaved and accumulate on endothelial cell surface, providing a nucleus for the C3 and C5 convertases of 
the AP, leading to C5 cleavage to C5a and C5b. C5a binds to its receptors on endothelial cells, and C5b 
forms the terminal C5b-9 complex. Both C5a and C5b-9 cause further exocytosis of VWF from Weibel-
Palade bodies that favor platelet adhesion and aggregation and amplifies the complement  activation 
cascade. In addition C5a  causes the shedding of thrombomodulin. The latter event results in impaired 
TAFI-mediated inactivation of C5a and thrombin-mediated platelet activation. Together the above events 
concur to platelet adhesion-aggregation and microvascular thrombosis. 
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